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Summary
E-, P- and L-selectin belong to the C-type lectin family of cell adhesion molecules that
initiate inflammatory response. Infammation per se is a physiologocal defense
mechanism, but excessive leukcyte extravasation leads to numerous pathoIogical and
disease states, as well as metastatic cancer spread. Leukocyte tethering and rolling
toward inflammatory site start with the interaction of selectins and the carbohydrate
epitope of their glycoprotein ligands, sialyl Lewisx. Therefore inhibitors of selectin-ligand
interaction are of high pharmaceutical interest as potent anti-inflammatory agents.
Tetrasaccharide sialyl Lewisx serves as a lead strucure in chemical and computational
search for selectin antagonists. Structural NMR and X-ray studies indicated binding
mode of sialyl Lewisx with E-, and P-selectin, but improved structural studies with the
second and third generation antagonists is missing.
We expressed recombinant human E-, P- and L-selectin/IgG as secreted proteins in
mammalian expression system and purified them to homogniety. Acitivity of the proteins
was confirmed with blocking monoclonal antibodies and ligand binding confirmed by
NMR.
Bioassays were developed in cell-free and cell-based formats with E-selectin/IgG to
evaluate inhibitory potencies of in-house synthesized selectin antagonists. Due to
variation and instabilities on day-to-day and batch-to-batch basis, assays were used only
for preliminary antagonists screen.
To enhance further structural studies, we developed a new system for the expression of
truncated form of human E-selectin (lectin and EGF-like domains). Initialy we tried to
express these two domains in E.coli, but refolding of expressed inclusion bodies was
inefficient. Therefore lectin and EGF-like domains of human E-selectin were expressed
as secreted form in baculovirus-infeced insect cells with a flag-epitope on its C-terminus.
Expressed protein (LecEGFFlag) was monomeric in solution, correctly folded and active,
as confirmed in the reaction with monoclonal blocking antibodies, and NMR studies.
Protein was expressed in two distinct glycosylation forms, with apparent molecular
weigts of 19.96 kDa and 21.15 kDa.
In addition, we developed for the first time a cell-free assay with truncated form of E-
selectin (aforementioned LecEGFFlag) for the evaluation of of E-selectin inhibitors. In a
proof-of-concept manner, three different E-selectin antagonists were tested and obtained
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IC50 values were in close agreement with published results. Reproducibility and stability
of the assay on day-to-day and batch-to batch basis make it suitable not only for the
preliminary screening, but also to quantify inhibitory potencies of E-selectin antagonists.
Developed system is suitable for expression and similar characterization of P- and L-
selectin as well.
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1 Introduction
1.1 Physiology of inflammation and leukocyte differentiation
Humans have to defend themselves against various different pathogens including
viruses, bacteria, fungi, protozoan and metazoan parasites. As a consequence,
numerous body-defending mechanisms agents have been developed. Inflammation is a
complex stereotypical reaction of the body in the response to damage of its cells and
vascularized tissues. The discovery of the detailed processes of inflammation has
revealed a close relationship between inflammation and the immune response.
Five basic symptoms of inflammation - redness (rubor), swelling (tumour), heat (calor),
pain (dolor) and deranged function (functio laesa) have been known since the ancient
Greek and Roman era. These signs are due to extravasation of plasma and infiltration of
leukocytes into the site of inflammation [1]. Early investigators considered inflammation a
primary host defence system, since inflammation is the key reaction of the innate
immune response. However, over-inflammatory responses lead to death, as in
anaphylactic shock, or debilitating diseases, as in arthritis and gout. According to
different criteria, inflammatory responses can be divided into several categories [2]. The
criteria include:
1. Time - hyperacute (peracute), acute, subacute, and chronic inflammation
2. Main inflammatory manifestation - alteration, exudation, proliferation
3. Degree of tissue damage - superficial, profound (bordered, not bordered)
4. Characteristic picture - nonspecific, specific
5. Immunopathological mechanisms
• Allergic (reaginic) inflammation
• Inflammation mediated by cytotoxic antibodies
• Inflammation mediated by immune complexes
• Delayed type hypersensitivity reactions
The inflammation brings the fluid, proteins, and cells from the blood into the damaged
tissues. Thus, mechanisms exist that allow cells and proteins to gain access to
extravascular sites where and when they are needed in case damage and infection have
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occured. The main features of the inflammatory response are: vasodilation, i.e.
widening of the blood vessels to increase the blood flow to the infected area; increased
vascular permeability, which allows diffusible components to enter the site; cellular
infiltration by chemotaxis, or the directed movement of inflammatory cells through the
walls of blood vessels into the site of injury; changes in biosynthetic, metabolic, and
catabolic profiles of many organs; and activation of cells of the immune system as well
as of complex enzymatic systems of blood plasma.
Inflammation can be divided into several phases. The earliest event of an inflammatory
response is temporary vasoconstriction. This is followed by several phases that occur
over minutes, hours and days later, as outlined below.
The acute vascular response follows within seconds of the tissue injury and last for
some minutes. This results from vasodilatation and increased capillary permeability due
to alterations in the vascular endothelium, which leads to increased blood flow
(hyperaemia) that causes redness (erythema) and the entry of fluid into the tissues
(oedema). If there has been sufficient damage to the tissues, or if infection has occured,
the acute cellular response takes place over the next few hours. The hallmark of this
phase is the appearance of granulocytes, particularly neutrophils, in the tissues. These
cells first attach themselves to the endothelial cells within the blood vessels
(margination) and then cross into the surrounding tissue (diapedesis). During this phase
erythrocytes may also leak into the tissues and a haemorrhage can occur. If the vessel
is damaged, fibrinogen and fibronectin are deposited at the site of injury, platelets
aggregate and become activated, and the red cells stack together in what are called
''rouleau'' to help stop bleeding and aid clot formation. The dead and dying cells
contribute to pus formation.
If the damage is severe, a chronic cellular response may follow over the next few days
as an appearance of a cell infiltrate composed of macrophages and lymphocytes. The
macrophages are involved in microbial killing, in clearing up cellular and tissue debris,
and they also seem to be very important in re-modeling the tissues.
Over the next few weeks, resolution may occur, meaning that the normal tissue
architecture is restored. Blood clots are removed by fibrinolysis. If it is not possible to
return the tissue to its original form, scarring results from in-filling with fibroblasts,
collagen, and new endothelial cells. Generally, by this time, any infection will have been
overcome. However, if it has not been possible to destroy the infectious agents or to
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remove all of the products that have accumulated at the site completely, it is walled off
from the surrounding tissue in granulomatous tissue. A granuloma is formed when
macrophages and lymphocytes accumulate around material that has not been
eliminated, together with epitheloid cells and gigant cells (perhaps derived from
macrophages) that appear later, to form a ball of cell.
Inflammation is often considered in terms of acute inflammation that includes all the
events of the acute vascular and acute cellular response (described above), and
chronic inflammation that includes the events during the chronic cellular response and
resolution or scarring. A large number of additional effects occur during inflammation.
These include: the production of acute phase proteins, including complement
components, by the liver; fever, caused by pyrogens acting on the hypotalamus in the
brain; and systemic immunity, resulting in part from lymphocyte activation in peripheral
lymphoid tissues.
1.1.1 Leukocyte differentiation
The cells of the immune system originate in the bone marrow, from where they migrate
to the peripheral tissues, circulating in the blood and lymphatic system. All the cellular
elements of blood, red blood cells, platelets, and the white blood cells of the immune
system, derive ultimately from the same progenitor or precursor cells-the pluripotent
hematopoietic stem cells in the bone marrow. The different types of blood cells and their
lineage relationships are summarized in figure 1 [2].
Figure 1.1: Hematopoiesis and leukocyte differentiation under the controlled by different cytokines.
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Interleukin-7 (IL-7) is the major cytokine that stimulates bone marrow stem cells to start
lymphoid progenitor, which is through activity of interleukin 6 (IL-6) transferred to B and
T lymphocyte [2,3]. Thrombopoietin (TPO) enhances production of megakaryocyte,
which will differentiate further to platelets under the activity of TPO and interleukin-11
(IL-11). Erythropoietin (EPO) stimulates pluripotent stem cells to ertythroid progenitor
production, and its maturation to red blood cells. On the other hand, stem cells
stimulated with granulocyte-monocyte colony-stimulating factor (GM-CSF) lead to
myeloid progenitor formation and sends cells down the path leading to granulocytes and
monocytes formation. Stimulated by macrophage colony-stimulating factor (M-CSF), the
myeloid progenitor cells differentiate into monocytes, the precursors of macrophages.
Under the influence of granulocyte colony-stimulating factor (G-CSF), myeloid
progenitors differentiate into neutrophils. Further stimulation by interleukin 3 (IL-3)
differentiates cells into basophils, and stimulation with interleukin 5 (IL-5) leads to
eosinophil formation. The myeloid progenitor is the precursor of the granulocytes,
macrophages, dendritic cells, and mast cells of the immune system.
• Granlocytes, also called polymorphonuclear leukocytes, have densely staining
granules in their cytoplasm. There are three types of granulocyte, all of which are
relatively short lived and are produced in increased numbers during immune responses,
when they leave the blood to migrate to sites of infection or inflammation.
Neutrophils, which are the third phagocytic cell of the immune system, are the most
numerous and most important cellular component of the innate immune response:
hereditary deficiencies in neutrophil function lead to overwhelming bacterial infection
which is fatal if untreated.
Eosinophils are thought to be important mostly in defense against parasitic infection,
because their increased number during this type of infection.
The function of basophils is similar and complementary to that of eosinophils and mast
cells.
• Macrophages are one of the three types of phagocyte in the immune system and
are distributed widely in the body tissues, where they play a critical part in innate
immunity. They are the mature form of monocytes, which circulate in the blood and
differentiate continuously into macrophages upon migration into the tissues.
• Dendritic cells are specialized to take up an antigen and display it for recognition by
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lymphocytes. Immature dendritic cells migrate from the blood to reside in the tissues and
are both phagocytic and macropinocytic, ingesting large amounts of the surrounding
extracellular fluid. Upon encountering a pathogen, they rapidly mature and migrate to
lymph nodes.
• Mast cells, whose blood-borne precursors are not well defined, also differentiate in
the tissues. They mainly reside near small blood vessels and, when activated, release
substances that affect vascular permeability. Although best known for their role in
orchestrating allergic responses, they are believed to play a part in protecting mucosal
surfaces against pathogens.
The common lymphoid progenitor gives rise to the lymphocytes. There are two major
types of lymphocyte: B lymphocytes or B cells, which when activated differentiate into
plasma cells that secrete antibodies; and T lymphocytes or T cells, of which there are
two main classes. One class differentiates on activation into cytotoxic T cells, which kill
cells infected with viruses, whereas the second class of T cells differentiates into cells
that activate other cells such as B cells and macrophages [4-6]. Most lymphocytes are
small, featureless cells with few cytoplasmic organelles and much of the nuclear
chromatin inactive. These cells have no functional activity until they encounter antigens,
which is necessary to trigger their proliferation and the differentiation of their specialized
functional characteristics.
Lymphocytes induce a specific immune response against any foreign antigen, because
each individual lymphocyte matures bearing a unique variant of a prototype antigen
receptor. In this way, the population of T and B-lymphocytes bear receptors of a high
diversity in their antigen-binding sites. The B-cell antigen receptor (BCR) is a membrane-
bound form of the antibody that the B cell will secrete after activation and differentiation
to plasma cells. The T-cell antigen receptor (TCR) is related to immunoglobulin, and is
specially adapted to detect antigens or pathogens derived from foreign proteins that
have entered into host cells.
A third lineage of lymphoid cells, called natural killer cells, lack antigen-specific
receptors and are part of the innate immune system. These cells circulate in the blood
as large lymphocytes with distinctive cytotoxic granules. They are able to recognize and
kill some abnormal cells, like tumor cells and virus-infected cells, and are important in
the innate immune defense against intracellular pathogens.
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Figure 1.2: The lymphoid organs and tissue distribution. Adopted from [2].
Both B and T lymphocytes originate in the bone marrow; B lymphocytes mature there
and T lymphocytes migrate to the thymus to undergo their maturation. Once they have
completed their maturation, both types of lymphocyte enter the bloodstream, from which
they migrate to the peripheral lymphoid organs: the lymph nodes, the spleen, and the
mucosal lymphoid tissues. Each of these tissues traps the antigen from sites of infection
and presents it to migratory small lymphocytes, thus inducing adaptive immune
responses.
1.1.2 Molecular mechanism of the inflammatory cascade regulation
The migration of leukocytes from the vasculature to the sites of pathogenic exposure is
one of the most important mechanisms of the innate immune system. In response to
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inflammatory signals produced by cytokines (TNF-α, IL-1, IL-6 and others), leukocytes
migrate through the endothelium toward the inflamed tissue [3], thus leave the blood
circulation. These events predominantly take place in the postcapilary venuls, which are
lined with specialized endothelial cells, and termed high endothelial venules (HEV).
Receptor-mediated adhesion to the endothelial cell wall is a pre-requisite for leukocyte
extravasation. Since this process includes several overlapping steps mediated through
different cell adhesion molecules, it is called inflammatory adhesion cascade [4], (figure
1.3).
Figure 1.3: Shematic representation of leukocyte adhesion cascade in inflammation. Adopted from [7].
Neutrophils are the predominant leukocyte subset that mediates the acute inflammation.
When an injury occurs, inflammatory mediators like histamine, thrombin and
lipopolisaccharide will induce cytokine release from the damaged tissue. Cytokine stimuli
direct neutrophil migration toward the inflamed tissues and stimulate endothelium to
transiently express P- and E-selectin [5,6] whereas L-selectin is constitutively expressed
on rolling neutrophils [8]. The interactions of selectin family of cell adhesion molecules
with their ligands expressed on either endothelium, or leukocytes, are of low affinity and
present a molecular base for transient leukocytes-endothelium contacts. At velocity of 2
mm/s, flowing leukocytes are directed from the blood flow toward the endothelial cell wall
and present the first events in the inflammatory cascade. The initial contacts are still
reversible and alternate with phases of free-moving cell. They are therefore termed
“leukocyte capture”, or “tethering” [9].
Based on this mechanism, the number of fast associating and dissociating ligand-
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receptor interactions increases, leading to leukocytes rolling across the affected
endothelium. The leukocytes are slowed down in this phase, rolling at 20 µm/s,
concentrating them locally on the vessel wall and enabling transmission of secreted
cytokines from endothelial cells [10]. The cytokine stimulus trigger expression and
activate other families of adhesion molecule: integrins on leukocytes interact with their
ligands from the immunoglobulin (IgG)-superfamily (ICAM-1, VCAM-1), that are
expressed on the activated endothelium [11]. This interaction is much stronger then one
mediated by selectins and leads to the firm leukocyte adhesion and subsequent
extravasation into the tissue. The endothelial cell monolayer in its resting state is
associated through homophilic interaction between the IgG superfamily molecule
PECAM-1. Homodimers are then formed with molecules on the opposing endothelial
cells [9,12]. Extravasation finally takes place when leukocytes integrins bind to PECAM-
1, interrupting the aforementioned homophilic interactions, allowing the leukocytes to
transmigrate to sub-endothelial matrix.
1.1.3 Adhesion molecules involved in leukocyte migration from blood
vessels during the inflammatory response
Endothelial cells lining the vascular spaces of postcapillary venules in peripheral tissues
are among the first regulators of inflammation. The upregulation of adhesion molecules
by endothelial cells, as well as the ability of endothelial cells to present chemo-attractant
cytokines, leads to the adhesion of leukocytes to the endothelium, a prerequisite step
before their transmigration into inflamed tissue [12-15]. The overlapping extracellular
adhesive properties of cell adhesion molecules important for leukocyte recruitment
during inflammation, namely integrins, the IgG-superfamily of adhesion molecules and
selectins are discussed in the following text.
1.1.3.1 Integrins
Integrins are a group of heterodimeric transmembrane glycoproteins found on different
cells that mediate cell-cell and cell-extracellular matrix adhesions [13]. All integrins
comprise one α- and one β-subunit, which together form an extracellular ligand-binding
site. Cytoplasmic tails of integrins provide phosphorylation sites and are related to the
integrin-mediated assembly of cytoskeletal linkages involved in signal transduction [16].
These serve to modulate many aspects of cell behavior, including proliferation,
survival/apoptosis, shape, polarity, motility, gene expression and differentiation. There
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are 8 different β- subunits (β1-β8) that associate with one of 18 α-subunits to form at least
24 known receptors in a variety of cells, including lymphocytes, leukocytes, and
platelets. Integrins are capable of mediating cell-cell binding but also are involved in cell
interactions with extracellular proteins such as laminin, fibronectin, vitronectin, and
fibrinogen. Integrins are mostly expressed in an inactive state. In case of leukocytes,
integrins are inactive in the “resting” state, but are rapidly activated upon cytokine
stimulation. The mechanism of integrin activation relays on a conformational switch
between the closed form of low affinity or “inactive” form, and the open form that is
active. This switch is coupled with ligand binding or with known activation stimuli, such
as metal ions. The leukocyte firm adhesion to the activated endothelium is mediated
primarily by integrins that consist of β2-subunits (CD18). These are macrophage antigen-
1 (Mac-1; αMβ2; CD11b/CD18), lymphocyte-associated function antigen-1 (LFA-1; αLβ2;
CD11a/CD18), and a third CD18 integrin (CD11c/CD18; αxβ2). LFA-1 is the predominate
integrin used for lymphocyte migration, whereas Mac-1 has emerged as the more critical
integrin in most models of neutrophil-dependent inflammatory responses [16-18]. Pre-
formed Mac-1 is stored in three separate PMN compartments: secretory vesicles,
specific-granules, and gelatinase granules and can be rapidly mobilized to the PMN
surface. This occurs after exposure to degranulation stimuli such as the bacterial peptide
formyl-methionyl-leucyl-phenylalanine (fMLP), as well as to weaker stimuli as LPS and
TNF-α. Inflammatory stimuli can also promote transcription and translation of Mac-1
genes, thus prolonging the integrin involvement during inflammation. Very late antigen
(VLA-4, α4β1 integrin) has been identified on both activated human lymphocytes and
neutrophils, and mediates tethering, rolling and firm adhesion [19,20]. Leukocyte
integrins mediate firm adhesion to the activated endothelium through the interaction of
their counter receptors of the immunoglobulin superfamily [21].
1.1.3.2 Immunoglobulin superfamily of adhesion molecules
The immunoglobulin superfamily of cell adhesion molecules comprises a very diverse
group of adhesive receptors. Members of this family are defined by the presence of one
or more copies of the IgG fold, a compact structure with two cysteine residues separated
by 55-75 amino acids, arranged as two antiparalel β sheets [20]. Typically IgG CAMs
have a large amino-terminal extracellular domain containing IgG folds, a single
transmembrane helical segment, and a cytoplasmic tail [22]. Members of the IgG CAM
function in a wide variety of cell types and mediate many different functions, including
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acting as receptors for growth factors and mediating cell-cell adhesion rather than cell-
extracellular matrix interactions [23,24]. Predominantly members of this family function
as adhesion receptors, including intercellular adhesion molecule-1 (ICAM-1; CD54),
intercellular adhesion molecule-2 (ICAM-2), vascular cell adhesion molecule-1 (VCAM-1;
CD106), platelet-endothelial cell adhesion molecule-1 (PECAM-1; CD31) and the
mucosal addressin cell adhesion molecule-1 (MAdCAM-1). ICAM-1, ICAM-2 and VCAM-
1 are involved in the adhesion of T cells to endothelial cells by serving as surface ligands
for the integrins LFA-1 (αLβ2) and α4β1 [12].
ICAM-1 and ICAM-2 (CD102) are expressed on a variety of haematopoietic and
nonhaematopoietic cells, including B and T cells, fibroblasts, keratinocytes and
endothelial cells. The expression level of ICAM-1 can be up regulated by various
cytokines such as TNF-α and IL-1β. ICAM-2, however, is expressed constitutively and its
expression is not cytokine-inducible. These molecules are counter-receptors for LFA-1
(CD11a/CD18). A portion of the cytoplasmic region of ICAM-1 has been shown to bind to
the cytoskeleton of COS cells transfected with the cDNA of human ICAM-1, indicating
homophilic interaction [12,24-26]. Linkage with the cytoskeleton may localize ICAM-1
within regions of the endothelial cell membrane in order to facilitate leukocyte adherence
and transmigration. The expression of ICAM-1 in primary melanoma is related to the
presence of distant metastases, although precise involvement of ICAM-1 in the process
of metastasis has not been clear yet. Elevated levels of soluble ICAM-1, which still retain
the binding site for LFA-1 in its extracellular domain, have been found in the serum of
melanoma and ovarian cancer patients. It has been suggested that this active form of
ICAM-1 can inhibit binding sites on cytotoxic T-cell and natural killer cells and that in the
presence of ICAM-1 tumor cells might escape immune destruction. Since human
melanoma cells have been shown to release ICAM-1, and its increased level in serum
results in a non-specific inflammatory response, it has been proposed that circulating
levels of ICAM-1 reflect the formation of metastases, possibly as a consequence of
facilitating disseminating tumor cell binding [27].
VCAM-1, a 90-110 kDa glycoprotein is expressed on the surface of activated
endothelium and variety of other cell types, including dendritic cells, tissue macrophages
and bone marrow fibroblasts. VCAM-1 expression on endothelial cells can be up-
regulated by several cytokines, such as IL-1β, IL-4, TNF-α and interferon-γ (IFN-γ).
VCAM-1 interacts with the leukocyte integrin α4β1 on many different cells including
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eosinophils, monocytes, and also certain tumor cells, and with α4β7 on activated
peripheral T cells [19,20]. Thus, α 4β1/VCAM-1 interactions, like LFA-1/ICAM-1
interactions regulates the movement of lymphocytes out of blood vessels to the
inflammatory sites. Interaction of VCAM-1 with α4β1 integrin expressed on certain tumor
types presents an important mechanism for the development of metastases in cancers
such as melanomas, osteosarcomas and neuroblastomas [14,21].
The platelet-endothelial cell adhesion molecule PECAM-1, also knows as CD31 or
endoCAM, is a 130 kDa glycoprotein found on endothelial cells, platelets, monocytes
and neutrophils [23,24]. Several observations suggest that PECAM-1 is involved in
leukocyte adhesion, transmigration, and particularly in the preferential migration of naive
and CD8+ T cells across HEV [28]. PECAM-1 is homologous to both CEA and ICAM-1
proteins and has been shown to contribute to both homotypic and heterotypic cell
adhesion by interaction with either itself or with the integrin αvβ3. Unlike ICAM-1, which is
expressed over the entire surface of resting endothelial cells, PECAM-1 is expressed at
intercellular junctions of endothelial cells and its surface expression is not increased by
treatment with cytokines, such as TNF-α and IL-1 or by combinations of TNF-α and IFN-
γ. Binding of mAbs to PECAM-1 enhanced CD8+ T-cell adhesion to fibronectin or
VCAM-1, but not to fibrinogen or collagen, suggesting that it may cause activation of
integrins containing α4 subunits such as α4β1 or α4β7. Inhibition of PECAM-1 expression
on leukocytes or endothelial cells by treatment with soluble PECAM-1 or blocking
PECAM-1 mAbs inhibits monocyte or neutrophil transmigration in vitro. Treatment of
either the endothelium or the leukocytes separately is equally effective, suggesting that
homophilic adhesive interaction is involved [12].
1.1.4 Excessive inflammatory reaction as a basis for pathological
processes
Excessive leukocyte accumulation in the inflamed tissue is a basis for pathological
inflammatory reaction, angiogenesis and tumor metastasis. In case of atherosclerosis,
myocardial and cerebral ischemia, hemorrhagic shock, thrombosis, diabetes-caused
microangiopathies, or rheumatoid arthritis, one has observed strong deregulation of
selectin expression and function in disease etiopathology. Atherosclerotic changes are
caused by accumulation of LDL (“low density lipoprotein”) in the blood vessel wall and
consequent inflammatory fibroid reaction. Monocytes are invading the inflammatory site
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to oxidize and remove materials from lipids and cholesterol, endothelial lumen
constraints, and arteries loose elasticity. The apparent monocyte’s invasion and
pathogenesis of atherosclerosis is mediated by E-, P-, and L-selectin and induced by
LDL. Higher expression of selectins, ICAM-1 and VCAM-1 and their correlation with the
atherosclerotic plaques was also proven in the animal models [26,29-31]. Nevertheless,
in E-selectin molecule, there are mutations typically found in young patients with hard
coronary disease that influence its functionality in vitro [31-33], whereas L-selectin
mediates “secondary capture” of leukocytes to the atherosclerotic liaisons. The level of
soluble selectins in serum was also thought to correlate with the expression of
atherosclerotic plaques, however, these observation are still contradictory [26,34-37].
In the case of apoplexy, or cerebral ischemia, there is an acute disruption of cerebral
oxygen supply, caused by the massive hemorrhage, or the closure of cerebral
atherosclerotic blood vessels. In myocardial infarction, however, a dysfunction of blood
circulation results in deficiency of myocardial oxygen supply, and irreversible damage of
the affected tissues. As a consequence of cerebral and myocardial ischemia, sometimes
reperfusion results in pathological acute inflammation, where leukocytes extensively
migrate in the tissue [38,39]. P- and E-selectine have been up-regulated in these cases,
and blockade of their function has been shown to significantly decrease excessive
neutrophile migration [40-42].
Hemorrhagic shock, a disparity between heart volume and actual systemic circulation
needs, is first manifested on the macrocirculatory level, and then as a microcirculatory
dysfunction. Together with subsequent recirculation, it is also considered as an
ischemia/reperfusion injury, and lead to the excessive neutrophile infiltration and
increased adhesion to the affected tissue. This may cause severe pathological changes
in organ that finally lead to the systemic organ failure. Blocking selectin function turned
out to be an effective and protective approach in many in vitro studies, as well as in
animal models [8,43-49].
One of the most prominent autoimmune diseases, rheumatoid arthritis is caused by
pathological reaction of the immune system. Pathophysiological incident is an
inflammation of the synovial membrane of the joints, characterized with a strong
infiltration of the phagocytic leukocytes. Synovial membrane is enlarged and presses on
the surrounding bones. This way synovial membrane liberates permanently inflammatory
mediators that support chronicle inflammation. Although the exact molecular
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mechanisms of rheumatoid arthritis have not been known yet, E-selectin accumulation in
rheumatoid tissue, and its active role in pathogenesis of rheumatoid arthritis is very well
documented. Serum levels of soluble E- and P-selectin have been used as the
molecular markers for the active inflammation in rheumatoid arthritis [50-53].
Antirheumatoid therapeutics probably exert partial effect on the adhesion of
polymorhonuclear neutrophils to the endothelial cells: they reduce cytokine mediated
adhesion and expression of E-selectine on activated HUVECs. In case of many
malignant diseases, primary tumor cells migrate through vascular system to different
sites in organisms in a complex process:
1. Tumor cells ablation and migration in surrounding area by adhesion on the
components of the exracellular matrix.
2. Hydrolytic activity of tumor cells, matrix destruction and consequent cell migration
3. Tumor cells proliferation through the blood and lymph, avoiding immune system,
and adhesion to appropriate part of blood vessels wall.
4. Tumor cells invasion through the endothelium and the extra cellular matrix in the
parenchyma beneath.
It is known that tumor cells can adhere to the endothelium, at least in some cases,
following the mechanism of leukocyte adhesion to the endothelium in the inflammatory
reaction. In addition, selectins play an important role in metastasis as well [54-58]. There
is a huge body of evidence that in case of colon carcinoma, tumor cells expression of E-
selectin ligands with the sLex and sLea epitopes correlates with the metastatic behavior
of the tumor [59-62]. For the breast tumor, aforementioned correlation is also worth,
whereas in other tumors it is still controversial. Cancer studies with animals have been
conducted mostly on colon and lung carcinomas, focusing predominantly on metastasis-
dependent induction and up-regulation of selectins [63-69]. Tumor tissues and serum of
patients have also been examined in order to determine and quantify changes in selectin
levels [5,69-84].
1.2 Selectins
The selectins mediate the initiation of the cell contact between leukocytes and
endothelial cell. This selectin-mediated docking of lekocytes to the blood vessel wall in
combination with the rapidly flowing blood stream leads to a rolling movement of
leukocytes on the endothelial cell surface. Capturing leukocytes from the rapidly flowing
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blood stream to the blood vessel wall is a very special example of cell contact formation,
which has to overcome considerable shear forces. Thus, in most cases, these
interactions are characterized by relatively rapid on/off kinetics of binding. The selectin
family of cell adhesion molecules is the most recently identified gene family of adhesion
molecules [3,5,46-49] that consists of only three member proteins. The members of this
family, termed L-selectin, E-selectin, and P-selectin, have cluster designations CD62L,
CD62E, and CD62P, whereas nomenclature corresponds to the expression site [85].
Selectins share an overall structure and primary sequences and exhibit similarities in the
cognate glycans that contribute to their adhesion function. Genomic organization of
selectins has been examined for human and mouse [86,87]. In situ hybridization
indicated that all three selectins are members of a gene complex on human
chromosome 1, bands q21-24. Human E-, P-, and L-selectin share a common structural
motif including a N-terminal C-type lectin domain, an epidermal growth factor-like
domain, a variable number of consensus repeats homologous to those in complement
binding proteins (CR domains), a membrane spanning segment, and a short cytoplasmic
region (figure 1.4).
Figure 1.4: Domain organization of selectins. Adopted from [58].
Amino acid sequence identity within the lectin domain among different selectins is 52%,
EGF-like domain 47%, and consensus repeats 35%. The high degree of conservation
supports the central role of lectin and EGF domains in interaction with carbohydrate
determinants of the ligands, but raises questions as to how the specificity of each
selectin for its ligand is accomplished.
The C-terminal part of the proteins is located in the cytoplasma and it is connected to the
cytoskeleton. The functional role of this part has not been thoroughly elucidated yet, but
it plays an important role in signal transduction. In comparison with the other parts of
molecule, the cytoplasmic tail is rather small, 17 amino acids in L-selectin, 32 amino
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acids in E-selectin, and 35 in P-selectin, followed by the single transmembrane domain.
Further molecular extension into extracellular part is accomplished through consensus
repeats. Each consensus repeat is 60 amino acids long, contains 3 disulfide bridges and
differs throughout the selectin family: human L-selectin contains 2, E-selectin 6, and P-
selectin 9 consensus repeats. The evidences for the role of consensus repeats are
partially contradictory. Majority indicates that, although the CRs are not required for
ligand recognition, they do enhance ligand binding affinity. It has been shown that the
reduction in the number of consensus repeats decreases the ability of P-selectin to
support leukocyte rolling [88]. This indicates the importance of sufficient distance
between plasma membrane and carbohydrate binding domain of selectins, which is
provided and mediated by consensus repeats. The L-selectin adhesion-blocking
antibody Mel 14 recognizes an epitope in the lectin domain. It showed very weak binding
to a construct lacking the CR domains, and a decrease in lectin-specific interaction with
the peripheral lymph node endothelium, suggesting again that the CR domains may be
involved in induction of lectin domain conformation and enhancement of its activity [89].
Similar data were obtained in case of E-selectin, where soluble constructs containing the
lectin and EGF-like domain with different number of consensus repeats have been
generated by several groups [90-92]. Experimental data showed decreased selectin
binding activity toward leukocytes or engineered cells, in case of reduced number of
consensus repeats. However, the studies with recombinant chimeric selectins generated
by domain switch between E- and L-selectin, and with not less then two CRs, implied
that only lectin and EGF-like domains were the minimal structural unit required for
specific ligand binding [92]. On the other hand, the functional importance of the CR
domains was also supported by the isolation of the mAb EL-246 with an epitope in a
common region of the CR domains of both E- and L-selectin. Since this antibody was
blocking the function of both selectins, these results demonstrated the presence of a
conserved epitope in the CR domains of L-and E-selectin crucial for leukocyte-
endothelial interaction [89].
Domain-deletion studies of E-selectin and domain-exchange studies between L-, and P-
selectin suggested that EGF-like domain is also involved in cell adhesion, either in
stabilizing the conformation of the lectin domain, or in direct interaction with the ligand
[90,93-99]. Studies with the blocking antibodies against EGF-like domain of L-selectin
showed the inhibition of L-selectin mediated cell adhesion [100,101], consistent with the
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studies done with a peptide derived from the EGF-like domain residues 127-139, which
effectively inhibited monocyte adhesion to activated endothelial cells [102]. However,
isolated EGF-like domain of P-selectin failed to inhibit HL-60 cell adhesion to CHO cells
expressing P-selectin, which may argue against the direct involvement of the EGF-like
domain in the adhesion. The experiments with the panel of monoclonal blocking
antibodies for all three selectins have determined the functional epitopes in the lectin
domains. Identification of the amino acids critical for the ligand binding in mutational
studies, and predictions based on comparison with the crystal structure of mannose
binding protein (MBP) was consistent [96,97,103]. These data were confirmed with the
X-ray structure of the lectin and EGF-like domains of E-selectin and aforementioned co-
crystallized complexes of E-, and P-selectin [99,104]. In case of E-selectin, lectin domain
possesses a globular structure with the very flat and shallow binding pocket for the sugar
ligand, whereas P-selectin LecEGF construct has a very similar conformation. The
movement of different loops in the EGF domain of P-selectin and slightly changed
surface amino-acids exposures causes minor differences in binding pockets, with
different charges present.
The regulation of selectins presence on the cell surface is important for the control of
leukocyte extravasation. In case of E- and P-selectin, this ensures that these selectins
are only present on the endothelium in inflamed tissues. L-selectin, in contrast, is
constitutively expressed on leukocytes, in agreement with its special function in the
continuous process of lymphocyte homing. E-selectin is induced by cytokines such as
TNF-_ or IL-1β and by lipopolysaccharide (LPS) as was first found for HUVECs
[100,105]. Induction occurred on the transcriptional level, with the expression profile
desand within 3–4 h after stimulation, maximal levels of E-selectin protein are expressed
at the cell surface and basal levels are reached again after 16–24 h [5]. The 5’ flanking
region of human E-selectin were sequenced and regulatory elements for the activation of
E-selectin promoter are NF_-B binding sites [106-110] and one is an ATF-binding
element [111-113]. Several other inducers, like interleukin-10 interleukin-3, oncostatin M
have been studied as well, which, however, differ in the overexpressed loci and
overexpression intensity [114-116]. LPS from gram-negative bacteria, and lipoteichoic
acid from gram-positive bacteria were also found to induce E-selectin expression [117].
Apart from soluble factors, leukocytes-contacting endothelial cell surface can also
modulate E-selectin expression [118,119].
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Inhibition of E-selectin mediated adhesion can be achieved with IL-4 through STAT6
signaling, glucocorticoids, transforming growth factor-β, and elevated cAMP can
counteract cytokine-induced expression of E-selectin [120-124].
P-selectin is inducible by two different mechanisms. It is stored in the _-granules inside
of platelets, and in Weibel-Palade bodies, wherefrom can be rapidly mobilized (minutes,
even seconds for platelets) to the cell surface of endothelial cells upon the stimulation
with thrombin, histamine, phorbol esters or Ca2+ ionophores [125]. Although both E- and
P-selectin are rapidly internalized, only P-selectin molecules can be recycled from
endosomes into the trans-Golgi network, where they are targeted to Weibel-Palade
bodies, or are delivered, as in case of E-selectin, into the lysosomes [126,127]. A
second regulation mechanism for P-selectin is similar to those observed for E-selectin,
whereas TNF-α stimulates the transcript and the protein level of P-selectin [128-130]. On
the contrary, in HUVECs P-selectin expression could neither be stimulated by LPS nor
by TNF-α  or IL-1β  but with oncostatin M and interleukin-4. L-selectin, which is
constitutively expressed on myeloid cells and large sets of the lymphocytes can be
down-regulated on the transcriptional level during lymphocyte differentiation from a naive
to memory cell type [131-133].
Induction of L-selectin mediated adhesion in the inflammatory process is achieved by the
up-regulation of L-selectin ligands upon cytokine activation, mostly PSGL-1 [105]. On
lymphocytes as well as on neutrophils, cell activation causes rapid down-regulation of L-
selectin within minutes by proteolitic cleavage of L-selectin at an extracellular part
proximal to the cell membrane. Proteolytic shedding occurs on neutrophils within 1-5
min, and can be induced by a variety of chemoatractants and activating factors such as
fMLP, leukotriene B4, IL-8, TNF, GM CSF, calcium ionophores but not by granulocyte
CSF, macrophage CSF, IL-1, or interferon-γ [134,135].
In addition to a direct role in leukocyte capturing, selectins and their ligands are involved
in signal transduction, and the up-regulation of endothelial selectins has also been
modified through complex signaling effects [136]. Different studies had implicated
nonreceptor tyrosine kinases such as c-Src, and the MAP kinase cascade in selectin
signaling, as well as c-JUN N-terminal kinase and p38 kinase regulation pathways [137-
139]. Selectins also play a role in triggering the activation of β2 integrins. The E-selectin
led to enhanced β2 integrin-mediated binding to co-expressed ICAM-1 in the tissue
culture monolayer. The trigger was blocked by the inhibitors of Erk/MAP kinase cascade,
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indicating that the glycoprotein counter receptor for E-selectin on neutrophils actes in
these cells by MAPK-dependent pathway. PSGL-1 on leukocytes also led to the
activation of β2 integrins, in process blocked with tyrosine kinase inhibitors, whereas L-
selectin expressed on neutrophils and cross-linked by antibodies, activates β2 integrins
through p38 MAP kinase [94,140-142].
1.2.1 Structural specificities of P-selectin
P-selectin is found within the Weibel-Palade bodies of endothelial cells and in α-granules
of platelets. Sequences within the cytoplasmic domain of P-selectin mediate sorting to
the granule through the interactions with molecules that direct this process. Splice
variants of P-selectin transcripts yield forms of P-selectin that are without a
transmembrane domain, consistent with the fact that some P-selectin is released as a
soluble form [143-148]. The cytosolic tail of P-selectin undergoes phosphorylation at
specific threonine, tyrosine, and histidine residues, and myristoylation at a single
cysteine in this domain. However, post-translational modifications are still not thoroughly
desribed in terms of functionality.
P-selectin expression is under transcriptional control, with induction by TNF-α, IL-1β, or
LPS. The role of P-selectin in leukocyte recruitment and inflammation is a function of
both acute and chronic expression of P-selectin by endothelium and by platelet
activation-dependent P-selectin expression. P-selectin -/- mice exhibit a substantial delay
in neutrophil recruitment in the context of acute inflammation relative to wild-type mice,
indicating that P-selectin plays an important part in the early phases of leukocyte
recruitment. Endothelial P-selectin contributes to chronic inflammation, whereas platelet-
derived P-selectin also contributes to leukocyte trafficking, as well as to wound healing
and blood clotting mediating the adhesion of neutrophils, monocytes and natural killer
cells. This adhesion represents a mechanism to augment the recruitment of leukocytes
and platelets to sites of vascular compromise. Platelet-derived P-selectin contributes to
hemostatic processes by its ability to stimulate monocytes to express tissue factor and
by facilitating fibrin deposition during clot formation, and can also mediate platelets
function in tumor angiogenesis [84,149,150].
Crystal structure of lectin and EGF domain (LE) of P-selectin has been solved as well as
the structure of P-selectin co-crystalized with sLex and N-terminus of the PSGL-1 [99].
The P-LE crystal structure has an overall conformation similar to that of E-LE, consistent
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with the 60% sequence identity between selectins in these domains. The sLex binding
site has a common feature, and the basis for the metal-dependency of selectin binding is
the coordination of a calcium ion by the side chains of Glu80, Asn82, Asn105, Asp106,
and the backbone carbonyl of Asp106. Differences in the binding site are defined by the
Ser97-Pro98-Ser99-Ala100. Structural reasons are also responsible for P-selectin lower
affinity toward sLex compared to E-selectin (7.8 mM vs.1 Mm, respectively). In the P-
selectin molecule there is a small number of contacts between lectin and EGF-like
domain [104,151,152] within the residue 135-139, which argues that this interface is
inherently flexible. P-selectin may be the most flexible in this region, because of
substitution of Gly138 for Asn138, which can not form stabilizing hydrogen bonds to the
lectin domain, and the flexibility of the molecule may be essential for maximizing
contacts between P-selectin and PSGL-1 on free flowing leukocytes.
1.2.2 P-selectin ligands
Carbohydrate binding epitope for P-selectin is fucosylated lactosaminoglycan from blood
group determinants, Lex, and of the higher affinity, its sialylated form, sialyl lewisx
(Neu5Acα2,3Galβ1,4[F u cα 1,3 ]G l c N A c - O -R) or its stereoisomer sialyl Lewsa
(Neu5Acα2,3Galβ1,3[Fucα1,4]GlcNAc-O-R) [7,148,153-155]. The affinity for sLex is in a
low millimolar range, but there are other glycoprotein ligands with the nanomolar binding
affinity for P-selectin. The higher affinity for these ligands is a consequence of either
carbohydrates composition presented, or multivalent interactions because of
oligomerization of many epitopes
The binding of P-selectin to neutrophils is abolished upon sialidase treatment,
suggesting that sialic acid might be a critical determinant required for P-selectin
recognition. However, the binding of P-selectin to neutrophils is of much higher affinity
than to nonmyeloid cells, originally suggesting that myeloid cells possess a unique
ligand(s) for P-selectin. P-selectin glycoprotein-1 (PSGL-1) is so far the best
characterized ligand for P-selectin, isolated using 125I-labeled P-selectin blotting and
affinity chromatography on immobilized human P-selectin. As a functional ligand, PSGL-
1 is expressed on essentially all blood leukocytes, myeloid, lymphoid and dendritic cells
wherefrom the purified ligand PSGL-1 is isolated, as a disulfide-bonded glycoprotein of
approximately 250-kDA [156,157]. In contrast to other selectin ligands, PSGL-1 binding
to P-selectin is characterized by high-affinity binding (Kd in the range of 100 nm) and
very fast association and dissociation rates [98].
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The cDNA encoding PSGL-1 was expression-cloned in COS cells transfected to
coexpress an _1–3(4)-fucosyltransferase (human FucT-III), which allows both sialyl Lex
and sialyl Lea synthesis in these cells. Each subunit of human PSGL-1 contains 70
serine and threonine residues in the extracellular domain that are potential sites for O-
glycosylation and three potential sites for N-glycosylation. The murine PSGL-1 also
contains numerous extracellular serine and threonine residues and two potential sites for
N-glycosylation.
Figure 1.5: PSGL-1 structural requirements. Adopted from [7].
Treatment of purified PSGL-1 with sialidase abolishes its binding to P-selectin, but
treatment of neutrophil-derived PSGL-1 with peptide N-glycosidase F, which removes
most, if not all, N-glycans on the molecule, does not affect its recognition by P-selectin
[154,158]. The involvement of O -glycans was supported by the observation that
treatment of either neutrophils or purified PSGL-1 with the O-sialoglycoprotease from
Pasteurella hemolytica, an enzyme that degrades sialylated mucins, blocks binding of
the cells or ligand, respectively, to P-selectin. In addition, when HL-60 cells are treated
with benzyl-_-GalNAc, which inhibits extension of O-glycans, the cells bind less to P-
selectin. Other studies demonstrated that treatment of isolated PSGL-1 with endo-_-
galactosidase, significantly reduces binding to P-selectin, thus indicating that
polylactosamine, presumably on O-glycans, may also be important for the binding. The
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structures of the O-glycans of native PSGL-1 purified from human HL-60 cells reveal that
most contain a simple Core 2 structure with one or two sialic acid residues and generally
lack fucose residues. Further binding epitope is determined by first twenty amino acids
on N-terminus of PSGL-1[155,159,160]. Sulfation as requirement for P-selectin binding
was confirmed by treatment of purified PSGL-1 with a bacterial aryl sulfatase that
abrogates binding of the molecule to P-selectin. The critical binding domain is in the
extreme amino terminus of PSGL-1. Furthermore, recombinant forms of PSGL-1 in
which the three tyrosine residues have been changed to phenylalanine also fail to bind
P-selectin. Such data point to a model in which the combination of tyrosine sulfate
residues and oligosaccharides on the protein are required for high-affinity binding to P-
selectin. Replacement of all three amino-terminal tyrosine residues with phenylalanine
abolishes binding of the recombinant PSGL-1 to P-selectin, but not E-selectin.
Interestingly, only one of the three potential tyrosine sulfate residues is absolutely
necessary for binding to P-selectin. Together with the threonine mutation to alanine,
these data support the model where the C-type lectin domain of PSGL-1 may contact
tyrosine sulfate residues and the sialyl Lex structure on a core-2 O-glycan at Thr-57.
The specific in vivo functions of PSGL-1 have been explored using blocking antibodies
to the protein and recombinant forms. Monoclonal antibody PL1and its F(ab) fragments
dramatically reduced rolling of human polymorphonuclear neutrophils and HL60 cells in
venules of acutely exteriorized rat mesentery, indicating that PSGL-1 is important in vivo
for rolling of myeloic cells in mesenteric venules at physiologic shear stress. In a rat
model of ischemia/reperfusion injury, treatment of animals with recombinant PSGL-1
significantly enhanced rat survival and liver function and recovery. PSGL- blocking
antibodies to mouse PSGL-1 blocks entry of T-helper-1 cells into inflamed areas of the
skin during a cutaneous delayed-type hypersensitivity reaction model [157].
1.2.3 Structural specificities of L-selectin
L-selectin is a glycoprotein that varies in size according to the type of leukocyte in which
it is produced. The protein is termed L-selectin and has been previously referred to as
LEC-CAM, LAM-1, CD62L. The polypeptide sequence derived from the cloned cDNAs
predicted a molecule corresponding to a type I transmembrane glycoprotein with a major
amino-terminal extracellular segment [46,161]. The amino-terminal segment of the
mature protein shows primary sequence similarity to other members of the C-type lectin
family. The amino-terminal 116 residues of mature L-selectin protein share
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approximately 25–30% amino acid sequence identity with other C-type lectins, especially
mannose-binding proteins. The functional contributions of each domain within L-selectin
have been examined using antibody blocking approaches [97] and recombinant L-
selectin chimeras. In general, these studies confirm that the CRD in L-selectin is directly
involved in adhesion interactions with glycan-based ligands, including especially amino
acids within the carboxy-terminal portion of the CRD. Such studies also indicated that
the EGF-like domain plays an important part in helping to maintain the CRD in its proper
configuration for ligand recognition, and the two CR repeat segments within L-selectin
are required to maintain it optimal [89]. Apart from ligand recognition, the cytoplasmic
domain of the receptor is essential for L-selectin to support leukocyte rolling and binding
of lymphocytes to HEV [162].
Unlike in case of endothelial selectins, crystal structure of L-selectin has not been solved
yet. Pioneer models [97,163] have been made based predominantly on the structure of
the rat manose binding protein, until the crystal structure of E- and P-selectin was
solved. Since the lectin domains of selectins are highly homologous, and hydrophobic
cores are absolutely conserved, it is ti expect that the structures of E-, P- and L-selectin
will share extensive similarity as well. L-selectin is expressed on blood monocytes,
neutrophils, subsets of natural killer cells, and T and B lymphocytes, including virtually all
lymphocytes of the “naive” phenotype, but not by lymphocytes that exhibit the “memory”
phenotype. L-selectin is also expressed in both early and mature hematopoietic cells in
the bone marrow, except that cells of the B-lymphocyte lineage seem to express this
molecule only near the latter stages of the B-lineage developmental program.
One unique feature that distinguishes L-selectin from other known adhesion molecules is
that it is cleaved from the cell surface within minutes after cellular activation in process
catalyzed by one or more metalloproteinases (secretases) [135,164]. L-selectin cleavage
generates a functionally active receptor that is present at relatively high levels (1-2
µg/ml) in serum therefore is proposed to moderate leukocyte/endothelial interaction and
leukocyte entry into tissue [165,166]. There is evidence that calmodulin regulates the
protease-dependent shedding process. It has been proposed that L-selectin shedding
serves to facilitate release of adhesion of cells from the endothelium during the
transmigration process [167].
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1.2.4 L-selectin ligands
Adhesion mediated by L-selectin is characterized by interactions of apparently low
affinity (0.1 mM range), exhibiting relatively rapid “on-rate” and “off-rate” characteristics.
These adhesive interactions operate predominantly under conditions of vascular shear
flow. Four glycoprotein ligands for L-selectin have been identified, which posses all
structural requirements for the successful binding: sulfation, sialylation and fucosylation
are required [168-170]. Initially, ligands were found on mouse lymph node HEV using
MECA-79. Glycosylation dependent cell adhesion molecule-1 (GlyCAM-1) is so far the
best characterized L-selectin ligand expressed by HEV of lymph nodes. This is a
secreted sialomucin [171,172] of 132 amino acids and 50 kDa, which contains numerous
serine and threonine residues with the high content of O-linked sugars. The sequence of
GlyCAM-1 does not predict a transmembrane segment, suggesting that any association
between GlyCAM-1 and the HEV cell surface must be mediated by virtue of a 21-residue
amphipathic helix at its carboxyl terminus, or more likely by interactions with one or more
other membrane-tethered molecules, as GlyCAM-1 binding to lymphocytes can stimulate
the activation of β1 and β2 integrins [173,174]. Protein is detectable in serum and has
been proposed to regulate the adhesive and/or activation state of L-selectin-bearing
leukocytes through interactions with L-selectin on such cells [175].
A second L-selectin ligand expressed by HEV is CD34, which is expressed throughout
the endothelial cells of the vasculature, on hematopoietic precursor cells, on a number of
embryonic fibroblast cell lines and in the brain [176,177]. Correctly glycosylated for L-
selectin recognition was expressed only in HEV of lymph nodes. CD34 is a type I
transmembrane sialomucin containing several mucin-like domains with numerous serine
and threonine residues predicted to be heavily O -glycosylated. Since CD34 is a
transmembrane glycoprotein, this L-selectin ligand is positioned to contribute
substantially to the process of tethering and adhesion of circulating lymphocytes to
lymph node HEVs. However, CD34 is clearly not the sole contributor of L-selectin ligand
activity in HEVs, since CD34-null mice maintain virtually normal L-selectin-dependent
lymphocyte homing activity [177].
A third molecule identified as an L-selectin ligand is termed MAdCAM-1, for mucosal
vascular addressin cell adhesion molecule [178]. MAdCAM-1 had been studied
previously as the ligand for the integrin-type lymphocyte homing receptor α4β7, a
molecule responsible for the bulk of lymphocyte homing to Peyer's patches. Biochemical
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experiments indicate that MAdCAM-1 expressed in mesenteric lymph nodes is
decorated with O-glycans that can support L-selectin-dependent leukocyte adhesion.
MAdCAM-1 is therefore predicted to maintain ligand activity for both L-selectin and the
α4β7 integrin [179,180] A fourth HEV-expressed L-selectin ligand is the transmembrane
sialomucin podocalyxin-like protein or PCLP. Like CD34, PCLP can be secreted, or
expressed on some vascular endothelia, but it is also expressed on the foot processes
of glomerular podocytes Levels of GlyCAM-1and secreted PCLP are downregulated 3-4
days after the induction of an immune response, whereas the levels of the cell-
associated ligands, CD34 and PCLP remain largely unaltered throughout the immune
response [181,182].
1.2.5 Structural specificities of E-selectin
The sequence of the human E-selectin cDNA predicts a type-I transmembrane
glycoprotein that belongs to the group of C-type lectins [5,95,183,184]. Structural
predictions and domain organization first were done in mutational studies [97]. To
increase the understanding of E-selectin structure and its interactions with the ligand, a
recombinant fragment of CRD and EGF-like domain of E-selectin was crystallized and
solved [104], as well as the structure of LecEGF domain co-crystalized with sLex [99]. E-
selectin posses 21 amino acids long signal sequence, cleaved in mature protein. An
extracellular, amino-terminal C-type lectin domain (carbohydrate recognition domain)
has 118 amino acids and forms a ligand binding site. This domain has 4 cystein residues
(Cys 19, 90, 109 and 117) that form 2 disulfide bridges in 1-4 and 2-3 pathways. Lectin
domain contains one potential N-linked glycosylation sites, the asparagine that is closest
to the N-terminus and is buried in the protein core. Overall fold of lectin domain is very
similar to the lectin domain of the rat mannose binding protein [185].
Epidermal growth factor-like domain shares the same general fold and arrangements of
disulfide bonds as other EGF-like domains [186]. It is a 36 amino acids long domain that
contains the 6 Cys residues forming 3 disulfide bridges (Cys122 and Cys133, Cys127
and Cys142, Cys144 and 153). Inner EGF-like domain, there are 2 N-glycosylation sites,
which are more surface-accessible. Interestingly, the interaction between lectin and EGF
domains is based only on the residues 135-139 of the EGF domain that make contact
with the lectin domain. These contacts include several hydrogen bonds that involve
main-chain atoms, whereas side chains of Glu135 and Gln30 is the only exception.
Although the contacts are limited, relative orientation of two domains is not prone to
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dramatic changes. The calcium binding site has been coordinated by the amino acids as
described on figure x and table x. It has been determined that E-selectin contains a high
affinity Ca2+ site with a KD of ≅ 3.5 µM [187]. However, at high Ca
2+ concentration, more
then one calcium was able to bind to E-selectin, consistent with compared
crystallographic data that differed in crystallographic conditions. When limited proteolysis
was used as a probe to monitor E-selectin conformation, Ca2+ binding protected the
protein from Glu-C endopeptidase [151,187,188]. This protective effect was further
augmented upon sLex binding, indicating that Ca2+ binding induces conformational
changes that facilitate ligand binding, which in turn, stabilizes Ca2+ binding. Loop
adjacent to the calcium binding region (residues 94-103), although does not directly
interact with it, adopts a conformation that tilts the loop toward Ca2+. Since Tyr94 and
Arg97 are critical for mediating cell adhesion, it is possible that unusual conformation of
this loop enhances proteins interaction with carbohydrate ligand. In case of Glu-C
digestion, major cleavage site was Glu98, within mentioned loop. Although proteolytic
fragments were still associated with each other through disulfide bonds, they did not
retain Ca2+, or ligand binding activity. Thus, maintaining the rigid conformation of this
loop is critical for E-selectin function. Residues Glu92 and Glu107, minor cleavage sites
are close to each other and adjacent to the Ca2+ site, and probably the removal of Ca2+
in E-selectin induces conformational changes in this region.
Consensus repeat domains in human E-selectin are 62 amino acids long and further
contribute to the N-linked glycosylation of the native protein, that can be up to 50% of
predicted molecular weight [90]. Whether this part is indirectly involved in binding or not,
is still not clearly understood. Short membrane spanning region of 21 amino aicds is
interesting in elucidating the mechanisms of E-selectin proteolytic cleavage, and
structural requirements for protease recognition. Cytoplasmic, intracellular domain is
involved in signal transduction events that are mediated through E- selectin, although
these mechanisms are still under investigation.
E-selectin expression during inflammation requires de novo gene transcription for
expression, and that is why it does not play significant role in the earliest phases (<2 h).
In E-selectin knockout mice, no defect of leukocyte recruitment to the inflamed
peritoneum is evident, unless P-selectin function is simultaneously blocked with
monoclonal antibodies [189]. The E-selectin serves an important role as a tissue-specific
homing receptor for leukocyte recruitment specifically to the skin, particularly for memory
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T cells. Leukocyte recruitment into human skin grafted onto severe combined
immunodeficient mice depends on E-selectin, as well as T-cell infiltration into sites of
cutaneous DTH, dermatologic disorders, and malignancy [190,191]. Since chronic
expression is frequently seen in the skin, it has been hypothesized that E-selectin serves
as a tissue specific “homing receptor” for leukocyte recruitment to the skin. Molecular
dynamics of adhesion receptors at the neutrophil membrane upon E-selectin binding,
show that E-selectin is unique among selectins in its capacity for clustering sialylated
ligands and transducing signals leading to neutrophil arrest in shear flow [94].
1.2.6 E-selectin ligands
E-selectin ligands are expressed by neutrophils, monocytes, eosinophils, memory-
effector T-like lymphocytes, and natural killer cells [184,190,191]. Each of these cell
types is found in acute and chronic inflammatory sites in association with expression of
E-selectin, thus implicating E-selectin in the recruitment of these cells to such
inflammatory sites [184,192]. E-selectin interaction with its ligands could be described as
a receptor-ligand-epitope interaction. Structural analysis of glycans present on the cells
that interact with E-selectin revealed glycoprotein and glycolipid components of the
myeloid cell membranes with the epitope defined as sialyl Lex tetrasaccharide as a
typical representative of a family of α2-3-sialylated and α1-3-fucosylated glycans that
exist on N-glycans, on lipid-linked glycoconjugates, and on O-glycans [193], figure 1.6.
Sialyl Lewisa is structural isomer that has also been recognized as E-selectin ligand
[194]. The latter set includes core-2-based lactosamine and polylactosamine chains.
PSGL-1, fucosylated variably, at one or more GlcNAc residues in the polymer has been
proposed as ligand for E-selectin [154] on neutrophils, HL-60 cells and T cells, without
necessity for the sulfation of exposed sugars. This binding is of lower affinity compared
to P-selectin and L-selectin binding to PSGL-1. Binding to E-selectin is also unaffected
by OSGP treatment, in contrast to P-selectin binding, which is abolished.
A second candidate E-selectin ligand is a glycoprotein purified from bovine γ/δ  T
lymphocytes, as a bovine homolog of PSGL-1 [195,196]. This protein has an unreduced
molecular mass of 250 kDa, and may also function as a ligand for P-selectin.
A third E-selectin ligand candidate, termed ESL-1, is a 150 kDa glycoprotein that has
been purified and characterized from mouse neutrophils and from murine myeloid
lineage cells Because of its location along the surface of microvilli, ESL-1 may function
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in a step after capturing. Although ESL-1 is a strongly preferred target for generation of
E-selectin –binding carbohydrates [196]. The human neutrophils had been found to
interact with E- selectin through L-selectin [197], in a binding that was dependent on the
sialic acid expressed on L-selectin. In recent studies has been demonstrated that that E-
slectin binding to neutrophils in suspension, or as they role on a monolayer cell substrate
in shear flow results in clustering of PSGL-1 and L-selectin, which was facilitated by fluid
shear and dependant on MAPK-regulated membrane transport processes [94]. Other
suggested E-selectin ligands include members of the non specific cross-reactive antigen
(NCA) family present on the human neutrophils [198], subpopulation of the β2 integrins
that carry sLex and the heavily sLex modified lysosomal membrane protein lamp-1 [199].
As already described, E-selectin affinity for the ligand epitope defined by sLex is 8-15
fold higher compared to P-selectin and L-selectin (0.8-1 mM) [200]. The insight into
molecular mechanism of this interaction was gained in co-crystalization of E-selectin
lectin and EGF-like domain with the sLex. These data revealed that the interactions were
almost entirely electrostatic in nature and that total buried surface area is relatively small
(549 Å2). The 3- and 4-hydroxyl groups of Fuc residue within sLex ligate the selectin-
bound calcium ion. These two groups make additional interactions with the protein side
chains that also bind the calcium ion. The 4-hydroxyl-group of galactose binds to the
side chain of Tyr94, while 6- hydroxyl group binds to the side chain of Glu92. The sialic
acid makes two interactions in the E-selectin, one to the side chain of Arg97, and the
other to the Tyr48. In P-selectin Arg97 is replaced by serine, thus eliminating an ion-ion
interaction and could partially rationalize higher affinity of sLex in E-selectin over P-
selectin [201].
Table 1.1: Interactions in binding site of E-selectin and sialyl Lewisx (bb: backbone, sc: side chain) [103].
Interacting moieties
Ca2+ -Fuc O-3
Ca2+ -Fuc O-4
Glu80 sc -Fuc O-4
Asn82 sc -Fuc O-4
Tyr94 sc -Gal O-4
Glu92 sc -Gal O-6
Arg97 sc -Gal O-1
Tyr48 sc -NeuAc COOH
Arg97 sc -NeuAc COOH
Ca2+ -Glu80 sc
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Ca2+ -Asn82 sc
Ca2+ -Asn82 sc
Ca2+ -Asn105 sc
Ca2+ -Asp106 bb
Ca2+ -Asp 106 sc
Figure 1.6: Model of E-selectin binding to sLex
1.2.7 Molecular mechanisms of selectin-ligand interaction
The principles that have emerged about the lectin-ligand interactions are following: the
binding sites are of relatively low affinity and are found in shallow grooves on the surface
of the proteins. Second, selectivity is mostly achieved via a combination of hydrogen
bonds (involving the hydroxyl groups of the sugars) and via van der Waals' packing of
the hydrophobic faces of monosaccharide rings against aromatic amino acid side chains.
Third, further selectivity can be achieved by additional contacts between the saccharide
and the protein, sometimes involving bridging water molecules or divalent cations.
Finally, the actual region of contact between the saccharide and the polypeptide typically
involves only one to three monosaccharide residues. As a consequence of all of the
above, these lectin-binding sites tend to be of relatively low affinity, but of high
specificity. The ability of such low-affinity sites to mediate biologically relevant
interactions in the intact system thus appears to require multivalency. Special molecular
mechanisms and contact between the cells are required for the recruitment of leukocytes
from the rapidly flowing blood stream.
To support leukocyte rolling, selectins have been proposed to have rapid kon (bond
association constant) and rapid koff (bond dissociation constant), as well as special
mechanical properties linking tensile forces and bond dissociation [202,203]. The ability
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to initiate rolling (capture or tethering) is most closely related to on rate, consistent with
the L-selectin being more efficient, because its intrinsic cellular on rate is higher then
those of vascular selectins. Actual rolling velocity, however, is determined predominantly
by the off rate; therefore, higher off rate caused higher rolling velocity. L-selectin indeed
has higher off rate, which might be due in part to shedding of the L-selectin, whereas E-
selectin has the slowest velocity. The differences in off rate between selectins are
reflected in bond life-times: the shorter the lifetime of the selectin-ligand bond, the higher
the off rate, and faster the velocity. Next important property of selectins to mediate the
rolling is the resistance to an increase in the off rate with increasing force applied to the
bond, phenomena termed “tensile strength”. This resistance to increased off rate is
important for the rolling, otherwise, selectin bonds would have very short lifetime, lower
then the minimum required to maintain rolling bonds on the trailing edge are broken,
whereas there would be no time for the new ones to form. Selectin ligand bond also
shows paradoxal lost of adhesion at very low shear, indicating requirements for a
threshold hydrodynamic shear, especially for L-selectin [204]. This is likely related to the
shorter bond lifetime of L-selectin, because very low shear may be insufficient to
promote new bond formation on the leading edge of the cell, before existing bonds
break. A threshold shear requirement may serve to inhibit leukocyte accumulation in
situations of abnormally low shear in the vasculature.
1.2.8 Development of selectin antagonists
Selectins are required for the earliest leukocyte recognition and rolling event and
therefore present an attractive therapeutic target to treat inflammatory diseases. Several
animal studies have successfully validated the use of selectin inhibitors for the treatment
of inflammation in applications such as asthma, arthritis, ischemia/reperfusion, and
transplantation [205-208]. SLex is a key structure mediating selectin-ligand interaction
and pharmacophores of sLex-selectin interaction have been described [209,210], figure
1.7.
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Figure 1.7: The bioactive conformation of sialyl Lex is docked into the lectin domain on the surface of E-
selectin.
However, according to the Lipinski’s “rule of 5” that defines optimal requirements for
potent new chemical entity, sLex is only a good carbohydrate scaffold that has to be
optimized toward lead and further toward new chemical entity that can reach the market
[211]. Therefore, based on the rational design of the bioactive conformation of the native
ligand, different approaches have been taken to improve its drugability, i.e. to simplify
sLex structure and improve stability, cost-effectiveness, and synthesis. Mimics of sLex
could be sorted on the basis of number of sugars in the molecule to three, two, and one
sugar-containing molecules, however, maintaining the key interactions with the protein
[212]. Several different glycommimetics have been developed on this carbohydrate
scaffold and E-selectin inhibitors with low micromolar range IC50 have been synthesized
[213-216]. Since the selectin-ligand interactions are multivalent, inhibitors presented in a
multivalent form should posses increased potency. Polymers, liposomes and protein
conjugates containing sLex or similar carbohydrates have shown increased binding to E-
and P-selectins relative to their monomeric derivatives [217].
Several other groups have produced libraries of compounds, fucopeptides or β-C
mannoside-based peptides [218-220]. Some of the earliest inhibitors of the selectins
were monoclonal antibodies directed against specific selectin molecules. These
antibodies have the advantage of a high degree of a specificity, but they cross reacted
with a few species, and were effective only at doses of 1-2 mg [221]. The most
advanced selectin inhibitor TBC-1269, a low molecular weight dimeric glycomimetic is
currently in the phase II clinical trial for childhood psoriasis whereas it failed to show any
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benefit in phase II clinical trial for asthma [222,223]. The anti-inflammatory effects of this
mimetic are still contradictory [224].
1.3 Recombinant protein expression systems
With the rapid progress in biotechnology, optimal protein expression is of great
importance, since it has to meet challenging requirements of structural biology,
chemistry and drug discovery. Parameters to be considered, when choosing an
expression system, are the nature of the protein to be expressed, amount of
recombinant protein needed in combination with the intended use, the design of a
suitable expression vector for an expression system (including a potential tagging) and
the availability or establishment of appropriate assay systems and a tentative purification
protocol for the recombinant protein. For each individual product, the most suitable
expression system has to be identified and optimized individually, by taking into account
the properties of product and organism. The overall decision criteria for the choice of an
expression system are the pharmacological activity profile of the yielded protein in
context with posttranslational modifications and rentability.
1.3.1 Mammalian expression system
Mammalian system for recombinant protein expression is particularly useful for the
expression of proteins with complex post-translational modifications, predominantly
disulfide bond formation and complex glycan pathways. Although expression of many
functional proteins can be achieved in E.coli, sometimes it is possible to express
extracellular domains of mammalian proteins exclusively in mammalian system.
Compared to the other expression systems, the yield, time and costs are more
consuming in mammalian systems, although significant progress has been done
especially in system optimization in preparative scale protein production [225,226]. The
key factors for success in recombinant protein expression are transfer techniques,
optimal cell culture maintenance and careful selection of expression plasmid [227,228].
Gene transfer via transfection plasmid leads either to stable integrated copies of the
transgene into the host genome (stable expression), or to an episomally replicating
plasmid which are gradually lost (transient expression). Preferable are mammalian
systems like CHO, BHK cells and myeloma cells for stable protein expression, and COS
cells for transient expression [229]. These systems have the further advantage of being
43
recognized as safe regarding infectious and pathogenic agents and therefore have a
higher acceptance by regulatory bodies.
1.3.2 Bacterial expression system
The most widely used recombinant protein expression systems are those bacterial
systems using Escherichia coli as host cell. E.coli can be easily genetically manipulated,
has a short doubling time and can be cultivated on inexpensive media. Strategies for
gene expression in E.coli include intracellular expression, secretion of the protein into
the periplasmic space and very rarely used protein secretion into the medium. However,
for functional analysis the expressed proteins have to be in their native state. Due to the
membrane structure, the low chaperone and foldase level and the high periplasmic
protease concentration, major problems arise that include cell toxicity, inefficient
translation, improper processing or post-translational modifications [230]. Some of these
problems can often be solved by testing differently tagged/non-tagged proteins and
E.coli strains, optimizing expression conditions by lower growth temperature and varying
the induction levels. Furthermore, it may be reasonable to test different E.coli strains
with different genetic background, because certain strains tolerate some proteins better
than others and allow higher levels of expression before forming inclusion bodies.
Modulation of the protein primary structure can also condition E.coli strains to exert a
strong influence on productivity and efficiency, mostly in the case of secreted proteins
[231,232]. The intracellular protein content is often a balance between the amount of
soluble protein in the cells, the formation of inclusion bodies and protein degradation. In
case when protein is only expressed as inclusion body, protein solubilization under
denaturing conditions and subsequent protein refolding [233] can lead to the correct
folded, native protein. The best refolding conditions have to be determined empirically
and are very specific for each protein, what can be time- and cost consuming,
sometimes even impossible.
1.3.3 Insect cells expression system
As an expression system, baculovirus infected insect cells characterize gene transfer via
viral infection on rather transient, then stable basis [228,234,235]. Large DNA portions
can be transfected by incorporation into baculovirus genome, and subsequently into
insect cells. Recombinant DNA transfer can be done in transfection (DNA of interest
incorporated into the viral genome prior to the transfection into insect cells), or co-
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transfection, where DNA of interest and linearized viral DNA are simultaneously
transfected into insect cells. Based on the chosen method, wide variety of vectors is
available. For the recombinant protein production, Autographa californica nuclear
polyhedrosis virus (AcNPV), and Bombyx mori nuclear polyhedrosis virus (BmPV) are
mainly employed. Insect cells mostly used are of the species Spodoptera frugiperda (Sf9
and Sf21 insect cells), and for the secreted proteins Trychlopusia ni (High fiveTM insect
cells). Baculovirus expression of recombinant proteins permits folding, post-translational
modification and oligomerization in manners that are often identical to those that occur in
mammalian cells. These enable proper proteolysis, N- and O-glycosylation, acylation,
amidation, carboxymethylation, phosphorylation, and prenylation. Proteins may be
secreted from cells or targeted to different subcellular locations. Protein expression can
be placed under the control of different promoters, dependent of the protein
characteristics. For secreted, glycosylated proteins an early promoter can improve the
functionality of the protein, but in lower yields, whereas stronger polyhedrin promoter
enhances the protein yield, and is mostly used, allowing levels of expression of up to
30% of the total cell protein. For commercial applicator, scale-up techniques are under
optimization, as well as construction of new innovative vectors and coexpression of
chaperons, foldases and folding factors [234, 236].
1.4 Elucidation of protein-ligand interactions
The analysis of molecular interactions is a key part of the drug discovery process. In the
case of structure-based drug design, major analyses are done using X-ray
crystallography, nuclear magnetic resonance, surface plasmon resonance and classical
competitive binding assays. X-ray crystallography and NMR are mostly used for
structural assessments of ligand binding site on the target, as well as the binding epitope
on the ligand, whereas surface plasmon resonance and binding assays quantify binding
constants in high throughput fashion [237,238]. Mutational studies and structure
prediction based on a similarity with already solved protein structures can generate very
good models [97,151]. However, X-ray crystallography of the target protein, or protein
co-crystallized with its physiological ligand or first generation compounds, is an absolute
must and necessity for the in silico generations of ligands and proof of concept. Major
drawbacks of X-ray crystallography are milligrams of pure, homogeneous protein that
are required, what can be very expensive if protein cannot be produced in E.coli. In
addition, it is not trivial to find the optimal crystallographic conditions and the procedure
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is not straightforward. Once solved, crystal structure reveals a static complex of protein
and ligand, whereas NMR gives a dynamic characterization of protein-ligand complexes,
on a time scale from pico/nano seconds to milliseconds. Small proteins often do not get
crystallized, whereas NMR has no such size limitations. Structure determination of
weakly bound ligands and theirs bioactive conformation, even if receptor is large, can be
easily assessed by NMR using NOEs, STDs, and T1rho relaxation time [209,210,215].
For structure determination, protein size limit is around 30-40 kDa, although large
deuterated proteins can be solved with TROSY experiments. Isotope labeling with 15N
for proteins 10-20 kDa, 13C and 15N for proteins > 20 kDa, and 13C, 15N and 2H for
larger proteins is highly recommended [237,239]. The choice between uniform or
selective labeling depends on recombinant protein source and prior knowledge about the
structure. Protein in milimolar range, 90% purity is required for structural studies,
whereas for an NMR screening few milligrams of non-labeled protein suffice. Surface
plasmon resonance exploit evanescent wave phenomenon, where binding of molecules
in solution to surface-immobilized receptors alters the refractive index of the medium.
This change is monitored in real time and can measure accurately the amount of bound
analyte, the kinetics of interactions with the koff and kon constants, or the amount of the
active protein in the sample [238]. Applicable through the whole drug discovery process,
SPR requires microgram amounts of proteins and ligands. Low-molecular mass drugs,
as well as multiprotein complexes can be used with the interaction affinities from
milimolar to picomolar range. Major drawbacks are sometimes complicated receptor-
immobilization procedure and purity of the sample.
Figure 1.8: Surface plasmon resonance sensogram
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Conventional bioassay is mostly used for screening and quantification of protein-ligand
interactions. Originally created for 96-wells performance, nowadays it is adopted to 384- and
even 2080-format, applicable in HTS and ultra-HTS screening. Bioassay is performed as
cell-based assay appropriate for target classes as ion channels, receptors, transcription
factors, or biochemical assay that utilizes isolated protein [217,240,241], figure 1.9. Typical
target classes here are kinases, proteases and binding proteins. Classical readout
technologies are colored enzymatic reactions, fluorescence polarization, fluorescence
intensity or time-resolved fluorescence. Major drawbacks of the assay are occasional
instability or too high sensitivity that might lead to false positive or negative results, as well
as compound interference with the readout technology.
Figure 1.9: Molecule-molecule type of biochemical assay for evaluation of E-selectin antagonists
E-selectin
PAA+
Streptavidin
peroxidase
Selectin
antagonists
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2 The Aim
The selectins family of adhesion molecules mediates the inflammatory process, i.e the
extravasation of leukocytes from blood vessels into the neighboring tissue. Although this
represents an essential defense mechanism, excessive or pathological leukocyte
accumulation results in numerous disease states and promotes metastatic cancer
spread. E- and P-selectin are expressed only as a consequence of an inflammatory
stimulus; time-limited and localized to the inflammatory area. Since their inhibition could
prevent local pathological inflammation at an early time-point, without undisered effects
on other tissues, selectins became a promising target for the pharmaceutical industry.
Detailed characterization of ligand-receptor interactions is a prerequisite for successful
drug discovery and development. In NMR and X-ray crystal structure studies interaction
of the lectin and EGF-like domains of E- and P-selectin co-crystalized with their natural
ligand sLex have been solved [188,209]. Based on these findings, molecular modeling
studies were developed in search for potent selectin antagonists [201]. To develop
second generation of E-selectin antagonists, improved structural studies have to be
performed with the more precise analysis of protein-carbohydrate interactions that define
selectin binding mode. These include crystal structure analysis with the first generation
of selectin antagonists that would support further modeling studies, NMR analysis with
15N/13C labelled protein, real-time kinetic studies using surface plasmon resonance
technology and microcalorimetric studies. In addition, synthesized antagonists have to
be rapidly screened in a reproducible and accurate bioassay. Therefore in the first step
our aim was to obtain and characterize active, recombinant E-, P- and L-selectin/IgG
that consist of lectin, EGF-like and consensus repeat domains of each of the selectins,
fused to the Fc part of human IgG. In the second step, we aimed to develop a cost- and
time-effective system to express and purify lectin and EGF-like domain of E-selectin in
preparative yields sufficient to meet requirements for structural studies. In addition,
expressed protein should be thoroughly characterized in terms of in-solution status
(monomer, dimer, oligomer) and activity. Therefore our aim is to express lectin and EGF-
like domain of human E-selectin in baculovirus-infected insect cells. We hypothesize that
lectin and EGF-like domains of E-selectin expressed in this system could be used in a
bioassay for evaluation of selectin antagonists. We aim to develop a cell-free assay that
will be more accurate and reproducible compared to exisisting E-selectin assays. This
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we will test in the proof-of-concept manner evaluating three known E-selectin
antagonists and comparing the results to the published [216].
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3 Materials and methods
3.1 E-, P-, L-selectin/IgG expression in CHO cells, purification
and characterization
For expression of E-, P- and L-selectin / IgG, stably transfected chinese hamster ovary
(CHO) cells were grown in the MEM α- medium (Invitrogen), supplemented with 5% FCS
(GIBCO) and 0.5 mg/ml gentamicin (GIBCO). Cells at 106 were seeded in 20 ml
conditioned medium in 75 cm2 flask for back-up cultures. Cells were confluent in 3 days
and then split and seeded for either a new back-up cultures or for production. Protein
production was carried out in the 160 cm2 culture flasks and in roller bottles, 420 cm2.
106 cells were seeded in 60 ml medium in 160 cm2 culture flasks and let to grow until
confluence for 5-6 days. Medium was harvested and new medium added to the cells in
the production phase, which lasted up to another two weeks. For production in roller
bottles 2x107 cells were seeded in 200 ml medium and grown as adherent cultures in 5%
CO2 atmosphere, at 37°C and 90 rpm speed. Cells were grown for 1 week before
starting the production phase, when 100 ml fresh medium was added and protein
production continued for up to total of three weeks. To establish the optimal conditions
for cell harvesting, small-scale analysis was done. Every day an aliquot of the
conditioned medium was collected and purified over protein A chromatography. Also, pH
value of the medium was daily controlled and cells examined under microscope. After
production, medium was harvested by centrifugation at 1000xg, 4°C and 20 min. pH
value of the supernatant with the secreted protein was adjusted to 7.6 and the salt
concentration was set up to 0.15 M NaCl. Medium was filtrated through 0.22 µm sterile
filter and prepared for protein A chromatography.
3.1.1 E-, P-, L-selectin/IgG purification on protein A affinity
chromatography
All purification steps were carried out at 4°C. For purification purposes, 5 ml protein-A
agarose column (BIO-RAD) was used on Fast Protein Liquid Chromatography (FPLC)
system BioLogic Duo-Flow (BIO-RAD) with the software BioLogic Duo-Flow 3.0 (BIO-
RAD). The column was equilibrated with 10 column volumes of binding buffer; TTBS
(0.15 M NaCl, 0.05 M Tris, 0.05% Tween 20, pH 7.6), until stable baseline. Conditioned
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medium was applied in 200 ml portions to avoid overloading of column. In the next step
unbound material was washed with 10 column volumes of binding buffer, followed by 50
ml washing buffer (0.005 M CH3CH2COONH4, pH 5.0) to remove all unspecific-bound
proteins. Proteins specifically bound to the column were eluted with 3 column volumes of
elution buffer (0.5 M CH3CH2COOH, pH 3.4). Usually 3.5-4 ml fractions were eIuted as a
single sharp peak. Immediately upon elution pH was adjust with 1 M Tris buffer to pH
7.0. Overall chromatography flow-rate was 1ml/min.
3.1.2 E-, P-, L-selectin/IgG purification by gel filtration
As a second purification step, gel filtration was performed to separate proteins bound
with Fc part of IgG to the protein-A agarose. Sephadex column 200 ml, (Amersham
Pharmacia) was equilibrated in TBS buffer (0.15 M NaCl, 0.05 M Tris, pH 7.6) until
stable baseline. Protein-A-eluted fractions were pooled together, concentrated up to 4 ml
and applied to the gel filtration column with a flow rate of 1 ml/min. Proteins were
separated in the total volume of 120 ml, in the 4 ml fractions. After SDS PAGE analysis,
E-sel/IgG-containing fractions were pooled together and concentrated in the Amicon
concentration device, 30 kDa cut-off. Concentration was done at 4°C, 4000 rpm in the
Sorvall centrifuge with H8-rotor.
3.1.3 SDS-PAGE electrophoresis and gel visualization
The whole purification procedure and final protein products, as well as all protein
characterizations were analyzed by SDS-PAGE electrophoresis. Denaturing gel, 8% and
protein samples were prepared according to the standard procedure [242] using buffers
described in the table 3.1, table 3.2, and table 3.3. For visualization, separated proteins
were predominantly Coomassie stained, and in cases when higher staining sensitivity
was required, proteins were stained with silver. During electrophoresis, the applied
current was 30 mA/gel in stacking, and 40 mA/gel in separating gel.
Table 3.1: Protocols for buffers used for SDS-PAGE
Buffer (10x) Running
buffer
(1x)
Separating gel
buffer
(1x)
Stacking gel buffer
(3x)
Reducing sample buffer
Components: 0.25 M Tris-HCl
2 M Glycin
1% (w/v) SDS
pH 8.3
1.875 M
Tris-HC
pH 8.8
1.25 M
Tris-HCl
pH 6.8
0.065 M Tris-HCl
20% (v/v)Glycerin
10% (v/v)
β-Mercaptoethanol
4% (w/v) SDS
Spatule tipp of
Bromphenolblau, pH 6.75
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Table 3.2: Protocol for 5 ml 8% stacking gel preparation
Substance Volume [ml]
H2O 2.3
30% Acrylamide 1.3
1.5 M Tris (pH 8.8) 1.3
10% SDS 0.05
40% APS 0.05
TEMED 0.003
Table 3.3: Protocol for 2 ml 5% separating gel preparation
Substance: Volume [ml]
H2O 1.4
30% Acrylamid 0.33
1.5 M Tris (pH 6.8) 0.25
10% SDS 0.02
40% APS 0.02
TEMED 0.002
3.1.3.1 Silver staining
Gels were stained with the prepared kit from Amersham, Pharmacia, according to the
supplier’s protocol [243].
3.1.3.2 Coomassie staining
Gels were fixed in the fixation solution for up to two hours, and incubated in the staining
solution for 2 hours. Destaining was done with several destaining solution exchanges.
Table 3.4 describes solutions used for Coomassie staining.
Table 3.4: Protocol for 1L Coomassie staining solutions
Fixation solution Volume [ml] Staining/solution
Destaining
Volume [ml]
CH3OH 75 CH3OH 75
C2H5COOH 100 C2H5COOH 100
H2O 825 H2O 825
- - Coomassie
Brilliant Blue
1 g
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3.1.4 Protein concentration determination by Bradford assay
Protein concentration was determined by Bradford assay [244]. The standard curve was
prepared using bovine serum albumine in a concentration range from 0-200 µg/ml. For
the preparation of Coomassie reagent, 10 mg Coomassie Brilliant Blue G-250 (BIO-
RAD) were dissolved in 10 ml 85% phosphoric acid and 5 ml 95% ethanol, and filled up
to 100 ml with water. Solution was filtrated prior to use.
20 µl protein samples were mixed with 50 µl 1M NaOH solution in an eppendorf tube. 1
ml reagent solution was added, and the reaction incubated at RT for 15 min. The
absorption, which is directly proportional to the protein concentration, was measured on
BIO-RAD Smart Spec spectrophotometer at 595 nm.
3.1.5 Mass spectrometry sequence analysis
Protein identity was confirmed by MS analysis. Single band representing purified protein
was excised from the Coomassie stained 8% gel and digested with trypsin overnight at
37°C. Cleaved fragments were analyzed by LC/MS on Mass Spectrometer Finnigan
TSQ 7000 and compared with predicted amino acid sequences.
3.1.6 Western blot analysis (Immunoblot analysis)
Western blot analysis performed on Trans-Blot SD Semi-Dry Electrophoretic Transfer
Cell BIO-RAD. Proteins were separated on 4% native polyacrylamide gel under native
PAGE (all buffer components as described in the tables 3.1, 3.2, and 3.3, without SDS),
at constant current of 20 mA/gel, and at 4°C. For the protein transfer to the nitrocellulose
membrane, the following buffers were prepared:
Anode buffer I: 0.3 M Tris, 20% methanol (v/v)
Anode buffer II: 0.025 M Tris, 20% methanol (v/v)
Cathode buffer: 0.4 M 6-aminocapronic acid, 20% methanol (v/v)
Nitrocellulose membranes and 12 pieces of Whatman-paper were prepared in dimension
6.5x8.5 cm. After proteins were separated, the gel was incubated in cathode buffer for 5
min. 4 filters were incubated in anode buffer I and 2 filters in anode buffer II. The
nitrocellulose membrane was first incubated for 2 min. in water, and then for 5 min. in
anode buffer II. Filters incubated in anode buffer I were first prepared and then filters in
anode buffer II, followed by membrane and the gel. The gel was covered with 6 filters
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soaked in cathode buffer and finally with graphic cahtode. Protein transfer was done at
14 V for 1 hour. Successful membrane transfer was verified by staining with Ponceau S
solution (SIGMA), and the membrane was immediately blocked for 1 h at RT in 3% BSA
in 2 mM Ca2+ TTBS-buffer. After blocking, the membrane was washed 3 times for 5 min.
with 2 mM Ca2+ TTBS-buffer and incubated with primary antibody at 10 µg/ml in 2 mM
Ca2+ TTBS, 0.1% NaN3 and 1% BSA. Incubation with primary antibody was done
overnight, at 4°C, followed by membrane washing 3 times for 5 min. The membrane was
shaked with the secondary antibody, the alkaline-phosphatase conjugated goat, anti-
mouse IgG for 1.5 hours at RT, and washed twice as described above, while last time in
2 mM Ca2+ TBS, instead of 2 mM Ca2+ TTBS-buffer.
For the membrane visualization, developing buffer was prepared with 0.1 M Tris, pH 8.8,
0.1 M NaCl and 0.005 M MgCl2.
NBT-BCIP substrate solution (40 µL) was added to 10 ml buffer, and alkaline
phosphatase catalyzed reaction was developed until violet protein bands appeared. The
membrane was washed in water to stop the reaction, dried and kept in the dark.
3.1.7 N- and O-deglycosylation
Deglycosylation was performed on the analytical scale with N-Glycosidase F (Roche)
under reduced and native conditions [245]. Reaction set-up (table 3.5) was optimized
according to the supplier’s prescription:
Table 3.5: Reaction set-up for deglycosylation under reduced and native conditions
Reducing conditions Native conditions
0.1 M NaPi 0.1 M NaPi
0.025 M EDTA 0.025 M EDTA
0.1% SDS 0.1% SDS
2% Tween-20 2% Tween-20
2 U N-Glycosidase F 2 U N-Glycosidase F
3 µg protein 3 µg protein
1 % 2-mercaptoethanol _
H2O up to 100 µl H2O up to 100 µl
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Deglycosylation in denaturing conditions required protein with all reaction components to
be boiled at 99°C for 5 min., prior to enzyme’s addition. PNGase F was added only when
sample were cooled down to RT. Components were mixed together and incubated at
37°C for up to 48 hours. For time course optimization, aliquots were taken at different
time points and extent of deglycosylation was analyzed by SDS-PAGE.
N-deglycosylation under native conditions was done as described for 6 hours and the
activity of deglycosylated protein was examined by native Western blot.
Combined deglycosylation
O-Glycosidase (Roche) was used in combination with N-Glycosidase in both reducing
and native conditions [246], as described in table 3.6. Aliquots were taken at different
time points and analyzed on SDS-PAGE.
Table 3.6: Reaction set-up for combined N-and O-deglycosylation
Reducing conditions Native conditions
0.02 M NaPi 0.1 M NaPi
0.025 M EDTA 0.025 M EDTA
0.1% SDS 0.1% SDS
2% Tween-20 2% Tween-20
2 U N-Glycosidase F 2 U N-Glycosidase F
3 µg protein 3 µg protein
1 % 2-mercaptoethanol _
2.5 mU O-Glycosidase 2.5 mU O-Glycosidase
H2O up to 100 µl H2O up to 100 µl
Separated deglycosylation
N-deglycosylation was performed first, under reducing conditions. After 6 hours, aliquot
was taken and the incubation buffer components adjusted to the ones described in the
table 3.7.
Table 3.7: Buffer exchange and reaction set-up for subsequent N- and O-deglycosylation
Reducing conditions
Buffer exchange
0.0175 M NaPi
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0.025 M EDTA
0.1% SDS
2% Tween-20
1.65 mU O-Glycosidase
57.45% H2O
After 18 h incubation with O-Glycosidase, deglycosylation extent was analyzed on 8%
reducing gel. To address the protein activity, reaction set-up in native conditions was
done and deglycosylated protein tested in native Western blot.
O-deglycosylation
Reaction set-up for O-deglycosylation and the incubation buffer were prepared as
described in the table 3.8, [246]. O-deglycosylation was performed for up to 24 hours.
Aliquots were taken after 3 and 24 hours and controlled by 8% SDS-PAGE.
Table 3.8: Reaction set-up for O-deglycosylation
Reaction conditions
10 µg protein
0.25 mU O-Glycosidase
Phosphate-citrate buffer up to 50 µl
N-Deglycosylation with N-Glycosidase A
Further N-deglycosylation was performed with N-Glycosydase A (Roche), according to
the manufacturer prescription and in conditions described in the table 3.9. Samples were
analyzed after 3 and 24 hours on reducing 8% SDS-PAGE.
Table 3.9: Reaction set-up for N-deglycosylation with N-Glycosidase A
Reaction conditions
10 µg protein
0.2 mU N-Glycosidase A
0.1% SDS
Phosphate-citrate buffer up to 50 µl
pH 5.5
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3.1.8 Molecular weight determination
Protein’s molecular weight was determined in native conditions using non-denaturing
protein molecular weight kit (SIGMA). Native PAGE was performed on the gels with
different acryl amide percentage, using buffers described in the table 3.10. The
molecular weights of selectins were determined by indirect calculation as described
[247].
Table 3.10: Buffers for non-denaturing molecular weight determination:
Electrode buffer
pH 8.3
Tris Buffer
pH 6.7
Sample buffer
pH 6.7
1.2 g Tris 5.98 g Tris 1 ml Tris buffer
5.76 g Glycine 0.46 ml TEMED 1 ml glycerol
ad 2 L H2O Ad 100 ml H2O 1 ml H2O + 0.25 mg Bromphenol
Blue
Protein samples were mixed in equal volumes with the sample buffer and loaded on the
gel. Front determination was done with sample buffer alone. The gels were run at 4°C
and 10 mA/gel. Rf-value and relative electrophoretic mobility on different gels were
determined as a function of molecular weight for each protein.
3.2 Expression of LecEGF domain of human E-selectin in
E.coli
3.2.1 General proceedings
All work with bacterial cultures was done in sterile conditions under laminar flow.
Commonly used medium and procedures are listed below and decribed in the tables
3.11-3.13. pH of the medium was set to 7.5 with 2N NaOH and autoclaved. Sterile
filtrated antibiotics solutions were added just prior to use. Autoclaved medium was
cooled down to 50°C and ampicilin stock solution at 100 mg/ml was added to the final
concentration of 150 µg/ml. Agar plates were prepared by adding 15 g agar/liter LB
medium. 25 ml medium was poored per plate, cooled down to RT and kept in dark at
4°C for 1 month.
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Table 3.11: Components for 1 liter LB medium
Bacto-Trypton 10.0 g
Yeast Extract 5.0 g
NaCl 10.0 g
Aqua dest. ad 1 liter
Table 3.12: Components for 1 liter TB medium
Bacto-Trypton 12.0 g
Yeast Extract 24.0 g
Glycerol 4.0 ml
Aqua dest ad 1liter
TB phosphate (10X) 100 ml (2.31 g KH2PO4,
12.54 g K2HPO4)
3.2.1.1 Preparation of CaCl2 competent cells [248]
Competent cells are used to take foreign DNA by transformation. Over-night culture of
DHα5 E.coli was done in 10 ml LB medium at 37°C, shaking. On the next day 50 ml LB
medium was inoculated with 4 ml over-night culture and was grown at the 37°C until the
O.D.600 of 0.5-0.7. All subsequent steps followed at 0-4°C. Cells were centrifuged at
3000xg for 30 min. and the pellet was resuspended in 10 ml of 50 mM CaCl2 solution.
Suspension was incubated on ice for 30 min. and the cells finally centrifuged at 2000xg
for 10 min. Final pellet was re-suspended in 1 ml 50 mM CaCl2 solution with 20%
glycerol and aliquot at 50 µl. Glycerol aliquots were freezed in liquid nitrogen, and stored
at -80°C.
3.2.1.2 Preparation of competent E.coli cells for electroporation
Table 3.13: Components for 1 Liter SOB-Medium
Bacto-Tryptone 20 g
Bacto-Yeast extract 5 g
NaCl 0.5 g
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250 mM KCl 10 ml
Aqua dest. ad 1liter
Desired E.coli strain was streaked on agar plates w/o antibiotics and incubated overnight
at 37°C. Single colony was picked and inoculated in 5 ml SOB medium without MgCl2
and cultures were grown overnight at 37°C, shaking.
Pre-cultures (250 ml) were inoculated in SOB medium supplemented with 10 mM MgCl2
at 1: 50 ratio and grown at 37°C up to O.D.600 of 0.5-0.7. Cells were harvested by
centrifugation in a GS3 rotor at 5000 rpm and 4°C for 10 min. Pellet was re-suspended
in 250 ml of 10% cold, sterile glycerol and centrifuged as described. Cells were
resuspended in 82.5 ml cold 10% glycerol and centrifuged again. Finally, the pellet was
resuspended in 1 ml cold 10% glycerol and cells aliquoted in 50 µ l in pre-chilled
eppendorf tubes. Cells were frozen in liquid nitrogen and stored at -80°C.
3.2.1.3 Bacterial glycerol stock preparation
A single colony was picked from the agar plate and grown in LB medium with ampicilin
at 37°C, until mid-logarithmic phase. 0.85 ml culture was mixed with 0.15 ml sterile
glycerol in an eppendorf tube, freezed in liquid nitrogen and stored at -80°C.
3.2.2 Cloning into pEZZ18
Plasmid vector pEZZ18 (Amersham, Pharmacia) contains ZZ domain of protein A
upstream from the multiple cloning site and enables recombinant protein’s secretion into
the medium.
3.2.2.1 Genomic DNA isolation from CHO cells
CHO cells expressing human E-selectin/IgG were trypsinized, resuspended and
centrifuged 5 min. at 13 000xg, followed by the washing 4 times with PBS buffer
(Invitrogen). Genomic DNA was isolated from the cells with WIZARD Genomic
Purification Kit (Promega). Genomic DNA was stored at 4°C.
3.2.2.2 PCR generation of Lectin and EGF-like domains (LecEGF) of human E-
selectin
The DNA sequence coding for the LecEGF of human E-selectin was amplified from
genomic DNA isolated from CHO cells in a Hot Start PCR. Restriction enzyme
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recognition sequences were introduced in the sequence: EcoRI restriction site at the 5’
end, followed by thrombin cleavage site, and BamHI site at 3’ end, as well as stop
codon.
Primer sequences:
LecEGFpEZZ18 (5’-Primer):
5’-ATG CGA ATT CGC TGG TGC CGC GCG GCA GCT GGT CTT ACA ACA CCT CCA
CG-3’
GAA TTC: EcoRI restriction site
CTG GTG CCG CGC GGC AGC: Thrombin cleavage site
LEZZ3 (3’-Primer):
5’-GCT CGG ATC CTT ACA GGG CTG TAC AGT TCA C-3’
GGA TCC: BamHI restriction site
TAA: Stop codon
Lyophilized primers were dissolved in sterile H2O at 100 pmol/µl and incubated at 65°C
for 5 min., followed by 3 min. shaking at 650 rpm. For the PCR reaction, primers were
diluted to 10 pmol/µl. Mastermix I was prepared as described in the table 3.14, and 25 µl
were pipetted in the special PCR-tubes (GeNunc 0.2ml, PP, RNAse- and DNAse-free).
Finally, mastermix II (table 3.15) was added without polymerase, which was added
directly to the reaction mix in the PCR machine at 94°C.
Table 3.14: Mastermix I
Nucleotide mix 10 mM 200 µM each dNTP 1 µl 1 µl
5’primer 10 pmol/µl 0.1-0.6 µM 2 µl 2 µl
3’primer 10 pmol/µl 0.1-0.6 µM 2 µl 2 µl
Template DNA 0.1-0.25 µg 1 µl 3 µl
Autoclaved H2O ad 25µl ad 25µl ad 25µl
Table 3.15: Mastermix II
Pfu-PCR-Puffer 10x 1x 5 µl
Pfu-DNA-Poly 1.25 U/reaction 1 µl
Autoclaved H2O. ad 25µl 19 µl
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PCR was performed using thermocycler BIO-RAD with the program described in the
table 3.16.
Table 3.16: PCR reaction parameters for LecEGF amplification
Initial denaturation 94°C 4’
Denaturation 94°C 60’’         30 cycles
Annealing 58°C 60’’         30 cycles
Elongation 72°C 30’’         30 cycles
Finale elongation 72°C 7’
Cooling 4°C -
Obtained PCR product was purified with GenPCR purification kit (SIGMA) according to
the manufacturer instruction.
3.2.2.3 DNA electrophoresis analysis
All DNA analyses were done by agarose gel electrophoresis in TBE buffer (table 3.17)
DNA fragments migrate in the agarose gel from cathode toward anode dependent on
their charge.
Table 3.17: 1 L TBE buffer
Tris 44.6 mM
Boric acid 44.6 mM
EDTA*2H2O 10 mM
3.2.2.4 Restriction enzyme digestion
Prior to the ligation, PCR generated insert, as well as plasmid vector were digested with
restriction enzymes EcoRI (New England Biolabs) and BamHI (New England Biolabs).
Both enzymes have 100% activity in the digestion buffer NEB-buffer 2. Reaction
components desribed in the table 3.18 were mixed and incubated at 37°C for 3.5 h.
Table 3.18: Restriction enzyme digestion set up
Insert Vector
Insert/Vector 60 µl 45 µl
Sterile H2O 3.5 µl 0.5 µl
NEB-buffer 2 (10x) 7.5 µl 5.5 µl
EcoRI 2 µl ≅ 4 U 2 µl ≅ 4 U
BamHI 2 µl ≅ 4 U 2 µl ≅ 4 U
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3.2.2.5 Dephosphorylation of the vector
After restriction enzyme digestion, vector was dephosphorylated with calf intestine
alkaline phosphatase (CIP) (Roche) in a reaction mix described in the table 3.19.
Table 3.19: Dephosphorylation reaction set up
Vector 55 µl
Sterile H2O 2 µl
CIP-buffer 10x 6.5 µl
Alkaline Phosphatase (1U/µl) 1.5 µl
Reaction components were mixed and incubated at 37°C for 1h, followed by enzyme
inactivation at 65°C for 10 min. Digested and dephosphorylated vector and insert were
further purified by agarose gel electrophoresis. Samples of total reaction mixtures were
prepared as described under 3.2.1.6. After the separation, bands corresponding to the
insert and vector were cut out from the gel under the UV light.
3.2.2.6 DNA-purification
DNA fragments from agarose gel were purified with the GenEluteTM Gel Purification kit
(SIGMA) according to the supplier’s prescription. DNA was eluted in 40 µl elution buffer
and stored at -20°C.
3.2.2.7  Ligation
Ligation is an ATP-dependent reaction, where recombinant ligase effectively joins blunt
or cohesive DNA ends. Ligase catalyzes formation of a phosphodiester bond between
OH- and phosphate- group of DNA strand. Different vector to insert ratio and reaction set
up was tested and successful reaction set up is given in the table 3.20. Ligation was
conducted over-night at 4°C.
Table 3.20: Ligation reaction set up
Vector 2 µl (0.1-5 µg)
Insert 5 µl (0.1-5 µg)
Ligation buffer 10x 1 x
ATP 10 mM 1 mM
Ligase 20-500 U
Sterile H2O Ad 10 µl
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3.2.2.8 Chemical transformation of competent E.coli cells
Transformation is a process of plasmid-DNA up-take in the competente bacterial cells.
The addition of CaCl2 to the cells makes the membrane porous, and the haet schock
enables DNA uptake.
Bacterial cells were thawed on ice and 100 µl cells were mixed gently with 5 µl ligation
mixture. Cells were incubated on ice for 30 min. and then at 42°C for 80 sec. Cells were
cooled down on ice for 3 min, 500 µl SOC medium (described in the table 3.21) was
added and phenotypic expression started for 1 h at 37°C and 550 rpm shaking. Finally,
cell suspension (100-400 µl) was plated on pre-warmed agar plates, containing 150
µg/ml Amp. When dried, plates were incubated at 37°C over-night.
Table 3.21: Components of 1 L SOC medium
D-Glucose 1M
MgCl2 2M
in LB-Medium
3.2.2.9 Plasmid isolation and clone analysis
For ligation and transformation controle, single colony was picked, inocculated in 3 ml
LB medium with the appropriate antibiotics and grown to stationary phase at 37°C.
Plasmid DNA was isolated from the cells with GFXTMMicro Plasmid Prep Kit (Amersham
Pharmacia) by alkaline lyses [248]. Final DNA was eluted in 70 µl TE buffer (table 3.22}
Table 3.22: TE buffer preparation
Tris 10 mM
EDTA 1 mM
pH set to 8 with HCl
Isolated plasmid DNA was first controled for the presence of correct fragment by
restriction enzyme digestion with EcoRI and BamH I, or EcoRI und PstI restriction
enzymes, and by PCR.
For the sequencing, single-clone culture was re-streaked on the agar plate in a dilution
maner. Plate with the grown colonies was sent to Microsynth GmbH Sequencing Group,
Balgach.
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3.2.2.10 Protein expression analysis by affinity chromatography on IgG sepharose
50 ml LB medium with 100 µg/ml ampycilin was inoculated with 0.5 ml culture and grown
over-night at 37°C. Medium was clarified by centrifugation at 4°C and 3000 g, sterile
filtrated and applied to IgG sepharose column. Affinity purification was done on FPLC
system (BIO-RAD). 2 ml IgG sepharose (Amersham, Pharmacia) was equilibrated with
10 column volumes of TTBS buffer, pH 7.6. After achieving stable base-line, clarified
medium was applied at the flow-rate of 1 ml/min. Column was extensively washed with
TTBS buffer to get stable base-line, and unspecificaly bound contaminants were washed
away with 10 mM acetate buffer, pH 5.0. Bound proteins were eluted in 5 column
volumes of 0.2 M acetic acid, pH 3.4. 1 M Tris was used to adjust pH to 7.6.
Chromatography fractions were analyzed on 15% SDS-PAGE.
3.2.3 Cloning into vector pET-15b
Cloning vector pET-15b (Novagen) enables inducible expression of recombinant
proteins with N-terminal His tag and possibilty of tag removal by thrombin.
3.2.3.1 PCR generation of LecEGF domain of human E-selectin
DNA sequence coding for LecEGF was PCR amplified as described in3.2.2.2 with
primers:
FW pET15LE (5’-Primer):
5’-AGA TCG ACA TAT GTG GTC TTA CAA CAC CTC CA-3’
CAT ATG: NdeI restriction site
LEZZ3 (3’-Primer):
5’-GCT CGG ATC CTT ACA GGG CTG TAC AGT TCA C-3’
GGA TCC: BamHI restriction site
TAA: Stop codon
3.2.3.2 Restriction enzyme digestion of insert and vector
Restriction enzyme digestion was performed as described under 3.2.2.3, with enzymes
NdeI and BamHI (New England Biolabs).
3.2.3.3 Vector dephosphorylation
Vector pET-15b was dephosphorylated as described under 3.2.2.4
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3.2.3.4 DNA-purification with GenEluteTM Gel Purification Kit
Insert and vector DNA were purified and prepared for ligation as described under 3.2.2.5
3.2.3.5 Ligation into pET-15b
The ligation reaction was prepared as described under 3.2.2.6, and conducted over-
night at 4°C.
Table 3.23: Ligation reaction set-up for ligation of LecEGF into pET-15b
Vector 4 µl (0.1-5µg)
Insert 6 µl (0.1-5µg)
Ligation buffer 10x 1.5 µl, 1 x
ATP 10 mM 1 mM
Ligase 20-500 U
Sterile H2O Ad 15 µl
3.2.3.6 Chemical transformation into E.coli
Transformation with ligation mix into E.coli DHα5 was done as described under 3.2.2.10.
For protein production, 1 µl plasmid DNA HisLecEGFpET-15b (0.1 µg) was transformed
into E.coli strains AD 494, Rosetta Gami and BL 21 (DE3), according to the same
procedure.
3.2.3.7 DNA isolation and clone analysis
DNA isolation was done as described under 3.2.13. Isolated plasmid DNA was
controlled for the presence of correct fragment by restriction enzyme digestion with NdeI
and BamHI, or NdeI und PstI restriction enzymes, and by PCR. For the sequencing,
DNA was isolated as described, eluted in sterile H2O and sent for sequencing to MWG
genomic company, Ebersberg, Germany, (www.THE-MWG.com), and Syngene AG,
Zürich, Switzerland.
3.2.3.8 Protein expression optimization
To establish the best conditions for HisLecEGF protein expression, LB medium and TB
medium were tested, as well as 3 E.coli strains: AD 494, Rosetta gami and BL 21(DE3).
3 ml overnight culture was prepared from all three strains in 2 different mediums. 50 ml
either LB, or TB medium with 100 µg/ml ampycilin was inoculated as described under
3.2.13, and cells were grown at 37°C until O.D.600 reached 0.6-0.8. The culture was
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inoculated with 1 mM IPTG. 1 ml aliquots were taken at different time points, for up to 24
h post-induction and protein expression analyzed on SDS-PAGE. Non-induced cells
were taken as negative control.
3.2.3.9 HisLecEGF purification in native conditions
Purification of HisLecEGF was done in native conditions using Ni-NTA (Ni2+-
Nitrilotriacetic acid) agarose (Qiagen), according to the manufacturer prescription.
Collected bacterial culture was centrifuged at 4°C and 5000xg for 20 min. Pelleted cells
were re-suspended in cell lyses buffer at 5 ml per gram wet weight. Lysozyme was
added at 1 mg/ml and incubated on ice for 30 min. Cells were sonicated on ice with 70%
output, 6x10 sec with 10 sec break. Cell lysate was centrifuged at 4°C and 10 000xg for
30 min. to pellet the cellular debris, and supernatant was filtrated through 0.22 µm sterile
filter. Collected soluble cytoplasmic fraction was mixed 1:1 with the binding buffer prior to
the immobilized-metal affinity chromatography. The affinity purification was performed on
the FPLC system Biologics (BIO-RAD). For purification of His-tagged protein, 5 ml BIO-
RAD column was assembled and packed according to the manufacturer prescription.
Column was equilibrated with 5 column volumes of lysis buffer with a flow rate of 1
ml/min, until stable base-line. Cell lysate was applied, and column washed with 10
column volumes of lysis buffer until stable base line. With 10 column volumes of wash
buffer, all non-specifically bound impurities were removed, and after achieving stable
base-line, his-tagged proteins were eluted in 3 column volumes of elution buffer. After
the use, column was kept in 30% sterile filtrated ethanol. All the buffers used (table 3.24)
were sterile filtrated through 0.22 µm filter.
Table 3.24: Buffers for Ni-NTA IMAC under native conditions
Lysis Buffer 50 mM NaH2PO4
300 mM NaCl
10 mM imidazole, pH 8.0
Wash Buffer 50 mM NaH2PO4
300 mM NaCl
20 mM imidazole, pH 8.0
Elution Buffer 50 mM NaH2PO4
300 mM NaCl
250 mM imidazole, pH 8.0
All chromatography steps were analyzed on SDS-PAGE.
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3.2.3.10 Isolation of inclusion bodies
250 ml collected bacterial culture was centrifuged at 4°C and 5000xg for 20 min. Cell
pellet was thoroughly resuspended in 12.5 ml ice cold wash buffer ( ratio 1:20 to the
starting culture), and protease inhibitor cocktail (Sigma) was added. Resuspended
culture was sonicated on ice with 70% output, in the intervals of 6x20 sec and 10 sec
break between. Cell resuspension was centrifuged at 4°C and 10 000g for 20 min., and
supernatants were preserved for the control purposes. Pellet was washed 5x in the
same manner, until extracted supernatant was cleared. In the last step insoluble material
was solubilized in denaturing binding buffer (table 3.25). Pellet was washed, sonicated
and centrifuged as described above, filtrated through 0.22 µm sterile filter and prepare
for the affinity purification.
3.2.3.11 HisLecEGF purification under denaturing conditions
Ni-NTA affinity column was prepared as described under 3.2.21. For the purification
under denaturing conditions, either 8M Urea, or 6M Guanidine were used as strong
chaotrops and denaturing agents. Column was equilibrated with 5 column volumes of
denaturing binding buffer until stabilized base-line.Isolated protein fraction was applied
at the flow rate of 1ml/min, and column was thoroughly washed with the binding buffer.
For the removal of non-specifically bound proteins, column was washed with 10 column
volumes of wash buffer. His-tagged proteins were eluted with 5 column volumes of low
pH elution buffer, and the column was immediately re-equilibrated with the loading buffer
of neutral pH. pH value of the eluted fraction was set up to 7.0 with 1 M Tris buffer. All
chromatography fractions were analyzed by SDS-PAGE.
Table 3.25: Inclusion bodies wash buffer and buffers for the Ni-NTA IMAC under denaturing conditions
Inclusion bodies wash buffer
100 mM Tris
pH 8.0
Lysis (Binding) Buffer
100 mM NaH2PO4
10 mM Tris
8 M Urea or 6 M Gu-HCl, pH 8.0
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Wash Buffer
100 mM NaH2PO4
10 mM Tris
8 M Urea or 6 M Gu-HCl, pH 6.3
Elution Buffer
100 mM NaH2PO4
10 mM Tris
8 M Urea or 6 M Gu-HCl, pH 4.5
3.2.3.12 Mass spectrometry analysis of proteins
Protein identity was confirmed by analysis of protease-digested fragments, and by mass
determination. Protein was eluted in either 8 M Urea, or 6 M GuHCl under denaturing
conditions, reduced with 10 mM DTT for 30 min. at RT, and alkylated when necessary
(to prevent re-oxidation of reduced disulfides with 50 mM iodoacetamide (final conc.).
Alkylation was done at RT for 15 min. in the dark, and reaction was stopped by
decreasing pH bellow pH 4.5. Protein was desalted on reverse-phase HPLC
(Amersham, Pharmacia) using C4 Vydac column for hydrophobic interactions. Protein
was eluted in 10-80% gradient of 0.1% TFA in methanol and 80% acetonitrile in H2O.
Protein presence in eluted fractions was confirmed by SDS-PAGE, and molecular weight
of the protein in volatile buffer was either directly analyzed or proteins were digested with
proteases. Proteins were digested with different proteases as follows: for the trypsin
digestion, 5 µg protein was digested in 0.1M Tris buffer, pH 8.0, overnight at 37°C, with
0.5 µg trypsin (SIGMA). For digestion of 5 µg protein, 1 µg V8 protease (SIGMA) was
used, and digestion was done in 0.1 M phosphate buffer, pH 6.8, overnight at 37°C. Lys-
C-protease (SIGMA) digestion was also performed in 0.1M Tris buffer, pH 8.0, for 45
min. at 37°C.
3.2.3.13 Protein refolding by dialysis
Protein was eluted as described in table 3.25, and 11 ml protein solution at 0.8 mg/ml
was reduced for 2h at 37°C with 0.1 M DTT. Reduced protein was diluted to 2M urea,
100 mM NaH2PO4, 10 mM Tris, pH 8.0, keeping protein concentration at 220 µg/ml, and
was stirred overnight at 4°C. Dialysis was done in buffers described in the table 3.26 in
tubes with 10 kDa cut off.
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Table 3.26: Protein refolding by dialysis, conditions
Tris-HCl, pH 8.0 EDTA GSH GSSG
100 mM 1 mM 10 mM 1 mM
100 mM 1 mM 1 mM 1 mM
100 mM 1 mM 1 mM 10 mM
First dialysis step was done at the ratio 1:40 of protein solution:dialysis buffer for 24 h at
4°C with buffer exchanges every 8-10h. After 24 hours protein solution was centrifuged
at 4°C and 10 000xg for 30 min. and dialyzed for another 48 h at 4°C against TBS
supplemented with 10 mM Ca2+, pH 7.6 at the same protein to buffer ratio, and buffer
was exchanged every 12 h. Aliquots were taken throughout complete procedure in
intervals of 4-12 hours and analyzed on SDS-PAGE and in an activity test. Second
dialysis set up was done with 5 ml protein solution at 1.55 mg/ml, which was reduced
with 100 mM DTT for 2h at RT. Protein was fast diluted with 45 ml cold H2O and dialyzed
in ratio 1:40 against 2 L of 25 mM Tris, pH 7.6 at 4°C. Since precipitates appear after 20
min., pH was raised to pH 8 with 1M NaOH, material was dialyzed overnight and was
ready for subsequent thrombin cleavage. Aliquots were also taken for the activity
analysis to monitor refolding.
3.2.3.14 Protein refolding by fast dilution and thrombin cleavage
Protein refolding by fast dilution was performed either as direct refolding, or with first His
tag removal and subsequent refolding, as described in tables 3.27-3.31. For the first set
up, protein that was eluted as described in table 3.25 at 1.55 mg/ml and reduced as
described. By fast dilution protein concentration was set at 100 µg/ml in cold buffer, and
refolding attempted as described in table. The quality of the material was checked on the
analytical RP-HPLC (Agilent Technologies).
Table 3.27: Protein refolding by fast dilution, set-up 1
Direct refolding (small scale, 10 ml total): effect of proteins ligands
• -IB isolation
• -Ni-NTA ⇒ 1.55 mg/ml, 120 mg/l total
• -Reduction with 100 mM DTT
• -HPLC check, soluble material
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• [HisLecEGF] decreased to 100 µg/ml
• Fast dilution in cold buffers
• 1M L-Arg
• 1:10 GSSG:GSH
• 1 mM EDTA
• pH 8.0
• 1M L-Arg
• 1:10 GSSG:GSH
• 1 mM EDTA
• 1:10 Fucose
• pH 8.0
• 1M L-Arg
• 1:10 GSSG:GSH
• 1 mM EDTA
• 1:10 NeuNAc
• pH 8.0
• 60 h stir at 4°C
• HPLC control
• SDS-PAGE, 4-20% Tris-Glycine gel, reducing and non-reducing conditions
• Scale up and gel filtration
• Scale up to 250 ml set-up for fast dilution ⇒ 25 mg protein
• Gel filtration: 4 peaks, SDS-PAGE, 4-20% Tris-Glycine gel ⇒ not visible ⇒
concentrating
• ELISA based screening with blocking monoclonal antibodies
 After HPLC control of each reaction, first reaction set up was scaled up to 250 ml to get
enough material for further activity investigation. After 60 h fast dilution, protein was
concentrated prior to the gel filtration in an Amicon 500 ml cell concentration device with
the cut off membrane of 10 kDa at 4°C for 3.5 h, and the volume was decreased to 0.5
ml (500x concentration factor). Material was filtrated through 0.22 µm sterile filter prior to
the application onto size exclusion chromatography column Sephadex (Amersham,
Pharmacia). Proteins were chromatographied in TBS buffer with 2 mM Ca2+ at 4°C and
the flow rate of 1 ml/min. Collected fractions were analyzed on SDS-PAGE and by
activity test.
Table 3.28: Protein refolding by fast dilution; set-up 2
Tag removal prior to the refolding (small scale, 5 ml total): Dilution and dialysis
• IB isolation
• Ni-NTA in 6 M GuHCl⇒ 1.55 mg/ml
• Reduction with 100 mM DTT
• HPLC check, soluble material
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• [HisLecEGF] decreased to 155 µg/ml
• Fast dilution 1:10 in H20, pH 7.4⇒ removal of 6 M GuHCl, 100 mM DTT and 1 M L-Arg
• Dialysis against 2 L H20 ⇒ precipitation in 20 min
• pH increase to 10 ⇒ soluble, stir for 24 hours
• Thrombin cleavage
• Human thrombin: cleavage ratio(w/w) thrombin:protein = 1:100
• Buffer adjusted to 50 mM Tris, 150 mM NaCl, 2.5 mM CaCl2 ⇒
• Precipitation upon CaCl2 addition, removed by EDTA
• Cleavage at pH 8.0 for 12 h at RT • Cleavage overnight at 20°C -37°C
• Precipitation, SDS-PAGE analysis, activity test
Table 3.29: Protein refolding by fast dilution; set-up 3
Tag removal prior to the refolding (small scale, 5 ml total): Dialysis and dilution
• IB isolation
• Ni-NTA in 6 M GuHCl⇒ 1.55 mg/ml
• Reduction with 100 mM DTT
• HPLC check, soluble material
• Dialysis 1:40, 2X against 6 M GuHCl, pH 8.0, 18 h at 4°C
• Dilution 1:10 in 50 mM Tris, 150 mM NaCl, pH 8.0, 2.5 mM CaCl2 ⇒
• Precipitation upon CaCl2 addition, removed by EDTA
• Thrombin cleavage
• Human thrombin: cleavage ratio(w/w) thrombin:protein = 1:100
• Cleavage in 50 mM Tris, 150 mM NaCl, w/o CaCl2, 18 h at 20°C
• After 18 h precipitation
• SDS-PAGE analysis, activity test, Bradford: 10 µg/ml HisLecEGF in supernatant
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Table 3.30: Protein refolding by fast dilution; set-up 3
Folding by dilution and dialysis, tag removal, oxidation
• IB isolation
• Ni-NTA ⇒ 1.55 mg/ml
• Reduction with 100 mM DTT
• HPLC check, soluble material
• Fast dilution: [HisLecEGF] decreased to 100 µg/ml ⇒ 37.2 mg in 372 ml in
• 0.1 M Tris-HCl, pH 8.0, overnight at 4 °C
• Concentration and dialysis:
• Amicon cell (cut off 10 kDa) 3h at 4°C conc. factor 7.44, 50 ml final
• Dialysis 1:40 against 50 mM Tris, 2 mM EDTA, pH 8.0
• Thrombin cleavage
• Human thrombin: cleavage ratio(w/w) thrombin:protein = 1:100
• Cleavage in 50 mM Tris, 150 mM NaCl overnight at 37°C
• Thrombin removal with benzimidine sepharose (Amersham, Pharmacia)
• Oxidation and folding
• GSSG:GSH
• 1 mM : 0.1 mM
• GSSG:GSH
• 1 mM :1 mM
• GSSG:GSH
• 10 mM :1 mM
• Dialysis against TBS+2 mM Ca2+
• Activity test
Table 3.31: Protein refolding by fast dilution; set-up 4
Folding by dilution, dialysis, tag removal
• IB isolation
• Ni-NTA ⇒ 1.2 mg/ml
• Reduction with 100 mM DTT
• HPLC check, soluble material
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• Fast dilution: [HisLecEGF] decreased to 68 µg/ml in 1.06 L cold buffer 0.1 M Tris-HCl,
pH 8.0, 1M L-Arg, 1 mM EDTA, 48 h at 4°C
• Concentration: 5 h at 4°C to 50 ml
• Dialysis 1:40 against 50 mM Tris-HCl, pH 8.0, 2X in 48 h total
• Thrombin cleavage
• Human thrombin: cleavage ratio(w/w) thrombin:protein = 1:100
• Cleavage in 50 mM Tris, 150 mM NaCl overnight at 37°C
• Thrombin removal with benzimidine sepharose (Amersham, Pharmacia)
• HPLC check: no correct peaks (aggregation w/o precipitation)
• SDS-PAGEanalysis: reducing, non-reducing conditions cleavage succesful, aggregates
in the sample
• Activity test
3.2.3.15 ELISA based screening on protein refolding and activity
ELISAs with monoclonal blocking antibodies against human E-selectin were performed
to test the correct folding and the activity of expressed LecEGF domain of E-selectin. As
postive control and standard molecule, E-selectin/IgG, produced as secreted protein in
CHO cells was used. NuncMaxiSorp plates (Invitrogen) were coated with 100 µl protein
in standard TBS buffer with 2 mM calcium, pH 7.6, (TAB) or appropriate folding buffer.
For the standard curve, E-sel/IgG was plated at 1 µg/ml - 0.05 µg/ml, and LecEGF in
various concentrations. Plate was incubated overnight at 4°C and washed 3 times with
TAB. Wells were blocked with 3% BSA in TAB at RT for 2h, and washed as described
above. 1 µg mouse, anti-human E-selectin mAb 7A9 [249] in TAB was added to each
well and the plate was incubated for 4 h at 37°C or at 4°C overnight. After the plate was
washed, a secondary antibody (SIGMA A-5278), peroxidase-conjugated goat anti-
mouse IgG diluted 1:6000 was added. The plate was incubated overnight at 4°C to allow
complex formation between the antibodies, and washed as usual. Ortho
 phenylen-diamine (OPD) tablets (SIGMA) were used as peroxidase substrate. Tablets
were dissolved in 0.05 M phosphate-citrate buffer, pH 5.0 at the final concentration of
0.4 mg/ml, and 10 µ l 35% H2O2 solution was added to 10 ml OPD-solution. 100 µl
substrate solution was added to each well and the color was developed for 5-10 min. at
RT before reaction was stopped by adding 1 M H3PO4.  Absorbance was measured at
490 nm in SoftMaxPro plate reader (Molecular Probes), and protein calculated from the
standard plot for E-selectin/IgG.
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3.2.3.16 HisTag cleavage with thrombin
The thrombin cleavage sequence in vector pET-15b is placed between HisTag and
LecEGF sequence. To generate native protein for further analysis, tag was cleaved with
thrombin. The optimization was done with the thrombin (Novagen), following supplier
prescriptions. Reaction set up was done at 1:25 and 1:100 dilution of the protease stock
solution (1U/µl) at 16°C for 22h. Cleavage was performed in both native and denaturing
conditions, as described in the table 3.32. Denaturing conditions were done in 6M
GuHCl, and for native conditions proteins were dialyzed against PBS.
Table 3.32:. Reaction set up for thrombin cleavage
1:25 in PBS 1:100 in PBS 1:25 in 0.6M
GuHCl
1:100 in 0.6M
GuHCl
Cleavage
Buffer 10x
1x 8 µl 8 µl 8 µl 8 µl
Thrombin
solution
dilution
1 µl 1µl (1:25)
= 0.04 U
1µl (1:100)
= 0.01 U
1µl (1:25)
= 0.04 U
1µl (1:100)
= 0.01U
Protein
solution
10 µg protein 64 µl 64 µl 32.3 µl 32.3 µl
H2O dest. Ad 80 µl 7 µl 7 µl 38.7 µl 38.7 µl
During 22h of protein digestion aliquots were taken at different time-points. Control
reaction was performed with the control protein (48 kDa) supplied by Novagen and was
cleaved in the two subunits of 35 and 13 kDa. Negative control was done with dilution
buffer instead of protein solution.
3.2.3.17 Screening for the refolding conditions on the asymmetrical field-flow
fractionator (Wyeth)
Proteins eluted from Ni-NTA IMAC in 6 M GuHCl, 50 Mm Tris, pH 8.0, were reduced in
100 mM DTT at RT and concentrated to 5 mg/ml. Sample status in solution and
concentration were controlled on analytical RP-HPLC.
For the screening set up, 50 µl protein solution at 5.2 mg/ml were fast diluted in 2 ml of
each of the buffers listed in table 3.34, in a 24-wells cell culture plate. Samples were
incubated at 4°C for 12-48 hours, and inspected visually for possible precipitation.
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Reaction conditions with no visible precipitation were further analyzed on AfFF matrix
and HPLC for protein status in solution. The best reactions conditions (table 3.33) were
scaled up to 50 ml, in which protein concentration was kept under 100 µg/ml.
Table 3.33: Reaction set up for optimal refolding conditions
Buffer 1b Buffer 1c Buffer 3c Buffer 13c Buffer 20b
0.5 M CHES, pH
9.5
0.5 M CHES, pH
9.5
0.5 M CHES, pH
9.5
0.5 M CHES, pH
9.5
0.5 M Tris, pH 8.0
1,2-propanediol,
25%
1,2-propanediol,
25%
2-etoxyethanol,
20%
Hexa-
decyltrimethylam
monium bromide,
10 mM
Octyl glucoside,
0.05%
83.2 µg/ml
protein
83.2 µg/ml
protein
83.2 µg/ml
protein
83.2 µg/ml
protein
83.2 µg/ml
3.4 mM GSH
0.5 mM GSSG
3.4 mM GSH
0.5 mM GSSG
3.4 mM GSH
0.5 mM GSSG
3.4 mM GSH
0.5 mM GSSG
3.4 mM GSH
0.5 mM GSSG
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Table 3.34: Buffer composition for the screening on the Asymmetrical Field-Flow Fractionator
Buffer
Components
A: 0.5 M citrate,
pH 8.0
B: 0.5 M Tris,
pH 8.0,
C: 0.5 M CHES,
pH 9.5
1. 1,2-propanediol, 25% 17 Lithium sulphate, 0.2 M.
2. 1,6-hexanediol, 10% 18. Magnesium formate, 0.2 M
3. 2-etoxyethanol, 20% 19. Na/K tartarate ,0.5M
4. 2-methyl-2,4-pentanediol (MPD), 30% 20. Octyl glucoside, 0.05%
5. Ammonium acetate, 0.2 M 21. Pentaerythritol propoxylate, 30%
6. Ammonium sulphate, 0.2 M 22. Polyacrylic acid, 20%
7. Bicine, 0.5 M 23. Polyethyleneglycol monomethyl ether 550, 10%
8. Di-ammonium tartrate, 0.2 M 24. Polyviniylpyrrolidone, 20%
9. Dioxane, 10% 25. Potassium thiocyanate, 0.1 M
10. Ethanol, 20% 26. Sodium chloride, 1 M
11. Ethylene imine polymer, 2% 27. Sodium citrate, 0.2 M
12. Heparin sulphate, 5 mM 28. Sodium malonate, 0.2 M
13. Hexadecyltrimethylammonium bromide, 10 mM 29. Sodium succinate, 0.2 M
14. Immidazole-HCl, 0.2 M 30. Tacsimate, 25% (v/v)
15. Isopropanol, 15% 31. Tert-butanol, 25%
16. Jeffamine M-600, 30% 32. Trimethylamine N-oxide, 0.2 M
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After 48 h of protein refolding in described buffer, the redox system (0.5 mM GSSG and 5 mM
GSH, respectively) was added to each reaction set up to get 1:10 final ratio of oxidized to
reduced agent. Because of the presence of 1.6 mM DTT in the buffer, 3.4 mM GSH and 0.5 mM
GSSG were added. To maintain the appropriate environment for redox reaction, solution pH
was controlled, and for CHES containing buffers adjusted to pH 8.0-8.5 with sulphonic acid.
Samples were incubated at 4°C for 48-72 hours, filtrated through 0.22 µm sterile filter and
concentrated in a Vivaspin 20 ml concentrator (7 kDa cut off) in an Eppendorf centrifuge 5804
R, at 3000 rpm and 4°C for the concentration factor 30. Refolding reaction was further analyzed
on gel filtration and controlled for the “in-solution” status on analytical RP-HPLC.
3.2.3.18 HisLecEGF expression in M9 minimal medium
Protein expression was optimized in M9 minimal medium with clone pET-15bHisLecEGF in E.
coli strains AD 494, BL 212 (DE3) and Rosetta gami. Medium was prepared as described in the
table 3.35 and supplemented according to the table 3.36. pH was set to 7.4 with 2M NaOH, and
the solution autoclaved.
Table 3.35: Components of 1 L M9 minimal medium
Na2HPO4 anhydr. 10.4 g
KH2PO4 3 g
NaCl 0.5 g
NH4Cl 1 g
Table 3.36: Supplements to M9 minimal medium
1M MgSO4 2 ml
1M CaCl2 0.1 ml
20% Glucose 10 ml
The solutions were sterile filtrated.
Prior to use, 12.1 ml were added per 1 L medium.
Biotin solution at 1 mg/ml and sterile filtrated thiamin solution at 10 mg/ml were added to the
medium at 1:100 and 1:1000 ratio, respectively. 3 ml culture set up was done from all 3 strains
in LB-medium with 50 µg/ml Ampicilin and was grown overnigt at 37°C. 240 µl cell suspension
was centrifuged at 4°C and 4000xg for 5 min., and pellets were resuspended in 4 ml M9 minimal
medium. The cultures were further cultivated at 37°C, until they reached OD600 of 0.6-0.8. 1 mM
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IPTG was added for induction. 500 µl aliquots were taken at different time points and analyzed
for protein expression on SDS-PAGE.
3.2.4 Cloning into pINompA I
Cloning vector pINompA I possesses secretion signal sequence of the bacterial protease, outer
membrane protein A [250]. DNA sequence coding for LecEGF domain of human E-selectin was
PCR amplified from genomic DNA as described under 3.2.2.2.
Primers’ sequences:
FW pINompALE (5’-Primer):
5’-ATC GGA ATT CCT GGT CTT ACA ACA CCT CCA
GAA TTC: EcoRI restriction site
LEZZ3 (3’-Primer):
5’-GCT CGG ATC CTT ACA GGG CTG TAC AGT TCA C
GGA TCC: BamHI restriction site
TAA: Stop codon
3.2.4.1 Restriction enzyme digestion of insert and vector
Restriction enzyme digestion was performed as described under 3.2.2.3, with the enzymes
EcoRI and BamHI.
3.2.4.2 Vector dephosphorylation
Vector pINompA I was dephosphorylated as described under 3.2.2.4.
3.2.4.3 DNA-purification with GenEluteTM Gel Purification Kit
Insert and vector DNA were purified and prepared for ligation as described under 3.2.2.5
3.2.4.4 Ligation into pINompA I
Ligation reaction was prepared as described under 3.2.2.6 and table 3.37 and was conducted
overnight at 4°C using DNA ligase (New England Biolabs).
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Table 3.37: Ligation reaction set up for ligation of LecEGF into pINompA I
Vector 4 µl (0.1-5µg)
Insert 6 µl (0.1-5µg)
Ligation buffer 10x 1.5 µl, 1 x
ATP 10 mM 1 mM
Ligase 20-500 U
Sterile H2O Ad 15 µl
3.2.4.5 Chemical transformation into E.coli
Transformation with ligation mix into E.coli DHα5 was done as described under 3.2.2.7.
3.2.4.6 Electro transformation into E.coli
Prior to the electroporation, the ligation mix was dialysed to remove salts present in ligation
buffer. 10 µl ligation mix was dialyzed against autoclaved H2O for 1 h at RT with the filter VSWP
02500 Typ VS, 0.025 µm (Milipore). Dialyzed mixture was added to competent cells and
carefully mixed. Cells were pipetted in the pre-cold electroporation cuvette. Electroporation was
done at 400 Ω, 1.75 kV and 25 µF with the time constant between 6-8 ms. Just after the electro-
pulse, 1ml SOC-medium was added to the cells which were subsequently incubated at 37°C,
and 550 rpm for 1 h. After phenotypic expression, 100-500 µl transformed cells were plated on
the agar plate and colonies grown overnight at 37°C.
Positive control was plasmid w/o insert, and for the negative control dephosphorylated vector.
3.2.4.7 DNA isolation and clone analysis
DNA isolation was done as described under 3.2.2.8
Isolated plasmid DNA was controlled for the presence of correct fragment by restriction enzyme
digestion with EcoRI and BamHI, or NdeI and PstI and by PCR.
For the sequencing, DNA was isolated as described, eluted in sterile H2O and sent for
sequencing to Firma Microsynth GmbH Sequencing Group, Balgach.
3.2.5 Cloning into pET-11c
pET-11c vector enables cloning of recombinant proteins without any tag, so that expressed
recombinant protein corresponds, is as native as possible.
79
3.2.5.1 DNA cloning and manipulation
All DNA manipulations were done as described in 3.2.2.2 to 3.2.2.9.
3.2.5.2 Optimization of protein expression
To find the optimal conditions for protein expression in terms of bacterial strain, time, and
medium composition, 50 ml culture set up was prepared as described under 3.2.3.8. 100 µl
culture was taken at different times and centrifuged for 5 min at 16 000g, RT and pellet was
resuspended in an appropriate volume of SDS-PAGE reducing buffer. Protein expression was
analyzed on SDS-PAGE.
3.2.5.3 Protein preparation and analysis on MS
Protein was isolated from the total cell protein and prepared for MS as follows: protein-prep from
250 ml culture was solubilized as described under inclusion bodies isolation. Vydac C18 column
was used for RP-HPLC. Buffer A for column equilibration and protein binding was 0.1% TFA in
H2O, and proteins were eluted in gradient of 60-75% B (80% acetonitrile in 0.1% TFA) at 1
ml/min B in 10 min. Collected fractions were analyzed by SDS-PAGE and protein-containing
fractions were pooled together and lyophilized. Lyophilization was done in dry ice, overnight,
resulting in 13.4 mg lyopihilized protein. Lyophilizate was dissolved at 2 mg/ml in 6M GuHCl,
and reduced further as described under 3.2.2.9. MS analysis of intact protein and protein
digests were prepared as described under 3.2.2.10 respectively.
3.2.5.4 Protein purification by ion-exchange chromatography
Inclusion bodies isolation from 750 ml culture was done as previously described, with extensive
wash in 0.1M Tris, pH 8.0, 5 mM DTT and in the presence of protease inhibitor. Final
solubilization step was done in 8M urea buffer, which was purified over Amberlite, an ion
exchanger resin. Anion exchange chromatography was done on Mono Q column, Amersham,
Pharmacia, first equilibrated with 10-column volume of buffer A (6M urea, pH 8.0, 1 mM DTT, 20
mM Tris). 30 ml protein solution, at 2.8 mg/ml were applied, and the ion exchange was done in
gradient 0-80% buffer B (6M urea, pH 8.0, 1 mM DTT, 20 mM Tris, 1M NaCl) in 60 min. with the
flow rate 1.5 ml/min. 4 ml fractions were collected and analyzed on SDS-PAGE.
3.2.5.5 Protein purification by RP-HPLC
Reverse phase HPLC was done on preparative scale on Source 5 RP column ST 4.6/150 with
the polystirene/divinyl benzene beads. Protein-containing fractions from ion-exchange
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chromatography were pooled together and starting material for RP-HPLC was 15 ml protein
solution at 2.3 mg/ml. Prior to the application, material was controlled on analytical RP-HPLC
and reduced with 100 mM DTT at RT for 30 min. Buffer A was 0.1% TFA, and buffer B 80%
acetonitrile in 0.1% TFA. Gradient was programmed at 0-50% B with the flow rate of 1% B/min,
followed by 50-95% B in 5 min. All eluted peaks were collected and analyzed on SDS-PAGE.
Fractions were pooled together and lyophilized overnight as described.
3.2.5.6 Optimization of RP-HPLC for LecEGF separation
RP-HPLC on analytical scale was done on Amersham RP-HPLC device on C4 column in order
to separate two expressed forms of LecEGF. 0.1% TFA in H2O was used as equilibration buffer
A, whereas elution buffer B was 0.1% TFA in acetonitrile. 50µl protein in 6M GuHCl, 5 mM DTT,
pH 8.0 at 100 µg/ml was injected, and different separations conditions were tested, as described
in the table 3.38. Eluted fractions were analyzed on SDS-PAGE.
Table 3.38: RP-HPLC conditions for LecEGF separation
Time
(min.)
(%A)  (%B) Flow
(ml/min)
Time
(min.)
(%A) (%B) Flow
(ml/min)
0.00 100 0 1.00 0.00 100 0.00 1.0
10.00 62.00 38.00 1.00 5.00 50.00 50.00 1.0
20.00 62.00 38.00 1.00 10.00 50.00 50.00 1.0
45.00 0 100.00 1.00 30.00 30.00 70.00 1.0
55.00 100 0.00 1.00 35.00 100 0.00 1.0
60.00 100 0.00 1.00
60.10 89.00 11.00 1.00
Time (%A) (%B) Flow Time (%A) (%B) Flow
0.00 100 0.00 1.0 0.00 100 0.00 0.5
5.00 50.00 50.00 1.0 5.00 50.00 50.00 0.5
20.00 45.00 55.00 1.0 10.00 50.00 50.00 0.5
30.00 30.00 70.00 1.0 30.00 30.00 70.00 0.5
35.00 100 0.00 1.0 35.00 100 0.00 0.5
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3.2.5.7 Protein refolding by fast dilution
Material lyophilized after RP-HPLC was dissolved in 6 M GuHCl, 10 mM Tris, pH 8.0, at 1 mg/ml
and was reduced for 30 min. at RT with 100 mM DTT. Fast dilution started at 4°C (Table 3.39)
in folding buffer with final protein concentration of 50 µg/ml.
Table 3.39: Procedure for fast dilution of LecEGF
• Lyophilizate dissolved at 1 mg/ml in in 6 M GuHCl, 10 mM Tris, pH 8.0, at 1 mg/ml and
reduced for 30 min. at RT with 100 mM DTT.
• Fast dilution and oxidation
• [LecEGF] decreased to 50 µg/ml in 16 and 20 ml, resp. in 0.5 M Tris-HCl, pH 8.0
0.05% dodecyl maltoside, 10 mM CaCl2, for 1 h at 4°C
• Added 0.5 mM GSSG for 5 days at 4°C
• HPLC control and protein concentration
• Dialysis
• Dialysis 1:30 against 150 mM NaCl, 50 mM Tris, pH 8.0, 0.05% dodecyl maltoside, 10
mM CaCl2  3 times in 72 hours total at 4°C
• HPLC control, protein concentration, SDS-PAGE and activity test
• HPLC check: correct, smaller peaks (still soluble material, no aggregation)
• Protein concentration: lower
• SDS-PAGE reducing, non-reducing: different species present
• ELISA –based activity test: inactive
• Dialysis to remove detergent and prolonged oxidation
• Dialysis 1:30 against 150 mM NaCl, 50 mM Tris, pH 8.0, 10 mM CaCl2
• 3 times in 72 hours total at 4°C
• Prolonged oxidation with 1 mM GSH and 0.1 mM GSSG
• HPLC control, protein concentration
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3.3 Expression of LecEGF domain of human E-selectin in
Baculovirus-infected insect cells
Baculovirus infected insect cells have been chosen as an expression system to facilitate proper
protein folding and disulfide bond formation in LecEGF domain of human E-selectin.
Recombinant protein was constructed with an N-terminal His tag, followed by the Precision
protease restriction site and N-terminus of native protein.
3.3.1 Intracellular expression of LecEGF
3.3.1.1 Cloning into pBacPack (BD Pharmingen)
Cloning into pBacPack generated recombinant LecEGF with an N-terminal His tag and
PrescissionTM protease (Amersham, Pharmaca) restriction site. DNA sequence coding for
LecEGF domain of human E-selectin was PCR integrated into pBacPack cloning vector as
described bellow (tables  3.40 and 3.41).
3.3.1.2 PCR generation of LecEGF
DNA sequence coding for LecEGF domain of human E-selectin was PCR amplified from
template plasmid pET-11cLE, in which sequence of LecEGF was cloned into vector pET-11c
Primers’ sequences:
ESE1 (5’- primer):
5’-GAA GTT CTG TTC CAG GGG CCC TGG TCT TAC AAC ACC TCC ACG
Underlined: Precision cleavage site: GAA GTT CTG TTC CAG GGG CCC
ESE2 (3’-primer):
5’-CTC GGT ACC AGA TCT TCT AGA TTC GTT ACA CAA TTT GCT TCA CAC TT
In bold: STOP codon: TAA
Table 3.40: PCR reaction set up for LecEGF amplification
dNTPs (10 µM) 0.6µl
Oligo 1(100 µM) 0.5 µl
Oligo 2 (100 µM) 0.5 µl
Template DNA
(plasmid)
0.3 µl = 0.05 µg
10 X Turbo Pfu buffer 5.0 µl
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Turbo Pfu 1.0 µ
Sterile H2O Add 50 µl
PCR reaction was done under following conditions (Table 3.41) with the hot start.
Table 3.41: PCR conditions for LecEGF amplification
Initial denaturation 95°C 5 min.
Denaturation 95°C 30 sec  45 cycles
Annealing 55°C 30 sec  45 cycles
Elongation 72°C 1 min  45 cycles
Final elongation 72°C 10 min
Pause 4°C ∞
After the amplification, PCR fragment was purified with the PCR purification kit from SIGMA,
according to the manufacturer instruction.
3.3.1.3 PCR integration of His-Precision-LecEGF (HPLE) into pBakPack [251]
For the integration of HPLE in vector pBacPack, following reaction set-up was used:
Table 3.42: PCR set-up for HPLE integration
PCR reaction was performed as for the usual amplification, except that elongation step was run
at 68°C for 2 min/kb of generated plasmid.
dNTPs (10 µM): 0.6 µl
PCR fragment 2.0 µl (200-300 ng)
Recipient plasmid 0.5 µl (50-100 ng)
Turbo Pfu
(Stratagene)
1.0 µl
10 X Turbo Pfu
buffer
5.0 µl
Sterile H2O Ad 50 µl
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Table 3.43: PCR conditions for HPLE integration into pBakPack
Initial
denaturation
95°C 30 sec.
Denaturation 95°C 30 sec  18 cycles
Annealing 55°C 30 sec 18 cycles
Elongation 68°C 13 min   18 cycles
Final elongation 68°C 10 min
Pause 4°C ∞
DpnI digestion
(10 U)
37°C 3 h
At the end of PCR reaction, restriction enzyme digestion was performed with DpnI to digest
methylated DNA originating from recipient plasmid.
3.3.1.4 Purification of PCR-integration product
 PCR integration mixture was purified. using the DNA gel extraction kit (Qiagen) according to
the manufacturer prescription. Finally, purified DNA was eluted in 40 µl sterile H2O.
3.3.1.5 Electro transformation into E.coli
E.coli cloning strain XL1-Blue was transformed with DNA by electroporation.
50 µl electrocompetent cells were thawed on the ice, 4 µl DNA was added and thoroughly
mixed. Cells with DNA were pipetted into pre-chilled electroporation cuvette (BIO-RAD), and
were pulsed at 1.5 kV, as described under 3.2.4.6. 1 ml SOC medium was added and
phenotypic expression conducted for 1 h at 37°C, 550 rpm shaking. 100 µl and 300 µl cell
suspension were plated on agar plates and incubated overnight at 37°C.
3.3.1.6 Colony PCR for colony analysis
Grown colonies were analyzed in PCR reaction with the specific LecEGF primers. PCR was
done in the set-up described in the table 3.36. Instead of template plasmid DNA, grown colonies
were touched with the sterile toothpick that was inoculated in the PCR mix and then in the wells
with LB medium.
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Table 3.44: PCR reaction set up for analysis of grown colonies
dNTPs (10 µM) 0.16 µl
Oligo 1(100 µM) 0.2 µl
Oligo 2 (100
µM)
0.2 µl
Template DNA
(plasmid)
_
10 X Taq Poly
buffer
2.0 µl
Taq Poly 0.5 µl
Sterile H2O Ad 20 µl
Reaction was prepared as master mix to avoid pipetting imprecision and was done as a hot start
PCR. 150 µl LB medium/well with the appropriate antibiotic was plated into 96-wells plate.
Single colony from the plates that were analyzed by PCR, were also inoculated in LB medium,
and the plate was incubated at 37°C. For colonies which were found to be positive by PCR, 3 ml
culture was started at 37°C in the 96-well plate. From 3 ml overnight culture in the LB medium
with the appropriate antibiotic. DNA was then isolated as described previously, with the Mini
Prep extraction kit (Amersham Pharmacia) and was sequenced with either standard primers, or
with the insert-specific primers.
3.3.1.7 Cloning into pFastBac (Invitrogen)
HPLE was subcloned into pFastBac to enable transfection of recombinant viral DNA into insect
cells.
3.3.1.8 PCR generation of HPLE compatible with pFastBac
PCR reaction was performed as described under 3.3.1.2
3.3.1.9 PCR integration of HPLE in pFastBac
PCR integration was done as described under 3.3.1.3.
3.3.1.10 Purification of PCR product
Purification of PCR-integration product was done as described under 3.3.1.4:
86
3.3.1.11 Transformation into E.coli
Transformation into E.coli XL Blue-1 was done as described under 3.3.1.5
3.3.1.12 Colony PCR for colony analysis
Colony PCR for colony analysis was done as described under 3.3.1.6.
3.3.1.13 Preparation of transposition agar plates for E.coli DH10Bac (Invitrogen)
Agar solution was prepared as described previously and autoclaved. When cooled to 55°C,
antibiotics stock solutions were added and mixed with the agar solution before pouring plates
under sterile conditions. Plates were stored in the dark at 4°C, stable for up to four weeks.
Aqueous solutions of compounds were sterilized by filtration through a 0.22 µm filter and stored
in small aliquots in light tight containers at -20°C.
Table 3.45: Antibiotics used for the preparation of transposition plates
Stock Solution Concentration Final concentration in agar
Kanamycin 50 mg/ml in water 50 µg/ml
Tetracycline 10 mg/ml in ethanol 10 µg/ml
Gentamycin 7 mg/ml in water 7 µg/ml
X-gal 100 mg/ml in methanol 100 µg/ml
IPTG 40 mg/ml in water 40 µg/ml
3.3.1.14 Transformation into E.coli DH10Bac and transposition reaction
DH10Bac chemically competent cells have viral DNA and transposases in the genome, which
enables transposition reaction between recombinant plasmid and viral DNA. DH10Bac
competent cells were thawed on ice and 100 µl aliquots were dispensed into 1.5 ml microfuge
tubes. 1 µg/5 µl recombinant donor plasmid was added and DNA was gently mixed with the
cells. The mixture was incubated on ice for 30 min. and was heat-shocked by transferring to
42°C for 45 sec. The mixture was chilled on ice for 2 min., 900 µl SOC medium was added and
suspension was incubated at 37°C with medium agitation (225) for 4-6 hours. Cells were serially
diluted using SOC medium to 10-1, 10-2 and 10-3. 100 µl of each dilution was spread evenly over
the agar plates with the appropriate antibiotics and plates were incubated at 37°C for 48 hours.
3.3.1.15 Clone analysis and bacmid DNA isolation
48 h after plating, white colonies containing the recombinant bacmid DNA were selected for
isolation of recombinant bacmid DNA. Before isolating DNA, candidate colonies were picked
and streaked to fresh plates containing X-gal and IPTG, to verify the phenotype. Plates were
incubated again for 48 h at 37°C.
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From a single colony that was confirmed to have a white phenotype, 4 ml LB medium
supplemented with 50 µg/ml kanamycin, 7 µg/ml gentamicin, and 10 µg/ml tetracycline was
inoculated and grown to stationary phase (up to 24 hours) shaking at 300 rpm. 1.5 ml of culture
was centrifuged at 14000xg for 1 min. Supernatant was removed and each pellet resuspended
in 0.3 ml of solution I (15 mM Tris, pH 8.0, 10 mM EDTA, 100 µg/ml RNase A). 0.3 ml of solution
II (0.2 N NaOH, 1% SDS) was added and gently mixed. Mixture was incubated at room
temperature for 5 min., when 0.3 ml 3 M potassium acetate pH 5.5 was added slowly and mixed
gently during addition. A thick white precipitate of protein and E.coli genomic DNA was formed.
The sample was incubated on ice for 10 min. and centrifuged for 10 min. at 14000 g. The
supernatant was transferred to the tube containing 0.8 ml isopropanol, mixed by gently inverting
tube a few times and incubated on ice for 10 min. The mixture was centrifuged for 15 min. at
14000xg, supernatant was carefully removed and 0.5 ml 70% ethanol was added to
microcentrifuge tube. After another centrifugation at 14000xg for 5 min., supernatant was
removed and the pellet was air-dried for 10 min. at RT. DNA was dissolved in 40 µl sterile water
and kept at 4°C. 0.9 ml recombinant bacmid culture was combined with 0.1 ml sterile glycerol,
and stored at -80°C as a glycerol stock.
3.3.1.16 PCR transposition control
PCR analysis was performed to verify the presence of transposed HPLE in DNA isolated from
E.coli DH10Bac. Reaction was performed according to the manufacturer instruction using M13
standard primers.
Primers’ sequences:
M 13 FW (5’ primer):
5’-GTT TTC CCA GTC ACG AC-3’
M 13 RW (3’ primer):
5’-CAG GAA ACA GCT ATG AC-3’
Table 3.46: PCR reaction set-up for the transposition control
dNTPs (10 µM) 1 µl
Oligo 1(10 µM) 1.25 µl
Oligo 2 (10 µM) 1.25 µl
Template DNA (100 ng) 1 µl
10 X Taq Poly buffer 5.0 µl
Taq polymerase 1.0 µ
Sterile H2O Ad 50 µl
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The PCR reaction was performed with the standard program recommended by supplier as
described in the Table 3.47.
Table 3.47: PCR reaction parameters:
Initial denaturation 93°C 3 min.
Denaturation 94°C 45 sec   30 Cycles
Annealing 55°C 45 sec   30 Cycles
Elongation 72°C 5 min     30 Cycles
Final elongation 72°C 7 min
Pause 4°C ∞
The PCR products were analyzed on a standard (1%) agarose gel.
3.3.1.17 Transfection into Sf 9 insect cells
Sf 9 insect cells used for transfection were grown as adherent cultures in TC100 medium
(Invitrogen) supplemented with 10% FCS (Invitrogen) in T-flasks (25 or 75 cm2, Nunc). Cells
were regularly passaged twice per week in 1:3 dilution. 3 days after splitting healthy, confluent
cells were used for transfection. After microscope inspection of the cells, medium was decanted
and attached cells thoroughly re-suspended in 10 ml fresh medium with serum. Cells were
seeded in a 6-well plate at 1x106 in not less then 1.5 ml SFM. Cells were let to attach for 20 min.
at RT.
2 µg of DNA were mixed with 100 µ l of SFM in PST tube I and 5 µ l Cellfectin reagent
(Invitrogen) with 100 µl of SFM in PST tube II. Cellfectin solution was added to the DNA mixture
and incubated at RT for 15 min., occasionally gently tapping the tube to mix the solution. 0.8 ml
SFM was added and the solution was ready for the transfection. Attached cells (max. 50-60%
confluent) were washed twice with 2 ml medium and finally 1 ml medium with prepared DNA
was added. Plate was incubated at 28°C for 5 h, and medium was aspirated and exchanged.
Plate was further incubated for 5 days, cells were inspected and medium was harvested for
plaque assay and viral amplification.
3.3.1.18 Viral amplification and plaque assay
Plaque assay was performed for isolation of single virus and viral titer determination. For this
purpose Sf 21 cells were used. Cells were cultivated as described under 3.2.16 and Sf 9 insect
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cells, grown in a T25 culture flask and resuspended in 12 ml TC100 medium with 10% serum.
Cells were plated at 106 cells/well in 12-wells plate. Cells were attached for 30 min at RT. Serial
10 folds virus dilutions were prepared (from 10-1 to 10-6) in 1.5 ml TC100 serum free medium
and mixed thoroughly in the plate. 0.5 ml virus suspension was given to the cells which were
infected for 1 h at RT. The 0.5% agarose overlay was prepared in Excell400 (JRH Bioscience)
medium+10% FCS and pre-warmed to 41.5°C. Viral suspension was removed from the cells
and 2 ml agarose overlay gently poored over the cells. The overlay was solidified in 20 min. The
plate was then sealed with parafilm and incubated 4-5 days at 28°C. To facilitate plate
inspection and viral counting after 4-5 days, 250 µl of neutral red solution was poored over the
agarose and incubate at RT for 1 h. Formed viral plaques were counted to calculate viral titar,
and single plaque was isolated for further amplification. Virus was amplified in Sf 9 suspension
cells at 1.2x106 cells/ml in SF 900 medium for 3-4 days at 28°C. The state of the culture
infection was determined by cell number, viability and cell diameter, using the CEDEX cell
counter (Innovatis, GmBH). The culture supernatant was harvested by centrifugation at 400xg,
for 10 min. at 10°C, when cell viability dropped below 90%. The titer of the viral stock was
determined again by plaque assay prior to the protein production.
3.3.1.19 Protein production analysis
Protein production was initially followed on a small scale by analyzing pellet from the first viral
amplification. 1 ml of insect cell culture supernatant was centrifuged as described above and
pellet was washed in 0.5 ml PBS buffer. Centrifugation step was repeated, final pellet
resuspended in 250 µl 5 X reducing SDS-PAGE buffer and analyzed on SDS-PAGE and
reducing, denaturing Western blot with anti-His tag antibodies. Time-course of protein
expression was also followed. Culture suspension of 106 Sf 9 cells/ml in Sf900 II medium
(GIBCO) was infected at M.O.I (multiplicity of infection) of 0.6, cells were grown in suspension at
28°C, 90 rpm and aliquots were taken at different time points, starting at 24 h p.i. (post
infection), up to 96 h p.i. For standard protein production, suspension of 106 Sf9 cells/ml was
infected at M.O.I of 0.6, cells were grown in suspension at 28°C, 90 rpm and harvested 72 h
post infection. Prior to the harvest, cells were inspected for cell number, viability and diameter,
and were centrifuged at 10°C, 1000 rpm for 10 min. Supernatant was decanted, and cells lysed
in a lysis buffer (0.05 M Tris, pH 8.0, 0.5 M NaCl, 1 mM PMSF, protease inhibitor cocktail, 0.5
ml). Cells were first resupenden and then sonicated on ice with burst at 70% output, 4x 20 sec
with 10’’ break in between. Finally, cell-lysates were centrifuged for 1 h at 4°C and 22000 rpm in
ultracentrifuge Sorval 1000. Cell pellet was washed twice as described, and isolated soluble
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cytoplasmic fracton was analyzed on SDS-PAGE, Western blot and by Ni-NTA affinity
chromatography under native conditions.
3.3.1.20 Ni-NTA purification under native conditions
Ni-NTA affinity chromatography was used to purify HPLE from soluble cytoplasm under native
conditions. The column was prepared and run as described under 3.2.3.9. Buffers used for
purification are described in the Table 3.48. All chromatography steps were analyzed on the
SDS-PAGE, and also in Western blot with mAb 7A9 and anti-His tag antibody.
Table 3.48: Buffers for Ni-NTA IMAC purification of HPLE under native conditions
Lysis Buffer
50 mM NaH2PO4
300 mM NaCl
10 mM imidazole, pH 8.0
Wash Buffer
50 mM NaH2PO4
300 mM NaCl
20 mM imidazole, pH 8.0
Elution Buffer
50 mM NaH2PO4
300 mM NaCl
250 mM imidazole, pH 8.0
3.3.2 LecEGF secretion into the medium
Cloning into pAcGP67a (Pharmingen) generated recombinant LecEGF with an N-terminal signal
sequence from insect acidic glycoprotein GP67. Either Flag peptide (DYKDDDK) was
introduced as a C-terminal tag, or recombinant protein was produced w/o any tag on the C-
terminus. DNA sequence coding for LecEGF domain of human E-selectin was PCR integrated
into pAcGP67a cloning vector, as described in the Table 3.49 and 3.50.
3.3.2.1 PCR generation of LecEGF
DNA sequence coding for LecEGF domain of human E-selectin was PCR amplified from
template plasmid pFastBacHPLE, in which sequence of LecEGF was cloned into vector
pFastBac.
Primers’ sequences:
ESEL1 (5’- primer):
5’-GCG CAT TCT GCC TTT GCG TGG TCT TAC AAC ACC TCC ACG
ESEL2 (3’-primer):
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5’-GGT CCC AGG AAA GGA TCA GAT TAC TTA TCG TCA TCG TCC TTG TAG TCC ACA
ATT TGC TCA CAC TTG
Underlined: Flag peptide (GGT CCC AGG AAA GGA TCA GAT TAC)
Underlined in bold: stop codon (TAA)
ESEL3 (3’-primer): 5’-GGT CCC AGG AAA GGA TCA GAT TAC ACA ATT TGC TCA CAC TTG
A-3’
Underlined in bold: stop codon (TAA)
Table 3.49: Cloning into pAcGP67a: PCR reaction set up for LecEGF+/-Flag
dNTPs (10 µM) 0.6 µl
Oligo 1(100 µM) 0.5 µl
Oligo 2 (100 µM) 0.5 µl
Template DNA
(plasmid)
0.3 µl = 0.05 µg
10 X Turbo Pfu buffer 5.0 µl
Turbo Pfu 1.0 µ
Sterile H2O Ad 50 µl
PCR reaction was done under following conditions with hot start.
Table 3.50: PCR conditions for LecEGF amplification
Initial denaturation 95°C 5 min.
Denaturation 95°C 30sec   45 Cycles
Annealing 55°C 30sec   45 Cycles
Elongation 72°C 1min     45 Cycles
Final elongation 72°C 10 min
Pause 4°C ∞
After the amplification, PCR fragment was purified with the PCR purification kit (SIGMA)
according to the manufacturer instruction.
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3.3.2.2 PCR integration of SSLecEGF+Flag (SSLecEGFFlag), and SSLecEGF into
pFastBac
For the integration of SSLecEGFFlag and SSLecEGF in vector pAcGP67a reaction set-up was
used as described under the 3.3.1.2., and the PCR conditions were as described in the 3.3.1.3.
At the end of the PCR reaction, restriction enzyme digestion was performed with Dpn I to digest
methylated DNA originating from recipient plasmid.
3.3.2.3 Purification of PCR-integration product
Purification of PCR product was done as described in 3.3.1.4.
3.3.2.4 Transformation into E.coli
E.coli strain XL1-Blue was transformed with plasmid DNA as described in 3.3.1.5.
3.3.2.5 Colony PCR for colony analysis
Grown colonies were analyzed in PCR reaction as described in 3.3.1.6.
3.3.2.6 Cloning into pFastBac
SSLecEGFFlag and SSLecEGF were subcloned into pFastBac to enable transfection of
recombinant viral DNA into insect cells.
3.3.2.7 PCR generation of SSLecEGFFlag and SSLecEGF compatible with pFastBac
PCR reaction was performed as described in 3.3.1.8.
ESEL4 (FW- primer):
5’-ATC CCG GTC CGA AGC GCG CGG ATG CTA CTA GTA AAT CAG TCA-3’
ESEL5 (RW-primer):
5’- CAG GCT CTA GAT TCG AAA GCG TTA CTT ATC GTC ATC GTC CTT GTA GTC-3’
ESEL6 (RW-primer):
5’-CAG GCT CTA GAT TCG AAA GCG TTA CAC AAT TTG CTC ACA CTT GAG-3’
3.3.2.8 PCR integration of SSLecEGFFlag and SSLecEGF in pFastBac
PCR integration was done as described in 3.3.1.9.
3.3.2.9 Purification of PCR product
Purification of PCR-integration product was done as described in 3.3.1.10.
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3.3.2.10 Transformation into E.coli
Transformation into E.coli XL Blue-1 was done as described in 3.3.1.11.
3.3.2.11 Colony PCR for colony analysis
Colony PCR for colony analysis was done as described in 3.3.1.12.
3.3.2.12 Transformation into E.coli DH10Bac and transposition reaction
Transformation into E.coli DH10Bac and transposition reaction was done as described in
3.3.1.14.
3.3.2.13 Clone analysis and Bacmid DNA isolation
Clone analysis and Bacmid DNA isolation was done as described under 3.3.15
3.3.2.14 PCR analysis of recombinant bacmid DNA
PCR analysis was performed as described in 3.3.1.16.
3.3.2.15 Transfection into Sf 9 insect cells
Transfection into Sf 9 insect cells was done as described in 3.3.1.17. Attached cells (max. 50-
60% confluent) were washed twice with 2 ml medium and finally 1 ml medium with prepared
DNA was added. The plate was incubated at 28°C, 5 h, and medium was aspirated and
exchanged. Plate was further incubated for 5 days, cells were inspected and medium was
harvested for plaque assay and viral amplification.
3.3.2.16 Viral amplification and plaque assay
Plaque assay was performed as described in 3.3.2.16.
3.3.2.17 Protein production analysis and optimization
Preliminary analyses of protein production were performed with both LecEGFFlag and LecEGF.
50 ml insect cells culture were infected at 106 cells/ml, M.O.I of 10 and were grown in
suspension at 28°C, 90 rpm shaking for 72 h p.i. Total culture was centrifuged at 10°C, 1000
rpm for 10 min., as well as 1 ml aliquot. Supernatant of 50 ml was filtrated through 0.22 µm filter
and stored for further purification. 1 ml aliquot was analyzed by SDS-PAGE for protein
expression in the supernatant and pellet. Optimization of protein production and subsequent
scale-up was done with recombinant LecEGFFlag. Insect cell line, time-course of expression
(as described under 3.3.14) and M.O.I. were optimized.
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3.3.2.18 Viral amplification for scale-up
Scale up of protein production was done in a mid-scale with 1.5 L medium. 300 ml amplified
viral stock was produced at 1.4x106 Sf 9 cells/ml in TC100 medium with 10% serum and at
M.O.I. of 0.1. Culture was grown at 28°C for 72 h and harvested by centrifugation under
standard conditions.
3.3.2.19 Production scale-up
LecEGFFlag was produced in 1.5 L culture of Hi 5 insect cells, Sf900 medium at 1.2x106
cells/ml and M.O.I 10 for standard conditions. Medium with secreted protein was harvested 72 h
p.i. and centrifuged at 5000 rpm, 20’ at 10°C. Conditioned medium was purified on an anti-Flag
chromatography.
3.3.2.20 Anti-Flag affinity chromatography
1 ml column (Amersham, Pharmacia) was packed with the mouse, anti-Flag M2 monoclonal
antibodies agarose matrix (SIGMA) as described for column preparation under 3.2.3.11.
Column was equilibrated at 1.0 ml/min. with 10 column volume of binding buffer (TBS) until
stable base line. Protein solution was applied at the same flow rate for 30-100 ml, and was
subsequently washed with 10 column volumes of binding buffer to remove unspecific bound
proteins. When the base line was stable again, specifically bound protein was eluted with either
0.5 ml 100 µg/ml Flag peptide solution (SIGMA) in TBS, or with 10 column volume of 0.1 M
glycine buffer, pH 3.5. After the run, column was equilibrated again in TBS buffer, and for longer
period was stored at 4°C in TBS with 50% glycerol.
3.3.2.21 Western blot with the anti-Flag antibodies
Western blot analysis with the anti-Flag antibodies (SIGMA) was done under native and
reducing conditions. In native conditions, reaction was done as described previously under
3.1.6, except that proteins were separated on 5-15% gradient native gel. Western blot in
reducing conditions was done according to the same protocol, with following differences in
performance. Proteins were separated on 15% reducing and denaturing SDS-PAGE, blotted to
the membrane and stained with Ponceau solution to verify electrotransfer. Membrane was
blocked for 1 h at RT in 5% skim milk solution in TBS buffer with 0.1% Tween 20. To the 10 ml
of this solution, 2 µ l antibody stock solution at 4.9 mg/ml was added and the membrane
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incubated at RT for 1 h. All wash steps, incubation with the secondary antibody and developing
reaction were done as described before.
3.3.2.22 NMR analysis of ligand binding
For NMR analysis, T1 rho relaxation time was measured, as well as STD to qualitatively verify
the ligand binding to the protein. Protein was concentrated in Eppendorf centrifuge 5408R, at
3500 g and 4°C for 15 min in a 7 ml concentration device (Amicon, 10 kDa cut-off). 110 µl
concentrated protein at 0.992 mg/ml were dialysed in a small dialysis device (Pierce) in 1:10
ratio of d2O at 4°C, with the buffer exchange every 3-12 h for 2 days.
3.3.2.23 Protein deglycosylation
Protein was deglycosylated with N-glycanase (PNGaseF) in native and denaturing conditions.
Optimization was done regarding the enzyme amount and used detergent. Reactions were
performed in 0.02 M Na-phosphate-buffer, pH 6.8. Aliquots have been taken at different time
points for reaction I (or it was performed over-night at 37°C). Finally, protein was deglycosylated
for 48 h at 37°C, with an enzyme addition after 24 h.
Table 3.51: N-deglycosylation in denaturing conditions, reaction set-up
Reaction I II III IV V
Protein 16 µg 4 µg 4 µg 4 µg 4 µg
EDTA 25 mM final 25 mM final 25 mM final 25 mM final 25 mM final
SDS 0.1% final 0.2% final 0.2% final 0.2% final 0.2% final
Tween 20 2% final 2% final 2% final - 2% final
NP-40 - 0.75% final 0.75% final - 0.75% final
2-mercaptoethanol 1% final 1% final 1% final 1% final 1% final
Enzyme 0.6 U/µg 1.2 U/µg 0.6 U/µg 3.0 U/µg 0.6 U/µg
Table 3.52: N-deglycosylation in native conditions
Reaction I II
Protein 16 µg 4 µg
EDTA 25 mM final 25 mM final
SDS - -
Tween 20 0.05% final 2% final
NP-40 - -
2-mercaptoethanol - -
Enzyme 0.6 U/µg 1.2 U/µg
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3.3.2.24 Size exclusion chromatography
Fractions eluted in anti-Flag chromatography, which showed presence of impurities were
submitted to the size exclusion chromatography on Sephadex column (Amersham, Pharmacia),
100 kDa exclusion. 100 ml column was equilibrated with 5 volumes of TBS buffer and 2 ml
protein solution at 0.927 mg/ml were applied at the flow rate of 0.5 ml/min. Chromatography was
done overnight at 4°C, 5 ml fractions were collected and analyzed on SDS-PAGE. Fractions
containing LecEGFFlag were pooled together and concentrated to 1.4 mg/ml.
3.3.2.25 Ion exchange chromatography
Anion exchange chromatography was performed for separation of two different glycosylation
forms of LecEGFFlag, which were both eluted in anti-Flag chromatography. Mono Q anion
exchange column (BIO-RAD) with 1.3 ml bed volume was equilibrated with binding buffer A (20
mM Tris, pH 8.0) until stable base line. 0.35 ml protein solution at 1.4 mg/ml were mixed with
0.7 ml binding buffer and applied to the column at the flow rate 0.3 ml/min. Column was washed
again with 4 column volumes of buffer A. Gradient was formed to 50% B (20 mM Tris, 1 M NaCl,
pH 8.0) in 15 ml, followed by steeper gradient up to 100% B in 6 ml. Buffer B was linear at 100%
for next 6 ml, and then in next 10 ml it dropped to 0% B. Eluted fractions were analyzed on
SDS-PAGE.
3.3.2.26 MS analysis
For molecular weight determination of LecEGFlag ESI/MS analysis was performed. Prior to the
measurement, protein sample was desalted. Desalting was done on the RP-HPLC 1100 (Agilent
Technologies) using C4 Vydac HPLC column. Prior to the protein load, column was equilibrated
in 98% buffer A (0.1% TFA) and 2% buffer B (80% acetonitrile in 0.075% TFA). 100 µl protein
solution at 1 mg/ml was applied to the column, and gradient was formed of 75% B in 60 min.
Two separated peaks were eluted, and chromatography profile was analyzed on SDS-PAGE.
Molecular weight of eluted proteins was determined by ESI/MS analysis.
3.4 Bioassay development
For the evaluation of selectin antagonists, bioassays have been developed in cell-free and cell-
based format.
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3.4.1 Cell-free assay
3.4.1.1 Sialyl Lewisa-polymer preparation
Biotinylated sialyl Lewisa-polyacrylamide polymer (Glycotech) was dissolved in Hepes buffer
(HAB: 20 mM Hepes, pH 7.4, 150 mM NaCl, 1 mM Ca2+) at 1 mg/ml and stored at -20°C.
Polymer complex with streptavidin-peroxidase (Roche) was prepared as described in the Table
3.53 and formed at 37°C for 2 h. Complex was kept at 4°C and it was stable over several
weeks.
Table 3.53: sLea-polymer-streptavidin-POD complex preparation
sLea-polymer 20 µL
Steptavidin-POD conjugate 80 µL
Fetal calb serum 20 µL
HAB ad 200 µL
3.4.1.2 Molecule-molecule assay development, optimization and IC50 determination for
selectin antagonists with E-, P-, L-selectin/IgG
100 µl mouse IgG1 antibody against human Fc-IgG (SIGMA) or recombinant human E-, P-, and
L-selectin/IgG were coated overnight at 4° C in flat bottom NuncMaxi Sorp 96-well plates.
Solutions were discarded and plate dried by gentle tapping on several layers of tissue paper.
Plate was washed three times with 200 µl HAB, blocked with 3% BSA in assay buffer at 4°C for
4 h and washed as described. Selectin antagonists were diluted in HAB, and 50 µ l of 2x
concentrated solution was added to each well, followed by the addition of 2x concentrated 50 µl
sLea–polymer-streptavidin-POD complex. Plate was incubated at 37°C for 4 h in a humid
chamber, and washed again as described above. In order to detect bound polymer, 100 µl/well
ABTS substrate solution (BIO RAD) was added and the color was developed 5-10 min.
Reaction was stopped by adding 100 µl/well 2% oxalic acid and the O.D. was measured at 415
nm with the spectrophotometer Softmax (Molecular Probes). IC 50 values for tested compounds
were calculated relative to the control polymer using software PrismPad. Optimization was done
regarding the amount of sLea-polymer and protein in standard assay conditions, incubation time
and temperature.
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Table 3.54: Optimization of the cell-free assay for E-, P-, L-selectin/IgG
Optimization
parameter
E-sel/IgG
(µg/ml)
P-sel/IgG
(µg/ml)
L-sel/IgG
(µg/ml)
sLea –polymer
 (µg/ml)
Temperature
(°C)
Conditions 0.3 3 3 0.03 37
Conditions 1.0 10 10 0.1 4
3.4.1.3 Molecule-molecule assay development, optimization and IC50 determination for
selectin antagonists with LecEGFFlag
Anti-Flag M2 monoclonal antibody, or LecEGFFlag were diluted to 10 µg/ml and 3 µg/ml,
respectively in either TBS or carbonate buffer for antibody, or HAB 20 for LecEGFFlag (HAB 20:
20 mM Hepes, pH 8.5, 150 mM NaCl, 20 mM Ca2+). 100 µl protein solution were plated onto
NuncMaxi Sorp 96-wells plate, overnight at 4°C. Unbound proteins were washed gently with 200
µl HAB 20, three times, and either LecEGFFlag was added to the coated antibodies, or plate
was blocked 3 h at RT with 200 µl 3% BSA in HAB 20. Plate was washed again as described.
Selectin antagonists were diluted in HAB 20, and 50 µl of 2x concentrated solution was added
to each well, followed by the addition of 50 µl 2x concentrated sLea-polymer-streptavidin-POD
complex. Plate was incubated at RT for 3 h, shaking at 57 rpm and washed again as described.
In order to detect bound polymer, 100 µl/well ABTS substrate solution was added and the color
was developed 5-10 min. Reaction was stopped by adding 100 µl/well 2% oxalic acid and the
O.D. was measured at 415 nm. IC 50 values for tested compounds were calculated relative to
the control polymer using software GraphPrismPad.
Table 3.55: Optimization of the cell-free assay for LecEGFFlag
Optimization
parameter
LecEGFFlag
(µg/ml)
sLea –polymer
(ng/ml)
Assay buffer. Temperature
(°C)
Conditions 0.3 30 TBS 37
Conditions 1.0 100 HAB 1 mM Ca2+ RT
Conditions 10 300 HAB 20 mM
Ca2+
-
Conditions - 1000 - -
3.4.1.4 Acute human promyelocytic leukemia cell line cultivation
For cell.based assay, acute human promyelocytic leukemia cell line (HL-60 cells) were grown in
suspension in RPMI 1640 medium (GIBCO), supplemented with 10% fetal calf serum and 1%
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penicillin-streptomycin (GIBCO) at 37°C in humidified atmosphere with 5% CO2. Cells
suspension was centrifuged at RT and 1000 rpm for 10 min. in 5804 R centrifuge (Eppendorf).
Pelleted cells were gently resuspended in PBS buffer, visually examined for viability and
counted. 5x104 cells/ml were seeded in 20 ml medium in T75 culture flask, and regularly
passaged twice a week.
3.4.1.5 Cell-based assay development, optimization and IC50 determination for selectin
antagonists
HL-60 cells were centrifuged as described and viability was examined (95-100%). Cells were
seeded at 9x105-1.2x106 cells/ml 24-36 h prior to the experiment. 100 µl/well selectins was
coated on the Nunc MaxiSorb 96-well plate and incubated overnight at 4°C. Plate was washed
2x with 200 µl HAB and gently tapped on the tissue paper. 200 µl 3% BSA in HAB was added to
each well and the plate was incubated for 3 h at RT. HL-60 cells, 2.2x107 cells/plate were
centrifuged as described and resuspended in 5 ml pre-warmed PBS with 5 µg/ml BCECF-AM
(Roche) fluorescent dye. Cells were then incubated for 30 min at 37°C in the dark. After the
incubation, cells were washed again in PBS and resuspended to the final of 2x105 cells/well.
Plate was washed as described and 50 µl of 2x concentrated tested compounds have been
added to the well. 50 µl of cell suspension was added to each well and plate was incubated at
37°C for 1 h. Plate was washed carefully 3 times in HAB and fluorescence was measured in
Fluoroskan II Perkin Elmer fluorometer at excitation wavelength of 485 nm, and emission
wavelength of 538 nm. Inhibitory potencies for selectin antagonists have been expressed as a
percentage of control, and calculated using software PrismPad. Optimization of cell-molecule
assay was done regarding the number of the HL-60 cells used in the assay, protein
concentration and the number of wash steps. The compounds that were tested in cell-molecule
assay have been described in the table 4.6.
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Table 3.56: Optimization of the cell-molecule assay
Optimization
parameter
E-sel/IgG
(µg/ml)
P-sel/IgG
(µg/ml)
L-sel/IgG
(µg/ml)
No.of HL-60
cells/well
Wash steps
Conditions 1 1 1 2x105 2x
Conditions 3 3 3 1x105 3x
Conditions 10 5 5
Conditions 10 10
Conditions 15 15
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4 Results
4.1 E-, P-, L-selectin/IgG expression in CHO cells and
characterization
4.1.1 E- and P-selectin/IgG expression in CHO cells
Standard expression conditions have been established for culture maintenance, protein
expression and production following published procedures [92]. Cells have been visually
inspected and their outlook, as well as viability, was the parameter to follow prior to medium
harvest. Cells reached 80% confluence after 3-4 days in 75 cm2 flasks and were seeded in
either 150 cm2 flasks in 60 ml medium at 106 cells/flask, or in roller bottles at 1.5-2x106 cells/ml
in 200 ml medium. After 5-7 days cells were confluent again, and medium with secreted protein
was harvested after 2 weeks.
Figure 4.1: CHO-K1 cells in logarithmic growth phase Figure 4.2: CHO-KI cells in production phase,
20% viability
4.1.1.1 Protein purification by affinity chromatography and size exclusion
chromatography
IgG-fusion proteins are eluted from protein A as single peaks (Figure 4.3 and figure 4.4).
Reducing SDS PAGE analysis of the eluted peaks has shown major protein bands at 148 kDa,
and 110 kDa, for E- and P-selectin/IgG, respectively. Minor impurities consisting of serum
albumin (66 kDa) and bovine IgGs (55 kDa and 25 kDa for heavy and light chains respectively),
were also detected. These are standard impurities from serum-containing media, and size
exclusion chromatography was used for their efficient removal. Figure 4.5 shows a typical size
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exclusion elution pattern with superimposed calibration markers (dotted line). SDS-PAGE
analysis of eluted fractions is shown in figure 4.6.
Figure 4.3: Protein A affinity chromatography of    Figure 4.4: 8% SDS-PAGE analysis of protein A chromatography
E-selectin/IgG. Protein was eluted at pH 3.4
A purification overview for E-selectin/IgG, starting with culture supernatant produced either
in roller bottles, or tissue flasks, is given in the table 4.1. Protein concentration was
determined by Bradford assay with BSA as standard.
Device Conditioned
medium
Protein A pool Size exclusion
pool
Total yield/L
(%)
Roller bottles
(total 1.5L)
15 mg 8.5-12 mg 4.9-9.6 mg 7.3 mg
(48.6%)
Lane 1: HMW
marker
Lane 2: Crude
extract
Lane 3-6: Flow-
through
Lane 7: Wash
Lane 8: Elution 1
Lane 9: Elution 2
Figure 4.6: SDS-PAGE analysis of size
exclusion chromatography. This method
efficiently separates E-selectin/IgG from BSA
aggregates and IgGs
E-selectin/IgGBSA IgG,heavy
chain
E-selectin/IgG
1     2       3      4      5       6     7      8        9
210 kDa
116 kDa
97 kDa
88 kDa
66 kDa
55 kDa
36 kDa
Figure 4.5: Size exclusion chromatography of E-
selectin/IgG. The protein elutes between the
peak of oligomers and thyroglobulin
Table 4.1: E-selectin/IgG purification overview with the protein concentration throughout the purification procedure.
Conditioned medium considers total proteins of cell culture medium subtracted from cell culture medium that
contains secreted proteins.
Lanes 1,2: BSA
aggregates
Lanes 3-5: -
Lanes 6-11: E-
sel/IgG
Lanes 12-14: IgG
Lane 15: HMW
standard
1   2  3  4 5    6     7      8   9   10  11  12  13  14   15
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T 160 flask
(total 1.5L)
1.45 mg total 0.695 mg 0.0625 mg 0.43 mg
(29.65%)
4.1.2 E-selectin/IgG characterization
The activity of expressed and purified protein was addressed in native immunoblots and ELISA-
based assays with a monoclonal blocking antibody, as described in materials and methods
section. The glycosylation status was examined by N-deglycosylation. NMR analyses were used
to confirm ligand binding to E-selectin/IgG (described in result section 4.1.2.6).
4.1.2.1 Immunoblot in native conditions
As previously described, immunoblots of E-selectin/IgG were performed using a monoclonal
blocking antibody (mouse anti-human E-selectin antibody 7A9). In native conditions, the
reaction was positive, whereas in reducing, or non-reducing, denaturing conditions no antibody
binding was observed. A typical membrane with a positive immunoblot reaction is shown in
figure 4.7.
4.1.2.2 N-deglycosylation of E-selectin/IgG
For N-deglycosylation with PNGaseF (N-glycanase), E-selectin/IgG was either denaturated or
deglycosylated under native conditions. E-selectin/IgG deglycosylation in denaturing conditions
after 48 hours is shown in figures  4.8, and 4.9. Results from a deglycosylation time-course
have shown no significant difference in the deglycosylation extent after 1 hour and 48 hours,
indicating that maximal deglycosylation takes place within an hour. The molecular weight of the
protein was extrapolated from the SDS-PAGE migration distances, and was 148 kDa for the
Lanes 1-5: E-selectin/IgG,
samples after gel-filtration.
Correspond to lanes 6-10 on
figure 4.6.
Figure 4.7: Nitrocellulose membrane blotted
with the native E-selectin/IgG, in reaction
with the mAb 7A9 and 2nd antibody AP-
conjugated.
   1               2                3                 4               5
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fully glycosylated protein under reducing conditions, and 108.3 for deglycosylated, reduced E-
sel/IgG.
Deglycosylation under native conditions was performed for 48 hours and analyzed by native
PAGE, as shown in figure 4.10. The difference in migration profile of deglycosylated and native
E-selectin/IgG indicates removal of N-linked sugar residues. Partial deglycosylation did not
affect binding activity toward monoclonal blocking antibodies, based on positive immunoblot
reactions.
Lane 1: HMW marker
Lane 2: -
Lane 3: E-selectin/IgG glycosylated
Lane 4: -
Lane 5: E-selectin/IgG 48 hours deglycosylated
Lane 1: E-selectin/IgG glycosylated
Lane 2: E-selectin/IgG 1 h deglycosylation
Lane 3: E-selectin/IgG 6 h deglycosylation
Lane 4: E-selectin/IgG 12 h deglycosylation
Lane 5: E-selectin/IgG 18 h deglycosylation
Lane 6: E-selectin/IgG 24 h deglycosylation
210 kDa
116 kDa
97 kDa
66 kDa
55 kDa
45 kDa
88kDa
Figure 4.9: 48 hours N-deglycosylation of E-
selectin/IgG in denaturing conditions, 8% gel.
Figure 4.8: Time-course of N-deglycosylation
of E-selectin/IgG in denaturing conditions, 8%
silver stained gel.
      1             2          3          4        5          6
       1       2         3         4       5
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4.1.2.3 Molecular weight determination of E-selectin/IgG
The molecular weight of E-selectin/IgG in both reducing and native conditions was determined
via indirect calculations, based on the protein’s migration in PAA gels. In reduced and denatured
conditions E-selectin/IgG has a molecular weight of 148 kDa. Molecular weight under native
conditions was calculated based on the standard curve shown in table 4.2, and found to be
829.85 kDa, possibly a hexameric form.
Protein -slope log(-slope) MW (kDa)/log MW % of gels run
α-Lactalbumin 2.0 0.3 14.2 / 4.15 7, 8, 9, 10
Carbonic Anhydrase 3.7 0.568 29 / 4.46 6, 7, 8, 9
Albumin, ch.egg 3.84 0.584 45 / 4.65 7, 8, 9, 10
Albumin, bov. serum, mon. 5.34 0.728 66 / 4.82 7, 8, 9, 10
Albumin, bov. serum, dimer 7.9 0.897 132 / 5.12 7, 8, 9, 10
Urease, trimer 12.59 1.1 272 / 5.43 4.5, 5, 5.5, 6
Apoferitin, monomer 13.24 1.12 450 / 5.65 4.5, 5, 5.5, 6
Urease, hexamer 16.78 1.2 545 / 5.73 4.5, 5, 5.5, 6
Apoferitin, dimer 28.622 1.46 900 / 5.95 4.5, 5, 5.5, 6
E-selectin/IgG 23.1 1.36 829.85/5.919 4.5, 5, 5.5, 6
4.1.2.4 E-selectin/IgG binding to the monoclonal blocking antibody 7A9
Binding of E-selectin/IgG to the mouse anti-human E-selectin monoclonal blocking antibody 7A9
was performed to address the intactness of the active site of E-selectin/IgG. In an ELISA based
assay, with a secondary enzyme-based colorimetric output, the binding was shown to be
concentration dependent, with a Kd of 0.72 ±0.03 µg/ml E-sel/IgG, or 4.86 nM.
Lane 1: Molecular weight marker:
Urease, trimer: 272 kDa, hexamer: 544 kDa
Lane 2: -
Lane 3: E-selctin/IgG native
Lane 4: -
Lane 5: E-selctin/IgG deglycosylated for 48 hours
Figure 4.10: 48 hours N-deglycosylation of
E-selectin/IgG in native conditions, 5% gel.
              1         2         3         4        5
Urease Hexamer
Urease Trimer
Table 4.2: Proteins used as standards for molecular weight determination of E-selectin/IgG in the native conditions. As
described in materials and methods, each protein was run on gels of different percentages. Migration distance plotted
versus gel percentage generated a slope that describes the migration profile of each protein. The migration profile
expressed as log (-slope) was plotted against the log of known molecular weights to generate a standard curve.
Molecular weight of E-selectin/IgG was extrapolated from this curve.
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E-selectin/IgG binding to the mAb 7A9
10 1 0.5 0.3 0.1
0.00
0.25
0.50
0.75
1.00
1.25
1µg/ml mAb 7A9
Kd=4.86 nM
E-selectin/IgG ( µg/ml)             
E-selectin/IgG binding to the mAb 7A9
0.0 2.5 5.0 7.5 10.0 12.5
0.00
0.25
0.50
0.75
1.00
1.25
E-selectin/IgG ( µg/ml)
Figure 4.11: Concentration-dependent binding Figure 4.12: Saturation binding curve of 4.11
of E-selectin/IgG to the mAb 7A9.
4.1.2.5 MS analysis for identity confirmation of E-selectin/IgG
MS analysis of a trypsin-digested E-selectin/IgG had covered the sequence to confirm the
identity of E-selectin/IgG.i
4.1.2.6 NMR analysis of E-selectin/ligand binding
STD NMR was done to analyze ligand binding to E-selectin/IgG. In addition to the mAb 7A9
binding, the intactness of the binding site on E-selectin/IgG was examined using STD NMR of
an E-selectin antagonist, BW69669. Spectra were recorded in presence and in the absence of
protein. In the presence of protein, several peaks appear in the STD spectrum indicating binding
of BW69669 to E-selectin/IgG. Comparison of the experimental and control data are shown in
the figure 4.13.
Figure 4.13: STD NMR of BW69669 on E-
selectin/IgG. Comparison with the control spectra
indicates binding of BW69669 to the protein.
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4.1.3 P-selectin/IgG expression and characterization
P-selectin/IgG was expressed secretorily in CHO cells in adherent cultures, in 175 cm2 tissue
culture flasks under the conditions described for E-selectin/IgG. The production phase lasted for
two weeks and 2.5 L medium were collected and purified.
An overview of the expression and production of P-selectin/IgG is presented in the table 4.3.
Fraction Conditioned
medium
Protein A pool Size exclusion pool Total yield
Concentration(µg/ml)
Total amount (mg)
950
9.45
163
2.15
1000
2.0
0.7mg/l in 2.5 L
⇒ 1.75 mg
Reaction with an antibody against human P-selectin, a mouse monoclonal blocking antibody
(CD62 P) was used to address the activity of the protein. In native western blots good binding of
the blocking antibody was observed. The final color reaction, catalyzed by a secondary
0.0
25.0
50.0
75.0
100.0% Buffer B
-0.25
0.00
0.25
0.50
0.75
1.00
1.25
1.50
1.75
2.00
-50.0
0.0
50.0
100.0
150.0
200.0
250.0
300.0
350.0
400.0
450.0
500.0
00:00:00 01:00:00 02:00:00 03:00:00 04:00:00 05:00:00
Fractions
Hr:Min:Sec mS/cmAU
Figure 4.14: Protein A chromatography profile of
P-selectin/IgG purification. P-selectin was eluted
as a single peak and analyzed on 8% SDS-PAGE.
Figure 4.15: SDS-PAGE analysis of the complete
P-selectin/IgG purification.
Lane 1: HMW marker, as described in figure 4.9
Lane 2: Crude extract
Lane 3: Flow through
Lanes 4,5: Wash
Lane 6: Elution
Lane 7: Size exclusion fraction, P-selectin/IgG at 110 kDa
Lane 8: Size exclusion, concentrated
1         2         3      4       5          6         7        8
Table 4.3: P-selectin/IgG purification overview with the protein concentration throughout the purification procedure.
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antibody, goat anti-mouse IgG coupled to alkaline phosphatase, was visible after less then 1
minute.
 
P-selectin/IgG binding to the mAb anti-CD62P
0.0 2.5 5.0 7.5 10.0 12.5
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8 2.5 µg/ml mAb anti CD-62 P
Kd= 13.47 nM
P-selectin/IgG (µg/ml)
For the quantification of the P-selectin binding to the blocking antibody, an ELISA-based assay
was performed, where P-selectin/Ig was serially diluted and incubated with 2.5 µg/ml antibody.
A secondary, HRP-conjugated antibody, with orto-phenilendiamine (OPD) as a substrate was
used for the next step. Binding was quantified at 450 nm, and a binding constant of 13.47 nM
could be calculated. The molecular weight of P-selectin/IgG was calculated in native conditions
to be 233 kDa, indicating that protein is a dimer.
4.1.4 L-selectin/IgG
L-selectin/IgG was expressed and purified as described for E- and P-selectin/IgG and is
available in purified form. Protein was assayed for the activity with a blocking antibody and was
shown to be active under native western blots. The molecular weight of the L-selectin/IgG was
calculated to be 87 kDa under reducing and denatured conditions, whereas native L-
selectin/IgG, according to the migration profile in native PAGE, had a molecular weight of 209.7
kDa, corresponding to a dimer.
Figure 4.16: Concentration dependent binding
of P-selectin/IgG to the mAb CD-62P.
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4.2 Bioassay development with E-, P-, and L-selectin/IgG
The availability of purified and active E-, P-, and L-selectin/IgG enabled the development of
molecule-molecule (cell-free) and cell-molecule (cell-based) type of assays to evaluate potential
selectin antagonists.
4.2.1 Cell-free assay
The cell-free assay used the reaction of protein coated to the wells and the ligand
oligosaccharide (sialyl Lewisa) presented by biotinylated polyacrylamide copolymer. Binding to
the protein of this copolymer matrix in the presence or absence of candidate inhibitors is
detected with the aid of streptavidin-peroxidase conjugate. The quantity of bound conjugate is
estimated from the rate at which the chromogenic substrate, ABTS, is oxidized to colored
products of λmax 414 nm by horseradish peroxidase. For the evaluation of standard conditions in
cell-free assay, several parameters were optimized. The amount of protein coated in the 96-well
plate, the amount of sLea polymer used as control, incubation time and temperature, and wash
steps. The optimal assay conditions are presented in table 4.4., with the screening results for
the controls BW69669 and sLex. E-selectin antagonists, with their structures and relative IC50
values, are presented in table 4.6 and 4.7. We had planned to measure selected antagonists in
three independent experiments. However the IC50 values of the tested compounds and controls
were fluctuating somewhat throughout the whole experimental set. As a consequence the IC50
determination has not been finalized.
Coating E-selectIn/IgG sLea polymer Control
Direct E-selecin/IgG 3 µg/ml 0.1 BW69669 (IC50=42.5±12 µM)
sLex (IC50=800 µM)
4.2.2 Cell-based assay
HL60 cells that express physiological ligand of selectin were successfully cultivated and
maintained according to the standard operating procedure given in the attachment. Standard
conditions for cell-molecule assay and the evaluation of selectin antagonists were optimized as
described in table 4.5. IC50 values in this assay are expressed relative to BW69669, known to
have 10-12 times higher affinity for E-selectin/IgG as compared to sLex. Final results are given
in figure 4.17 and table 4.6.
Table 4.4: Optimized standard conditions in cell-free assay for studies of E-selectin-carbohydrate interactions.
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Coating HL60 cells/well Incubation time/
temperature
Wash steps Control
Direct E-selecin/IgG
1 µg/ml
100 000 1 hour
37°C
3 BW69669
IC50=200±80µM
BW 69669 Mittelwert aus 8 Platten an 3 versch. Tagen, 2 Einwaagen (n=24)
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Antagonist IC50 (µM)
BW75145 140±70
BW75757 146.7±73.3
BW186211 83.3±17
BW2091 50±10
BW69669 BW75757 BW75145
O
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O
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O
HO OH
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H
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O
Table 4.5: Optimized standard conditions of a cell-based assay for studies of E-selectin-carbohydrate interactions.
Figure 4.17: BW69669-mediated Inhibition of E-selectin/IgG
binding to HL60 cells. Data represent the average of three
independent experiments done in triplicates. Typically for this cell-
based assay, BW69669 has a higher IC50 value (200 µM), as
compared to the cell-free assay, although in a good agreement.
Table 4.6: IC50 values for E-selectin antagonists obtained with a
cell-based assay. Data represent an average of three
independent experiments done in triplicates.
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Table 4.7: Structures of E-selectin antagonists synthesized in house and tested in cell-free and cell-based assays.
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In conclusion P- and L-selectin/IgG have been preliminary tested in cell-free and cell-based
assay and standard conditions were established for both. The optimized assay conditions are
listed in the table 4.8.
Protein in cell-free assay sLea polymer Protein in HL60 assay Incubation time/temp.
P-selectin/IgG 5 µg/ml 0.3 µg/ml P-selectin/IgG 10 µg/ml 4 hours/4°C, 37°C
L-selectin/IgG 5 µg/ml 0.3 µg/ml L-selectin/IgG 5 µg/ml 4 hours/4°C
4.3 Expression of lectin and EGF-like domain of human E-selectin in
E.coli
The milligram amounts of protein that would be necessary to conduct the desired structural
studies, directed our strategy toward bacterial expression systems. Constructs comprising the
lectin and EGF-like domains of human E-selectin (further in the text referred to as LecEGF)
were cloned to yield recombinant fusion proteins with different tags to facilitate protein
expression and purification. Different cloning strategies were carried out and are described in
this chapter.
4.3.1 LecEGF cloning into pEZZ18
Cloning vector pEZZ18 has an export sequence that contains the so called ZZ domain of
staphylococcal protein A. Fused to this sequence a recombinant protein of interest should be
secreted in the culture medium. This should also improve protein folding and stability.
Genomic DNA was isolated from CHO-K1 cells expressing E-selectin/IgG, as described in the
materials and methods. Plasmid pcDNA/Neo codes for E-selectin/IgG and it was used as a
template for the amplification of the LecEGF domain of human E-selectin.
Table 4.8: Optimized standard conditions for cell-free and cell-based assay with P- and L-selectin/IgG. for studies of
selectin-ligand interactions.
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PCR amplification with the described primers (see materials and methods section) generated a
fragment of 514 bps. The 5’ primer had 4 bases prior to the EcoRI restriction site, followed by a
thrombin cleavage site (24 bases). To maintain the open reading frame, one base (G) was
inserted just prior to the sequence coding for LecEGF and annealing to the template DNA was
done with the first 18 bases corresponding to the LecEGF sequence. The 3’ primer introduced a
stop codon after the LecEGF sequence and a BamHI restriction site followed by the 4 bases
necessary for the optimal restriction digestion. Although the 5’ primer, that was 51 bases long,
had a melting temperature of 62°C, in PCR primers were successfully annealed at 58°C. The
analysis of PCR products is presented in figure 4.18 and a molecular weight standard, DNA
marker X (Roche), used for all DNA analyses, is schematically presented in figure 4.19.
A PCR fragment of the expected size was successfully amplified whereas negative controls
without template DNA (lanes 4 and 7) did not give any product, indicating that the obtained
product was a result of a specific reaction.
Plasmid pEZZ18 (4054 bp) was initially expressed in an E.coli expression strain (DH_5).
pEZZ18 was isolated from E.coli using alkaline-lysis and analyzed by restriction enzymes
(NdeI/EcoRI, NdeI/BamHI) digestion to verify plasmid identity. Multiple cloning sites of pEZZ18
contain recognition sequences of several restriction endonucleses, including EcoRI and BamHI.
Insert and vector were therefore digested with these two endonucleases, electrophoresed on
1% agarose, and excised from the gel. After purification, both DNAs were controlled in another
electrophoresis to verify purity and molar ratio between these two DNA fragments. Figure 4.19
shows control of the vector and insert, prior to the ligation.
Lane 1: DNA marker X:
Lane 2: PCR 1
Lane 3: PCR 2
Lane 4: PCR – ctrl.:
Lane 5: PCR 3
Lane 6: PCR 4
Lane 7: PCR – ctrl.
Lane 8: DNA marker X
Figure 4.19: DNA marker X,
with the designated bases.
517/506 bp
Figure 4.18: Analysis of PCR amplified
LecEGF fragment for cloning into pEZZ18.
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Intensity of the two DNA bands was similar, and since the molecular weight ratio of the insert
and vector was 1:9, molar ratio was the same.
The ligation reaction was set up with these DNA fragments, predominantly using the ratios
described under materials and methods. The afore mentioned E.coli strain DHα5, as well as
another competent E.coli cloning strain, Top10, were either electroporated or chemically
transformed with the ligation mixtures. In total, 31 clones were cultivated, DNA isolated and
analyzed. The analysis included restriction enzyme digestion with EcoRI/BamHI endonucleases
to generate a 496 bp insert and 4059 bp DNA that corresponds to the plasmid pEZZ18.
EcoRI/PstI digestion cuts the DNA sequence in the EGF domain and generates 3 fragments of
315, 150, and 4059 bps. Control PCR was done with the primers used for the starting LecEGF
amplification or with an intern 5’ primer (FWZZLE) that contains a 21 bp sequence of the EGF-
part of the LecEGF. Figure 4.21 shows restriction enzyme digestion control of pEZZ18LecEGF.
Figure 4.20: 1% agarose gel analysis of
purity and molar ratio between plasmid
pEZZ18 DNA, and LecEGF DNA.
Lane 1: DNA marker X
Lane 2:-
Lane 3: LecEGF digested,
purified,
Lane 4:-
Lane 5: Plasmid pEZZ18,
digested, purified
Figure 4.21: Restriction enzyme digestion of
pEZZ18LecEGF with EcoRI/BamHI and EcoRI/PstI
Lanes 1, 15, 16, 25: DNA marker X
Lanes 2, 6, 9, 12, 17, 21: undigested DNA
Lanes 3, 7, 10, 13, 18, 22: pEZZ18LecEGF
EcoRI/BamHI digestedl
Lanes 5, 8, 11, 14, 19, 23: pEZZ18LecEGF
EcoRI/PstI digested
1      2     3    4     5
   1        3       5        7        9       11     13    15
  16      18     20      22      24
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4.3.1.1 Protein expression analysis
Isolated pEZZ18LecEGF DNA that had an insert of the expected size after restriction enzyme
digestion and PCR control, was transformed into the production E.coli strain AD 494, which
should allow formation of disulfide bonds. Cells were grown overnight at 37°C in LB medium
with 100 µg/ml Ampicillyn. Intracellular or secreted protein overexpression was analyzed by
SDS-PAGE. Usual for non-inducible expression systems, there was no strong and clear
overexpression. Culture medium and periplasmic fraction were subjected to IgG-sepharose
affinity chromatography since proteins containing the ZZ domain of protein A should bind it. The
protein eluted from this affinity column was a polypeptide of about 15 kDa, as revealed by SDS-
PAGE in reducing conditions, corresponding to the sole ZZ domain of protein A (14 kDa).
Identity of the band was confirmed also by dot blot analysis with a mouse IgG conjugated to the
alkaline phosphatase. Sequence analysis of different clones has revealed that the sequence of
the fusion protein was incorrect: either deletion or insertion has happened in the DNA sequence,
always in the domain of the 5’ primer. These had resulted in the shift of the open reading frame
and it was actually only the ZZ domain with few (5) amino acids of LecEGF that could have
been correctly translated before the appearance of the stop codon. After sequencing 31 clones,
this strategy was abandoned and another mode of expression of LecEGF in E.coli was
addressed.
4.3.2 LecEGF cloning into pINompA I
Plasmid vector pINomp A has a secretion sequence of the outer bacterial membrane protease A
that should direct expressed protein to the periplasm. The oxidative environment of periplasm,
in comparison to the cytoplasmic one, is more favorable for correct expression of proteins with
disulfide bridges. The recombinant protein should be fused to the signal sequence and, upon
correct processing would have an additional Met-Ser prior to the first Trp of E-selectin. Genomic
DNA isolated from the CHO-K1 cells that expressed human E-selectin/IgG was used as a
template to PCR amplifies the LecEGF domain. The forward primer introduced an EcoRI
restriction site and one additional base prior to the LecEGF sequence in order to maintain the
open reading frame. The 3’ primer introduced a stop codon followed by a BamHI restriction site.
PCR was done as described, and reaction products controlled on 1% agarose gels. The
amplified fragment should be 514 bps in lenght, corresponding to the size of the fragment on
figure 4.22. After restriction enzyme digestion of LecEGF and of the plasmid pINompA with
EcoRI and BamHI restriction enzymes, ligation reactions were started as described in materials
and methods. Further cloning steps were conducted as described for pEZZ18. Restriction
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enzyme digestion analysis of positive clones is shown in figure 4.23. 3 clones were sequenced
but the sequence of each clone had point mutations, insertions or deletions at the very
beginning of the sequence coding for LecEGF. This shifts the open reading frame and creates a
random sequence with a stop codon within the LecEGF domain. Ultimatively, the attempt to
export LecEGF over the bacterial periplasmic membrane failed and this cloning strategy was
abandoned as well.
4.3.3 LecEGF cloning into pET15b
Plasmid vector pET15b enables expression of fusion proteins with an N-terminal 6XHistidine tag
followed by a thrombin cleavage site for tag removal. This is an efficient system for protein
expression that can be induced with IPTG. However protein expression is directed into the
bacterial cytoplasm, disadvantageous for proteins with disulfide bridges. pET15b has a multiple
cloning site with NdeI and BamHI restriction enzymes. The DNA sequence coding for LecEGF
domain was amplified as described. The 5’ primer introduced a NdeI restriction site, whereas
the 3’ primer introduced a stop codon and a BamHI restriction site. PCR products analysis is
Figure 4.22: PCR amplification of LecEGF for
cloning into pINompA. PCR products analysis
  1       2         3        4       5           6 Lane 1: DNA marker X
Lanes 2-5: PCR product analysis
Lane 6: -ctrl.
Figure 4.23: Restriction enzyme digestion of pINompALecEGF
with EcoRI / BamHI and EcoRI / PstI.
Lane 1: DNA marker X
Lanes 10, 13, 16: Non-digested pINompALecEGF
Lanes 11, 14, 17: EcoRI / BamHI digested pINompALecEGF
Lanes 12, 15, 18: EcoRI / PstI digested pINompALecEGF
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shown in figure 4.24 and restriction digestion control of the analyzed clones with pET15b
HisLecEGF in figure 4.25.
The generated PCR product was of about the expected size of 512 bps. The expected size of
the fragment after restriction enzyme digestion should be 496 bp in length and the obtained
DNA band visible in lines 5 and 6, figure 4.25 were of about the expected size. PCR was also
done for control purposes prior to the sequencing and in total 6 clones were sequenced, 5 of
which were correct.
Further experiments were done with the clone named HLE2 (His LecEGF 2).
4.3.3.1 HisLecEGF expression, purification and refolding
E.coli strains AD 494 (DE3), BL 21 (DE3), and Rosetta gami (DE3) were transformed with HLE2
and, on SDS-PAGE, HisLecEGF was clearly overexpressed, giving a band between 20 and 24
kDa consistent with the expected molecular weight (21.85 kDa). Protein expression conditions
were optimized based on a time-course, temperature and culture media using SDS-PAGE
analysis and visual inspection of the expression level. Expression in the E.coli BL 21 (DE3) for
12 hours at 37°C in TB medium was the best condition. On a small scale these results were
Lane 1, 8: DNA marker X
Lanes 2, 3, 5, 6: PCR product
Lanes 4, 7: negative control
Lanes 1, 14: DNA marker X
Lanes 2, 4, 6, 8, 10, 12: undigested DNA
pET15bHisLecEGF
Lanes 3, 5, 7, 9, 11, 13: DNA
pET15bHisLecEGF digested with NdeI/BamHI
Figure 4.25: Restriction enzyme digestion of
pET15b HisLecEGF. Three positive clones
were sequenced.
Figure 4.24: Amplification of LecEGF for
cloning into pET15b. 1% agarose gel analysis.
      1       2     3      4      5      6     7      8
  1   2    3   4    5    6   7    8   9   10  11  12  13  14
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confirmed after preliminary protein purification and concentration following Ni-NTA
chromatography. The comparison of expression is given in table 4.3 and figure 4.24.
E.coli strain Temperature Medium Total yield ( Ni-NTA pool)
AD 494 (DE3) 30°C / 37°C LB / TB 20 / 22 mg/L
BL 21 (DE3) 30°C / 37°C LB / TB 38 / 120 mg/L
Rosetta gami (DE3) 30°C / 37°C LB / TB 4.5 / 8 mg/L
Initially protein purification on a Ni-NTA column was done under native conditions. A soluble
bacterial cytoplasmic fraction was isolated and subjected to Ni-NTA chromatography. Ni-NTA
chromatography under native conditions did not yield any pure protein. The variety of proteins
that were present in the eluat is rather typical for Ni-NTA chromatography in case where there is
no appreciable amount of overexpressed his-tagged protein, what indeed was the case. This
indicated that the majority of the protein was produced as an insoluble inclusion bodies fraction.
Extensive inclusion bodies washing and solubilization in 8M urea or 6M GuHCl were therefore
applied. Results are shown in figure 4.27. The final solubilized fraction contained much less
contaminant proteins and the overall yield of purified HisLecEGF was 100-120 mg/L medium.
Figure 4.26: Time-course expression of HisLecEGF in
E.coli AD 494, BL 21, and Rosetta gami. Arrows point
overexpressed HisLecEGF.
Table 4.9: Overview of the tested expression conditions during the optimization of HisLecEGF expression.
Lanes 1, 8, 16: LMW standard
Lanes 2-4: Expression, 0h post induction (p.i.)
Lanes 5-7: Expression, 3h p.i.
Lanes 9-11: Expression, 6h p.i.
Lanes 12-14: Expression, 9h p.i
Lanes 17-19: Expression, 12h p.i
Lanes 20-22: Expression, 18h p.i
66 kDa
45 kDa
36 kDa
29 kDa
24 kDa
20 kDa
14 kDa
1      3     5       7    9     11    13    15  16      18        20     22
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Protein purified on Ni-NTA under denaturing conditions is shown in figure 4.28 and its SDS-
PAGE analysis on figure 4.29. The protein thus purified was analyzed by MS. The complete
sequence was confirmed with fragments obtained by trypsin, V8, and C-Lys digestion and the
molecular weight of the intact protein confirmed as 21 350 Da. The first methionine in the
sequence was not processed, rather typical for bacterial protein expression. Since the protein
Peak 1↓
Peak 2↓
Peak 1↓
Peak 2↓
Figure 4.27: HisLecEGF enrichment by
inclusion bodies solubilization with 8M urea or
6M GuHCl. 15% SDS-PAGE, coomassie
staining.
Lane 1: Low molecular weight standard
Lanes 2-4: Protein isolation, wash in 0.1 M Tris-HCl,
pH 8.0, soluble fraction
Lane 5: Protein isolation, 5X wash in 0.1 M Tris-HCl,
pH 8.0, insoluble fraction
Lane 6: Protein isolation, 5X wash in 0.1 M Tris-HCl,
pH 8.0, soluble fraction
Lane 7: Protein isolation, 5X wash in 6 M GuHCl, pH
8.0, insoluble fraction
Lane 8: Protein isolation, 5X wash in 6 M GuHCl, pH
8.0, soluble fraction
Figure 4.28: Chromatography profile on Ni-
NTA column under denaturing conditions.
Figure 4.29: SDS-PAGE analysis of
chromatography profile on Ni-NTA column
under denaturing conditions.
Lane 1: Crude extract
Lane 2: Flow through
Lane 3: -
Lane 4: LMW standard
Lane 5: -
Lane 6: Elution, peak 1
Lane 7: Elution, peak 2
1      2        3       4         5       6      7        8
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isolated in the presence of 8M urea showed an increase in molecular weight of 28 Da, all
subsequent protein solubilizations were done exclusively in 6M Guanidine-HCl to avoid
carbamoylation.
Refolding experiments were tried with purified, denatured HisLecEGF either by dialysis or fast
dilution. Dialysis led to a quantitative protein precipitation with no active protein in the soluble
fraction as tested with the blocking mAb 7A9 either in western blot or in ELISA based assays.
Fast dilution was used as an alternative approach. Initial tests were monitored by analytical RP-
HPLC. In reduced state the protein was easily eluted from the column, whereas oxidation
caused fast formation of protein aggregates, which did not elute from the column. SDS-PAGE
analysis, however, showed the presence of different protein forms in solution as shown in figure
4.30. By size exclusion chromatography it was possible to isolate separate forms, including the
monomer fraction (figure 4.30 and figure 4.31). These fractions were subjected to the usual
activity screen, but the observed activity was minor as compared to a positive control (figure
4.33).
97 kDa
66 kDa
45 kDa
31 kDa
21 kDa
14 kDa
Lane 1: Folding standard, non-reduced
Lane 2: Folding in 1M L-Arg, non-reduced
Lane 3: Folding in 1M L-Fuc, non-reduced
Lane 4: Folding in 1M NeuNAc, non-reduced
Lane 5: -
Lane 6: Folding standard, reduced
Lane 7: Folding in 1M L-Arg, reduced
Lane 8: Folding in 1M L-Fuc, reduced
Lane 9: Folding in 1M NeuNAc reduced
Lane 10: MW standard
Lane 10: MW standard
Figure 4.30: 4-20% gradient gel for the SDS-
PAGE analysis of the refolding conditions.
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11 24 28 32
U
V
  2
80
  n
m
Fraction No.
22
HLE refolding: Activity screen with mAb7A9
1 0.5 0.4 0.3 0.2 0.1  20 22 24  25 27 29 -C.
0.0
0.1
0.2
0.3
0.4
0.5
0.6
E-selectin/IgG ( µg/ml)
HLE fraction total
Protein fractions
HLE activity screen
Figure 4.31: Size exclusion chromatography
profile of HisLecEGF after initial folding screen.
Lane 1: Fraction 11
Lane 2: Fraction 24
Lane 3: Fraction 28
Lane 4: Fraction 32
Lane 5: Prot. Standard
Lane 6: -
Lane 7: Fraction 11 non-red.
Lane 8: Fraction 24 non-red.
Lane 9: Fraction 28 non-red.
Lane 10: Fraction 11 non-red.
1        2      3      4      5      6    7      8      9      10
Figure 4.33: ELISA-based refolding screening with
mAb 7A9.
Figure 4.32: SDS-PAGE analysis of size
exclusion chromatography of HisLecEGF
presented in figure 4.31.
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Extensive optimization of refolding conditions was not successful and did not result in any
sufficiently active protein. An overview of the screening results is presented in the table 4.10.
Refolding
method
Fast
dilution
Tag removal /
dialysis
Dialysis/
tag removal
Fast dilution/
concentration/
tag removal
Fast dilution/
concentration/
dialysis/
tag removal
% active
protein
1.08 Precipitation 0.27 3.68-0.17 0.01%
4.3.3.2 Screening of refolding conditions
Asymmetrical Field-Flow Fractionation (AfFF) screening was used to find the best buffer
composition preventing protein precipitation and promoting correct protein folding prior to
oxidation. Light scattering and UV detection were combined to screen for, and distinguish
between folded protein structures or protein aggregates. Among 95 buffer conditions examined,
5 were chosen for scale-up, and figure 4.34 shows the best screen result. In these conditions
there was neither observable protein precipitation nor aggregation as confirmed by analytical
RP-HPLC. After the addition of redox reagents (GSH, GSSG), however, quantitative
precipitation occurred, except in solution with buffer 20b, which contained 0.05% n-
octlyglucoside in 0.5M Tris, pH 8.0. Unfortunately, a gel filtration run performed on a 
concentrated sample after refolding and oxidation in this buffer did not yield any protein
whatsoever. In a repeated experiment, the concentration step was monitored by RP-HPLC and
revealed protein precipitation on the membrane of the concentrating device as soon as a
concentration factor of 5 was achieved (volume reduced 5 times), with only about 7% of the
protein remaining in solution. Activity of this fraction was tested with the blocking antibody but
only 0.3% of the total protein was active.
Table 4.10: Different approaches were tested in order to refold active HisLecEGF. Refolding set ups are described in
material and methods section. Percentage of the active HisLecEGF is calculated as a fraction of total protein
subjected to refolding.
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4.3.4 LecEGF cloning into pET11c
Plasmid vector pET11c directs expression of recombinant proteins in the bacterial cytoplasm
w/o any tag. This is an advantage of the system, especially for complex protein folding, as
folding of HisLecEGF was. Protein expression is IPTG-inducible and the vector is compatible
with DE3 E.coli production strains. PCR amplification of LecEGF introduced NdeI  and BamHI
restriction sites on the 5’ and 3’ DNA end, respectively. Ligation and subsequent electroporation
into E.coli DHα5 were also successful, as controlled by restriction enzyme digestion (figure
4.36). 4 clones have been sequenced, and 3 sequences were correct. A clone named LE2 was
chosen for further experiments.
Lane 1: Set up 13c, suspension
Lane 2: Set up 13c, pellet
Lane 3: Set up 13c, supernatant
Lane 4: Set up 20b, suspension
Lane 5: Set up 20b, supernatant
Lane 6: Set up 20b, pellet
Lane 7: Low MW standard
Lane 8: Set up 20b, non-reduced
Figure 4.35: SDS-PAGE control of protein folding in
different buffers as result of the AfFF screen.
Different fractions were analyzed to address the
status of the protein in different refolding solutions.
Volume (ml)
U
V
 2
80
 n
m
Figure 4.34: AfFF report in the screen for the optimal folding
conditions. Light scattering and absorption at 280 nm showed
protein behavior and the soluble fraction amount in each buffer.
       1         2        3         4        5       6          7        8
Protein monomer fraction
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4.3.4.1 Protein expression analysis, purification and refolding
E.coli BL 21 (DE3), AD 494 and Rosetta gami were chemically transformed with the DNA LE2.
A protein running at expected molecular weight of 18 kDa was overexpressed together with
another shorter species, both however exclusively in inclusion bodies.
Further protein characterization was done by MS analysis of in-gel digests of both lower and
higher molecular weight overexpressed proteins. This revealed that the shorter protein lacked
the C-terminal last 30 amino acids, whereas the sequence of the higher molecular weight
protein was correct. On analytical RP-HPLC, it was not possible to really separate these two
protein species. A first purification attempt was performed by anion exchange chromatography
in 8M urea. Figure 4.38 shows the isolated crude extract fraction, where full-length protein was
the predominant species.
Figure 4.36: Restriction enzyme digestion of
the pET11cLecEGF, with the undigested DNA
of 6153 bps, and LecEGF of 478 bps.
Lanes 1, 15: DNA marker X
Lanes 2, 4, 6, 8, 10, 13:
Undigested pET11cLecEGF
Lanes: 3, 5, 7, 9, 11, 14:
pET11cLecEGF digested with NdeI, BamHI
Figure 4.37: SDS-PAGE analysis of protein expression
in BL 21 (DE3).
   1   2   3   4   5   6   7   8   9  10  11  12  13 14 15
    1       2       3      4       5     6     7        8      9 Lane 1: BL 21, pET11c induction 0
Lane 2: BL 21, pET11cLecEGF 2, induction 0
Lane 3: BL 21, pET11cLecEGF 8, induction 0
Lane 4: -
Lane 5: Low MW standard
Lane 6: -
Lane 7: BL 21, pET11c 10h post induction
Lane 8: BL 21, pET11cLecEGF 2, 10h post induction
Lane 9: BL 21, pET11cLecEGF 8, 10h post induction
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Since protein purification and separation of the two LecEGF species by anion exchange was not
successful, preparative RP-HPLC was performed. As shown in figure 4.39, this method was
partially successful but the intact species was present only in fraction 1, whereas fractions 3-6,
containing both, were pooled together. Both pools were lyophilized.
Refolding was tried in parallel with both samples and there was no visible precipitation or
aggregate formation as monitored by analytical RP-HPLC. Upon oxidation, a peak shift to
shorter retention time was observed, a good indication of successful disulfide formation.
However, the activity of the recovered protein was only 2% as compared to a positive control.
The RP-HPLC conditions were optimized in an attempt to improve the separation of the two
protein species prior to the any refolding trial, but this was not possible. Since the yields and the
activity were very low, the strategy was abandoned.
Figure 4.38: Inclusion bodies fraction
solubilized in 8M urea. 15% SDS-PAGE.
Lane 1: LMW standard
Lane 2: Fraction soluble in 8M urea
Lane 3: Insoluble pellet
Figure 4.39: LecEGF purification on preparative
RP-HPLC.
.
Lane 1: Fr. 1, RP-HPLC
Lanes 2-10: Fr. 2-10 RP-HPLC
Lane 11: MW standard
    1         2       3
1      2      3      4     5       6      7      8     9      10    11
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4.4 Expression of lectin and EGF-like domains of human E-selectin
in baculovirus-infected insect cells
Baculovirus-infected insect cells have been chosen for LecEGF expression as a eukaryotic
expression system that facilitates correct protein folding and disulfide bond formation. The
system is potentially effective on time- and cost-scale for the preparation of the amounts of
protein necessary for structural studies.
4.4.1 LecEGF cloning and expression into pFastBac: intracellular
expression of a His-tagged protein
DNA coding for LecEGF (1-157) domain was successfully PCR amplified and PCR integrated in
the plasmid pBacPak. DNA sequence was amplified with primers that enabled PCR intergration
into the pFastBac cloning vector and a construct His-Prescission-LecEGF (pFastBacHPLE) was
generated. Positive clones were screened by PCR and DNA sequenced. E.coli DH10Bac was
transformed with the generated pFastBacHPLE and, after 48 h growth and selection, 10
colonies were further analyzed. A 2850 bps fragment was amplified by PCR with M13 standard
primers. This corresponds to the size of bacmid DNA in between these two primers and the size
of His-Prescission-LecEGF (HPLE).
Sf9 insect cells were successfully transfected with the transposed bacmid DNA DH10BacHPLE.
A first preliminary screen for protein expression has revealed the presence of a 20.1 kDa protein
expressed in the cells and reacting positive with anti-His antibodies, as shown in figure 4.41.
Figure 4.40: HPLE expression kinetic analysis
in Sf9 insect cells. Overexpressed HPLE is
designated.
Lane 1: Transf. 1
Lane 2: P1 ampl.
Lane 3: +ctrl., His tagged protein
Lane 4: TL 42h p.i.
Lane 5: TL 54h p.i.
Lane 6: TL 66h p.i.
Lane 7: TL 72h p.i.
Lane 8.: LMW marker
Lane 9.: -ctrl., non-transf. Sf9 cells
1       2       3        4        5        6      7       8          9
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In parallel to the protein expression optimization, a plaque assay was performed and a single
viral clone isolated, purified and titer determined. The P2 viral titer that was used in further
experiments was 0.6 pfu/ml.
4.4.1.1 LecEGF purification and analysis
Since LecEGF had an N-terminal His tag, and was expressed intracellularly, Sf9 insect cells
were lysed under mild native conditions and that extract was purified over a Ni-NTA column.
Fractions eluted with either an imidazole gradient or isocraticly at 500 mM imidazole in native
conditions contained a variety of proteins. Under a variety of different conditions tested the
elution profile seemed to be rather unspecific. Western blot analysis of cell lysate with anti-His
antibodies was negative in both native and denaturing conditions, whereas it was positive for
the rest of insoluble cell material tested under denaturing conditions. In agreement, western blot
analysis with mAb 7A9 was also negative. To improve expression and production conditions
different parameters were optimized, but the results were unchanged. Table 4.11 shows a
summary of the optimization parameters tested to express and produce active LecEGF.ii
Figure 4.41: HPLE anti-his WB during expression
kinetic analysis samples. Positive signals indicated by
arrows appear only 66 and 72h p.i. at MW of 20 kDa.
Lane 1: Transfection1
Lane 2: P1 ampl.
Lane 3: +ctrl.
Lane 4: Total cell lysate 42h p.i.
Lane 5: Total cell lysate 54h p.i.
Lane 6: Total cell lysate 66h p.i.
Lane 7: Total cell lysate 72h p.i.
Lane 8: LMW marker
1     2          3          4      5         6           7         8
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Viral Data Cell line Infection
conditions:
M.O.I Time course/
Temperature
Protein
isolation
methods:
Protein
isolation
methods:
4.6x107 pfu/ml
-Sf9
suspension
culture
-Sf21
-High five
-1x106 cells/ml
-1.2X106
cells/ml
-1.0
-0.6
-0.06
-72h p.i
-39-84h p.i.
//
-28°C
-21°C
-Cell lysis
-Sonication
-Ultracentrifuge
Cell lysis+
Detergents
-0.1%NP-40
-0.5%NP-40
-0.1% Triton
x-100
-1% NP-40
4.4.2 LecEF cloning and expression in baculovirus infected insect cells:
protein secretion into the medium
In order to express the LecEGF domain of E-selectin as a secreted form, the signal sequence of
endogenous insect acidic glycoprotein 67 was fused to the N-terminus of LecEGF to direct its
secretion into the medium. For analytical and purification purposes a Flag-tag was introduced
on the C-terminal of the EGF-like domain.
4.4.2.1 LecEGFFlag cloning and expression
The LecEGF sequence was successfully PCR amplified with 5’ and 3’ overhangs enabling PCR
integration into vector pAcGP67a. The purified mixture was electroporated into E.coli XL-1 Blue
electro competent cells. Grown colonies were screened by PCR and positive ones have been
sequenced. DNA coding for LecEGF with signal sequence and Flag epitope (SSLecEGFFlag)
was subcloned into the vector pFastBac, as described above. The colony PCR screening
procedure was as described, using primers that anneal to the vector sequence (3’ MG 593) and
FWZZLE that starts at bp 152 of the LecEGF sequence. 6 positive clones were isolated and
sequenced, and Figure 4.42 shows a screen result. 5 colonies were sequenced, 4 were positive
and DNA of clone 2 was taken for further cloning into E.coli DH10Bac and transposition reaction
to generate bacmid DNA containing SSLecEGFFlag.
Table 4.11: Different parameters known to influence protein expression and production in insect cells were tested to 
produce functional and active LecEGF, i.e. His-Prescission-LecEGF (HPLE).
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Bacmid DNA was isolated as described in materials and methods and those with the highest
purity and concentration were chosen for the transfection experiments. After initial infection of
Sf9 insect cells, the virus was purified by plaque assay and amplified. Titer of the virus to be
used in further infections was determined. LecEGFFlag production and secretion in the medium
was followed on small scale for 96 hours by SDS-PAGE and Western blot with anti-Flag
antibodies. As shown in the figure 4.43, LecEGFFlag secretion in the medium started 48 h post-
infection (p.i.), whereas maximal protein secretion was achieved at 72 and 96 hours p.i. There
were still some amounts of unsecreted and unprocessed LecEGFFlag in the cells but this
protein fraction was not further analyzed.
In order to improve yields of the secreted LecEGFFlag, apart from a time-course optimization,
the influence of M.O.I. and an alternative cell line (Trichopulsia Ni, referred to as Hi5TM) were
optimized as well. Table 4.12 shows the best protein production conditions.
Lane 1: DNA marker X
Lanes 2-6: PCR product,
screen of colonies1-5.
             1     2       3       4       5         6
Figure 4.42: Colony PCR screens with the
primers FWZZLE and MG 593 amplified a
fragment of the expected 479 bps.
Figure 4.43: Time-course analysis of the
LecEGFF expression. Arrows indicate
LecEGFF secreted in the medium.
Lane 1: -ctrl: Medium of the non-infected Sf9 cells
Lane 2: Conditioned medium of infected Sf9 cells,
48h post-infection (p.i.)
Lane 3: Conditioned medium of infected Sf9 cells,
72h (p.i.)
Lane 4: Conditioned medium of infected Sf9 cells,
96h (p.i.)
Lane 5: LMW marker
Lane 6: -ctrl: Pellet of the non-infected Sf9 cells
Lane 7: Pellet of the infected Sf9 cells, 48 h p.i.
Lane 8: Pellet of the infected Sf9 cells, 72 h p.i.
Lane 9: Pellet of the infected Sf9 cells, 96 h p.i.
    1       2      3      4     5      6     7      8     9
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Cell line Medium Viral titer No. cells M.O.I.
Expression
time Temp.
Sf 9
H5 √
Sf 900
No serum
No antibiotic
9.6 x107 1x106
3-10
10 √
48-96h
72h √
28°C
4.4.2.2 LecEGFFlag purification and characterization
LecEGFFlag was purified using a commercial M2 monoclonal anti-FLAG antibody resin, as
described in materials and methods. Eluted under mild conditions with competing flag peptide,
the protein was purified to homogeneity in a single step as judged by SDS-PAGE and shown in
figure 4.44. A Western blot analysis of eluted protein, as well as fractions of flow through and
conditioned medium with the anti-Flag monoclonal antibody M2 is shown in figure 4.45.
According to the LecEGFF migration profile on reducing SDS-PAGE, the protein shows an
apparent molecular weight of 20-24 kDa.
Activity of the LecEGFFlag secreted into the medium was addressed in a native western blot
with the mAb 7A9. The recombinant protein gave positive signals in this reaction, indicating that
Table 4.12: Optimized conditions for LecEGFF protein production. Parameters that influence culture conditions and
rotein production have been subjected to extensive optimization.
Lane 1: LMW marker
Lane 2: Crude extract, Sf 9 cells conditioned medium
Lane 3: Elution
Lane 4: Flow through
Figure 4.44: LecEGFF purification
profile over the Anti-flag affinity
chromatography.
Figure 4.45: Western blot analysis of
Anti-flag chromatography fractions.
1      2         3      4
Lane 1: LMW marker
Lane 2: Elution
Lane 3: Flow through
Lane 4: Crude extract, Sf 9 cells conditioned medium
Lane 5: Cell pellet
1    2     3     4     5
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the LecEGF of E-selectin was correctly folded upon expression (figure 4.46). Western blot
analysis with the M2 Anti-flag antibodies in native conditions was also positive; indicating that
the C-terminal end of the EGF domain is free in the space, and accessible to the anti-flag
antibodies.
Further protein characterization addressed the aggregation state of the expressed (exported)
protein in solution. Since the migration profile on SDS-PAGE in non-reducing and native
conditions was the same as in reducing conditions, it could be concluded that the protein is
monomeric. The glycosylation status of LecEGFF was analyzed by treatment with PNGaseF
under both native and denatured conditions. While deglycosylation of denatured LecEGFF
completely removed N-glycans (as judged by SDS-PAGE), in native conditions there was a shift
in migration profile but two bands were still present in the sample pointing to two predominant
glycosylated forms. Figure 4.47 shows N-deglycosylation in denaturing conditions.
Figure 4.46: Western blot analysis under native conditions with anti-E-
selectin blocking antibodies 7A9. Proteins were separated on 5-15% %
gradient native gel to analyze both E-selectin/IgG and LecEGFFlag.
Lane 1: LMW standard
Lane 2: -
Lane 3: LecEGFFlag glycosylated
Lane 4: N-deglycosylation, 15 min.
Lane 5: N-deglycosylation, 30 min.
Lane 6: N-deglycosylation, 45 min.
Lane 7: N-deglycosylation, 60 min.
Lane 8: N-deglycosylation, 48 h.
Figure 4.47: Time-course of N-deglycosylation
of LecEGFFlag with PNGaseF. Protein was
denatured and reduced prior to the
deglycosylation that was complete after 48
hours, when a single protein band was
detected.
 1     2      3         4          5         6       7       8
Lane 1: E-selectin/IgG
Lane 2: -
Lane 3: P-selectin/IgG
Lane 4.: -
Lane 5.: L-selectin/IgG
Lane 6.: -
Lane 7.: LecEGFFlag
Lane 8.: LecEGFFlag deglycosylated
  1      2       3        4        5       6        7         8
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In order to control the deglycosylation extent, glycosylated and deglycosylated LecEGFFlag
were stained with Schiff reagent since only proteins with bound glycans give a positive reaction.
Since deglycosylated LecEGFFlag did not react with the Schiff reagent, we concluded that all
glycans had been removed from the protein and that deglycosylation was complete.
4.4.2.3 Mass spectrometry analysis and NMR analysis of LecEGFFlag
Molecular weight of the expressed LecEGFFlag was determined by LC/MS. Prior to the MS
analysis protein was desalted on an analytical RP-HPLC Vydac C4 column, with the concomitant
separation of the two differentially glycosylated protein species. The first eluted fraction was the
one with higher molecular weight (with higher sugar content and therefore more hydrophilic).
Molecular weight determination has shown heterogeneity of these isoforms, with a predominant
mass at 21151.87 Da and 19958.57 Da, respectively.
NMR analysis of the binding activity of LecEGFFlag was done in the presence of an
antagonistic sLex tetrasachharide mimetic BW69669  that has 12 times higher affinity as
compared to the carbohydrate epitope sLex. STD NMR and T1 rho relaxation time were
measured in the presence of protein and significant change in STD NMR was observed, as
shown in figure 4.48.
4.4.3 Bioassay development
In order to evaluate potential E-selectin antagonists, a bioassay was developed using the
recombinant LecEGFFlag as a target molecule. Biotinylated polyacrylamide-sLea polymer (PAA-
sLea) coupled to streptavidin peroxidase, should bind to LecEGFFlag. The intensity of the
colored reaction using the chromogenic substrate ABTS, can quantitatively describe PAA-sLea
230 µM BW 69669
23 µM LecEGFF
230 µM BW 69669
Figure 4.48: STD of BW69669 in presence
and absence of LecEGFFlag indicates ligand
binding and confirms protein activity.
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binding to the LecEGFFlag. A preliminary screen was done to establish the best assay
conditions with different protein and polymer concentrations, as shown in figure 4.49. Having
established the best protein concentrations, the affinity for sLea-polymer was assayed, as shown
in figure 4.50.
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The optimal protein and polymer concentration to give stable signal were chosen as 3 µg/ml
LecEGFFlag and 100 ng/ml polymer, because these had at least 5x higher O.D. values as
compared to background, what is considered as stable signals. All the subsequent tests were
done under these conditions.
IC50 of LecEGFFlag toward the sLe
a polymer was determined as 274.5-356.5 ng/ml, or 54-62
nM. All IC50, shown in table 4.8 were calculated as relative to this value. Measurements were
done in triplicates or quadruplicates of three independent experiments and were overall
reproducible. 3 different E-selectin inhibitors, as well as negative control (Fucα1-3, GlcNAc)
were tested in this assay, and the results obtained are presented on figure 4.52 and in table
4.13.
Figure 4.50: Determination of IC50 value for
sLea polymer toward LecEGFFlag, as a
measure of binding affinity.
Figure 4.49: Optimization of LecEGFFlag and
sLea-polymer concentration for bioassay. The
standard optimal conditions were chosen in
respect to the signal to background ratio.
133
       
LecEGFFlag+sLe a polymer binding
BW 75757, BW 75145, BW 69669 inhibition
-10 -5
25
50
75
100
125
BW 75757
BW 75145
BW 69669
0 1 2 3
log (?g/ml)
sL
ea
 p
o
ly
m
er
 b
in
d
in
g
(%
 o
f 
co
n
tr
o
l)
Antagonist IC50 (µM) Signal/
Bckg.
Signal/
Noise
Ctrl±SD Bckg±SD
BW69669 63±6.4 10-13 11-20 1.06±0.19 0.06±0.028
BW75757 28±3 12-15 18-22 1.14±0.12 0078±0.03
BW75145 29.3±1 10-16 15-17 1.38±0.2 0.082±0.02
sLea-polymer Kd=63.1±8.2 nM 0.075±0.01
ln contrast to cell-free assay, cell-based assay with HL-60 cells showed very weak binding of
LecEGFFlag compared to E-selectin/IgG, even as a control. Different incubation times and
temperature were tested, but a stable control signal was not obtained.
FIgure 4.51: Concentration dependence curve of
BBW 69669. Data presented are means of three
independent experiments done in triplicates.
Figure 4.52: Superimposed concentration
dependence curves of E-selectin antagonists
tested in a bioassay. Data present three
independent experiments done in triplicates.
Table 4.13: E-selectin antagonists, sLex mimetics analyzed in a molecule-molecule assay with LecEGFFlag and
sLea polymer. Calculated IC50 values are relative to sLe
a polymer as control.
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5 Discussion
5.1 E-, P-, L-selectin/IgG expression, purification and
characterization in CHO cells
For the efficient production of recombinant proteins, a variety of expression systems are
available. Depending on the nature of the protein of interest and the amounts of protein
necessary to conduct the desired studies, the most appropriate expression system is to be
chosen. Limiting factors may be, however, the nature of the protein and its complex structure,
folding pattern, or post-translational modifications. In this case the protein should be expressed
in an environment as similar as possible to its natural counterpart. The expression conditions
have additionally to be optimized to get optimal expression levels versus time- and cost-scale.
Since their discovery in the late 80-es, recombinant human selectins were expressed on
analytical and preparative scale for both functional and structural studies. A large body of
evidence has defined chinese hamster ovary (nomenclatured in the text as CHO cells) and
green African monkey cells as a mammalian systems optimal for expression of recombinant
selectins [92,97,99,252-254]. Selectins are transmembrane proteins with extracellular domains
(Lectin, EGF-like and consensus repeats) involved in ligand binding. Lectin and EGF-like
domains contain 5 disulfide bridges and the whole molecule has eleven potential N-
glycosylation sites. These data imply complex post-translational modifications and the necessity
for the protein to pass through the Golgi and the oxidative environment of the endoplasmic
reticulum for correct protein folding, disulfide-bond formation and N-glycosylation. Since
glycosylation itself is not a pre-requisite for the activity of selectins [151], differences in
glycosylation profiles of hamster, monkeys and humans do not influence protein activity. Other
post translational modifications have not been thoroughly investigated for selectins so far,
except for phosphorylation, which takes place only intracellularly and is implied in signal
transduction.
Although one of the advantages of using cells such as CHO for expression is the possibility to
closely mimic glycosylation patterns found in humans, over the production process duration, the
degree of glycosylation can vary (several glycans, one glycan or no glycans bound to the
peptide-backbone).
In different expression strategies, recombinant selectins have been mostly expressed as fused
to the human/mouse Fc part of immunoglobulin [92,240,253,254]. There are many arguments
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for this approach that works not only for selectins, but also for many different extracellular
protein-domains expressed in this fashion. The production of receptor-immunoglobulin constant
region chimera enables good secretion and easier purification using very simple protein A
purification protocols. The ability of these molecules to dimerize is expected to add to the avidity
of the interactions between the receptor and its ligands. First designed for CD4
immunoadhesins for AIDS therapy, the human heavy chain IgG1 constant region cassette was
thoroughly characterized [255]. Subsequently, the murine homing receptor, a non-
immunoglobulin superfamily member, was successfully produced exploiting this strategy [86]. It
was demonstrated that the joining of molecules near the hinge region resulted in chimeric
molecules that were both efficiently synthesized and dimerized in the absence of any light chain
production. These molecules might find the utility as the modulators of inflammatory proceses
and may be exploited as affinity reagent to isolate endothelial and cell ligands. A novel antibody-
like form of human selectins was shown to be very suitable to bioassay development as well,
since it can easily be coupled to any affinity or coating support [252]. Throughout a number of
different selectin studies, the originally described expression strategy was modified in such a
way that recombinant selectins containing different extracellular parts were not secreted into the
medium, but expressed on the cell surface via fusion to CD16 (component of low affinity Fc
receptor, FcgRIII), which contains a signal sequence for cell surface anchorage via
glycosylphosphatidylinositol (GPI) linkeage [256]. In addition, recombinant proteins containing
only selectin domains have been expressed in secreted form, [91], [151], as fused to the ZZ
domain of protein A and either secreted or expressed on the cell surface [257]. Extracellular
expression and secretion of selectins in the medium was usually governed by the native signal
sequence, which, in the absence of a membrane anchor, led to production of soluble selectins.
This has enabled the measurement of binding both in solution and on solid surfaces preventing
any artifacts introduced by either low or high levels of expression on the cell surface.
E-, P- and L-selectin/IgG described in this study were constructed as IgG-fusion chimeras
(figure 5.1), where the lectin (carbohydrate recognition domain-CRD), the EGF-like domain, 6
consensus repeat domains each for E-, and P-selectin and 2 for L-selectin were fused to the
hinge region of human IgG1 immediately after the last consensus repeat domain. The
endogenous signal sequence of each of the selectins directed protein expression into the
medium. Amino acids 1-155 for E-, and L-selectin, and 1-157 for P-selectin, constitute the lectin
and EGF-like domains, whereas boundaries of expressed consensus repeats were taken as
amino acids 535 and 332 for E-and L-selectin respectively, and amino acids 540 for P-selectin.
The resulting PCR products were spliced in a PCR-amplified product consisting of a few bases
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from the 3’ end of the CH1 domain and the complete hinge region and CH2 and CH3 domains
of genomic human IgG1. The resulting chimeric selectin/IgG cDNAs were introduced at the NotI
restriction site of the expression vector pcDNA/Neo. Chinese hamster ovary cells were
transfected with the isolated pcDNA/neo and positive, producing transformants were selected in
gentamicin (G-418) containing medium. Production conditions were set up based on the general
rules for protein production in CHO cells [225,258] considering seeding density and cell life- and
production-cycles. In order to enhance the expression of recombinant protein, selectins DNA
sequences were placed behind the potent SV-40 promoter in frame with the neo gene for
gentamicin resistance and cells were cultivated in medium with high G-418 content (0.5 mg/ml).
Analysis done on a small scale compared protein production of adherent cultures grown in
culture flasks and in roller bottles. While the growth phase was rather similar for both cultivating
systems, the production in roller bottles resulted in higher protein yields, as is presented in table
4.1. The production time was prolonged in this system, which provides for better aeration and
medium circulation. Yields of 7.3 mg/L medium, based on protein A chromatography, have far
exceeded published results and represent a significant improvement over the initial 2 mg/L
protein produced in culture flasks. All productions were done on a laboratory small scale and
generated sufficient protein for analytical characterization, structural studies and bioassay
development. Protein expression analysis revealed that expressed selectins were exported,
soluble IgG recombinants. Purification of recombinant selectins was done on protein A resins,
exploiting the affinity between the constant region of immunoglobulins and staphylococcal
protein A. The dissociation constant for this interaction has been determined to be 2x10-8M
[260]. Although the Fc part of human IgG1 preferentially binds to protein A, some bovine IgG
could be detected in eluted fractions. These data are rather consistent with published results
[92], because the binding specificity of protein A toward human Fc/IgG is not high enough to
completely eliminate binding of other IgGs present in the medium. Although 5% fetal calf serum
used in cell medium was found to be on optimal concentration, this rather high serum
percentage led to contaminations of bovine IgGs in purified fractions. As a polishing step, size
exclusion chromatography was done using either a small 15 ml Sephadex column for analytical,
or a 200 ml Superose column for preparative applications. E- and P-selectin/IgG were both
successfully separated from the rest of contaminating proteins by size exclusion. The
chromatographic profile of the two columns has shown differences and has raised questions on
the oligomerization status of E-selectin as will be discussed later. The molecular weight of the
purified proteins was calculated in reduced and denatured conditions, based on the protein
migration profile on 8% SDS-PAGE. As indicated in results, figure 4.4, E-selectin/IgG migrates
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at about 148 kDa, whereas P-and L-selectin/IgG migrate at 110 and 87 kDa, respectively.
Based on protein sequence the molecular weights of monomer E-. P-and L-selectin/IgG
constructs were calculated to be 83.37 kDa, 85 kDa, and 56.84 kDa, respectively. The higher
apparent molecular weight of the proteins in SDS-PAGE analysis indicates a high glycosylation
extent of all of three selectins. Non-reducing SDS-PAGE indicated high molecular weight
proteins exceeding the calibration range of the standards. Although the best method to address
the molecular weight of the soluble proteins in native conditions would be mass spectrometry,
the high molecular weight of recombinant selectins was well outside the range for MS analysis
[261]. In native conditions, the molecular weight was examined by size exclusion
chromatography and native PAGE. Based on the molecular organization of Fc-IgG chimeras,
the theoretical molecular weight of each IgG chimera in native conditions is expected to be the
double of what is found in reducing and denaturing conditions, namely 296 kDa, 220 kDa, and
174 kDa for E-, P-, and L-selectn/IgG respectively. When chromatographed on a 15 ml size
exclusion Sephadex column and compared with standard proteins of known molecular weight,
E-selectin/Ig was eluted between the peaks corresponding to protein aggregates and
thyroglobulin (670 kDa), indicating a molecular weight of 840 kDa. These data would point to an
oligomerization of E-selectin/IgG in solution in native conditions (or an oligomerization that takes
place on the size exclusion matrix). Similar observations have been reported in some of the
previous E-selectin characterization studies , however not for the E-selectin/IgG chimera but for
a construct consisting of the lectin domain, EGF-like and 6 consensus repeat domains. In this
study the apparent molecular weight of this soluble E-selectin was 310 kDa, whereas in
reducing conditions on SDS-PAGE the protein migrated at 80 kDa. Further analyzes of this
construct with equilibrium analytical ultracentrifugation have revealed that soluble E-selectin
was an elongated monomer and that its abnormal behavior on size exclusion chromatography
was an artifact, probably caused by the protein non-globular structure and its interaction with the
column material. We tried to address the nature of this complex oligomerization that were
formed by reproducing the same size exclusion conditions, except for the running buffers, which
were either buffer with 8 M urea or phosphate buffer with and without calcium. The
chromatographic pattern was unchanged in 8 M urea, pointing to covalent interactions that were
calcium independent. The 200 ml size exclusion chromatography was done without a calibration
with standard proteins. Here E- and P-selectin/IgG eluted in front of contaminating IgG
molecules, consistent with the protein molecular weight. The size of this column yields to higher
resolution and is suitable for preparative scale separations. However, for several reasons, size
exclusion was abandon as an appropriate method to determine the molecular weight of the
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proteins. IgG fusion proteins do not have globular shape and additionally protein interactions
with the chromatographic matrix can cause retention and influence the elution profile. As
already described [262], high protein glycosylation can also enhance the interaction with the
chromatographic matrix. For these reasons we decided to address the question of the molecular
weight of selectin/IgG chimeras in native state by native PAGE. The results obtained indicated a
complex oligomerization state of E-selectin/IgG, whereas the molecular weights of P-, and L-
selectin/IgG were in agreement with what had been observed for reduced and denatured
proteins. In native PAGE proteins migrate not only depending on their molecular weight but also
on their shape and overall charge. To avoid misinterpretation based on these factors, proteins
were run on different percentage gels and a constant was generated, which described the
migration profile of each of the tested proteins [247]. A similar approach for characterization of
different E-selectin constructs was described recently [94], where the predominant part of the E-
selectin/IgG fraction was reported to be 300 kDa and a 5% protein fraction a dimer thereof. In
our case the protein migrates homogenously as an 840 kDa protein. However, this approach
has not been really validated and the results are questionable. It is also possible that in
equilibrium in solution, the protein exists in different forms: as a cluster but also as a dimer. For
ligand binding studies, the characterization of the protein part that carries the ligand binding site
was of higher importance. Based on the E-selectin/IgG construct used, the monomeric molecule
has 1 lectin domain and therefore 1 ligand binding site. In case of P- and L-selectin/IgG there
was no indication for protein oligomerization, which is consistent with published data [125,263].
Selectin dimerization or oligomerization happens in vivo and in vitro and enhances ligand
binding, but this is mediated exclusively through the transmembrane and cytoplasmic part of the
protein [264,265]. The above mentioned study done by Green et al. [94], has analyzed also E-
selectin constructs made with lectin and EGF-like domain fused to the Fc part of IgG, as well as
lectin and EGF-like domain alone. Only constructs that contained 6 consensus repeats fused to
the Fc-IgG formed oligomers in solution. One could presume therefore that, in case of E-
selectin/IgG, consensus repeats contribute to the oligomerization. However, partially
contradictory are studies where LecEGF with 6 consensus repeats did not oligomerize but was
found to have a rod-like shape of an asymmetric monomer. Taken together, in the case of E-
selectin/IgG consisting of lectin, EGF-like domain and 6 consensus repeat domains, the
consensus repeats and the Fc part of IgG could promote molecular clustering and oligomer
formation. High increase in molecular weight as compared to what is expected for the protein
sequence is consistent with the fact that E-, P-, and L-selectin have 11, 7 and 8 potential N-
linked glycosylation sites in their extracellular domains, respectively. As already mentioned,
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many different recombinant selectins have been produced in animal cells, predominantly CHO
and COS cells, but the exact glycosylation profile of these proteins has not been described so
far [266]. CHO cells can produce complex and hybrid N-linked structures. These can be
incompletely processed and are termed high mannose carbohydrates, or partially processed
and then substituted with GlcNAc (± Gal ± Sia) and called hybrid moieties. Molecules that are
completely processed to the core sugar sequence and subsequently elongated to contain
GlcNAc (±Gal ± Sia) at both the Man α (1,3) and the Man α (1,6) sugars are termed complex
moieties. Different studies have shown that in animal cells the majority of glycoproteins posses
high mannose- or complex-type asparagine-linked oligosaccharides [7,267]. To characterize the
high molecular weight, we have addressed the glycosylation profile of recombinant E- and P-
selectin/IgG by enzymatic cleavage with different glycanases, including PNGaseF, PNGaseA
and O-glycanase [268]. Other lines of evidence showed that the treatment of the extracellular
part of the protein with PNGaseF removed 78% of all posttranslational modifications, whereas in
our experiments 62.5% of carbohydrates were removed in an extensive, denaturing (up to 48
hours) treatment with PNGaseF, section results, figure 4.5 [5]. Similar results were obtained in
N-deglycosylation of E-selectin/IgG for NMR studies [269].
In case of P-selectin, and L-selectin/IgG, N-deglycosylation decreased the molecular weight by
about 65%, and 45% respectively. O-linked glycosylation or ubiquitination were proposed as
post-translational modifications on E-selectin in the early work of Bevilacqua. However, in our
experiments protein treatment with O-glycanase did not noticeable affect the molecular weight.
Interestingly, the crystal structure determination [151] of E- and P-selectins’ lectin and EGF-like
domain, in complex with sLex [188], has confirmed that complete N-deglycosylation does not
affect ligand binding nor the protein capability to block neutrophile adhesion to the endothelium.
These data would indicate that, at least in lectin und EGF-like domains, there are no other
posttranslational modifications apart from N-glycosylation, which can be successfully removed.
A brief overview of the glycosylation extent of E-selectin produced in animal cells has been
given by Li et al. [90]. In this work it was demonstrated that glycosylation within the lectin and
EGF-like domains increases the molecular weight predicted from protein sequence by 8 kDa, in
the first two consensus repeats by another 26 kDa, and in the last four consensus repeats by 41
kDa, or 13 and 15 kDa per consensus repeat. Deglycosylation in native conditions was
performed to address the contribution of sugars on protein activity. In native gel, there was a
clear difference in the migration profile after extensive (48 h) deglycosylation. Consistent with
published data, the protein binding site was still functional, as judged by positive binding of a
blocking monoclonal antibody, described below.
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Throughout the work with E-selectin, a monoclonal blocking antibody (7A9, mouse IgG1
subtype) was used to address protein activity. This antibody has been raised against IL-1
stimulated HUVEC, expressing E-selectin [270]. X-ray structure of the antibody has revealed a
groove in the binding site, where probably E-selectin binds to the antibody. The lectin domain
loop between β-strands β4 and β5 with exposed Tyr-94 and Arg-97 side chains, known to be
involved in ligand binding, interact with the antibody, which is consistent with its blocking
function [249]. This antibody shows blocking activity in vitro, blocking protein adhesion to the
HL-60 cells, and inhibiting granulocytes adhesion to the stimulated HUVECs in a concentration
dependent way. Different experimental set-ups were performed to investigate binding
characteristics of E-selectin/IgG and mAb 7A9. This interaction is clearly calcium dependent,
consistent with the general requirements of this ion for selectin activity. For binding and
functional studies, native Western blot conditions were to be used, since reduced and denatured
protein does not bind the antibody. Appearance of two bands on the western blot membrane
(figure 4.5) is due to the heterogeneous glycosylation profile of the protein that, however, does
not influence its activity. The binding constant of E-selectin/IgG toward the 7A9 antibody was
characterized with a Kd of 5 nM, typical for an antibody-antigen interaction. There was no cross
reactivity between mAb 7A9 and L- and P-selectin, as experimentally confirmed in parallel
native Western Blots.
The functionality of expressed P-, and L-selectin/IgG were characterized in a reaction with
different specific monoclonal blocking antibodies, anti-human CD62P, a mouse IgG1κ in case of
P-selectin/IgG, and an anti-human CD62L, LAM1-116, a mouse IgG2aκ antibody in case of L-
selectin [145,146,271]. Both glycosylated and non-glycosylated form of the proteins reacted with
these antibodies, in a calcium-dependent manner and only under native conditions. Blocking
antibodies against both P-, and L-selectin were highly specific without any cross reactivity with
other proteins of this familly.
Figure 5.1: Shematic representation of E-selectin/IgG
141
5.2 Expression of lectin and EGF-like domain of human E-selectin in
E.coli
The expression of cloned genes in E. coli for the production of recombinant proteins has
provided a valuable system for studying protein structure and function. Production of
recombinant proteins in E.coli is the basis of the multibillion dollars biotechnology industry.
Bacterial or smaller eukaryotic proteins are usually easily over-produced in E.coli, whereas
more complex, mammalian proteins are often more difficult to express in an active form.
Proteins have been successfully produced in either the cytoplasmic or periplasmic space of
E.coli. In general, proteins are more easily produced in the cytoplasm, but often aggregate into
insoluble inclusion bodies, necessitating a refolding step. Proteins or protein domains that are
normally secreted or extracellular part of the protein, have better chance to properly fold in
E.coli when they are exported into the more oxidizing environment of the periplasmic space
where disulfide bond formation can take place [272,273]. To obtain efficient translocation of a
recombinant protein across the cytoplasmic membrane is often difficult and there is no
guarantee of proper folding. In addition, proteins produced in the periplasm can also aggregate
into insoluble inclusion bodies. Some fusion proteins are designed to cross both inner and outer
bacterial membranes and are secreted into the media. This has drawbacks, however, and can
be undesirable, due to the harsh agitation and oxidizing conditions of the culture during growth.
Proteins secreted into the media can undergo unwanted modifications such as over-oxidation
and deamidation.
The observation that deglycosylation of E-selectin does not affect protein activity [151] directed
our expression strategy toward E.coli. On time and cost scale, this expression system would
have been by far the most appropriate for the planned structural studies. For NMR studies, it is
desirable to incorporate 15N/13C isotopes into the protein sequence. This has led our effort to
express the lectin and EGF-like domains of human E-selectin in E.coli as a minimal active
protein part of 18.5 kDa. However, lectin and EGF-like domains of E-selectin belong to the
extracellular part of the protein. Consequently, these domains are post-translationaly modified
on three N-linked glycosylation sites and have five disulfide bridges, two of which are in the
lectin domain, and three in the EGF-like domain. Although these disulfide bridges are not
directly part of the ligand binding site, their contribution to the overall protein structure and
stability is significant. In the native protein, disulfide bonds are formed between Cys residues
C19-C119, C92-C111, C124-C135, C129-C144 and C146-C155, following the 1-4, 2-3, 5-7, 6-8
and 9-10 pattern, figure 5.1. These challenging protein characteristics and the complex disulfide
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pattern have directed our strategy to express LecEGF as a fusion protein secreting in the
medium.
5.2.1 Lectin and EGF-like domain (LecEGF) secretion into the medium
The construction and use of fusion vectors based on the gene for staphylococcal protein A has
been described for secretion of proteins into the culture medium, and for the rapid recovery of
the fusion proteins from crude lysates by affinity chromatography (human insuline-like growth
factor). It was demonstrated that fusion proteins containing only two (EE or ZZ) of the five ( A, B,
C, D, E, Z) IgG-binding domains of protein A were secreted into the growth medium of E.coli
[274,275]. These findings led to the construction of the so called pEZZ18 plasmid vector with
the described features of secretion- and IgG binding. pEZZ18 has both the lac UV5 and
staphylococcal protein A promoters. The system is not inducible, but expression can be
increased by heat shock i.e., by raising the culture temperature to 44°C for 2-6 hours during the
stationary growth phase [274]. Promoters were fused to the export domains of protein A
followed by a multiple cloning site.
Fusion protein with the 14 kDa long ZZ domain of protein A should have improved protein
solubility and secretion and also facilitate single-step protein purification by IgG-sepharose
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Figure 5.1: LecEGF of E-selectin with designated cysteins involved in formation of five disulfide bridges.
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chromatography. The DNA sequence coding for human E-selectin was available from isolated
genomic DNA of recombinant CHO cells. A fragment of 512 bps coding for the lectin and EGF-
like domains was amplified as described in material and methods (3.2.2.2). In our case one
base (G) had to be added to the cloned DNA sequence in order to maintain the open reading
frame. The initial methionine at the transcription start was provided by the vector, whereas the
stop codon for the transcription termination had to be provided by the insert. For further
structural protein studies, it would have been necessary to remove the ZZ tag from the protein.
Therefore, a thrombin cleavage site has been introduced into the sequence between the ZZ and
the LecEGF domains. EcoRI and BamHI restriction sites were introduced to the 5’ and 3’
primers, respectively, and the stop codon after the amplified selectin sequence. These features
have led to a 51 base pairs long 5’ oligo, with a rather high melting temperature of 72°C as
compared to 58°C for the 3’oligo. Although the 5’ oligo was extraordinary long, analysis of its
composition did not indicate any significant possibility for hairpin formation or primer-dimer
formation.
Consistent with this observation, initial cloning reactions were performed with high efficiency
and reproducibility using standard PCR conditions and did not require any significant
optimization. Successfully transformed E.coli cloning strains Top10 and DHα5, generated
sufficient number of colonies who’s DNA obviously contained desired insert. E.coli strain AD
494 (DE3) was chosen for protein expression and production, since this strain is lacking the
tyoredoxin gene and should facilitate disulfide bond formation even in the cytoplasm of E.coli.
Once transformed into E.coli AD 494, it was not possible to detect recombinant protein in any of
the bacterial expression compartments. Follow-up sequence analyses done on over thirty
clones have revealed mutations, deletions or insertions of a single base, mostly within the
sequence of the 5’ primer, or just after it. Shortening the size of this oligo to 24 bps did not
abolished mutations, although all the cloning and PCR steps were done with Pfu polymerase
that has a proofreading activity. The fact that mutations have always been located either in the
region covered by the 5’ oligo or close to the beginning of the LecEGF protein sequence, and
that were always on different position lead us to believe that this was a host protection mediated
mechanism. Mutated DNA resulted in the shift of the open reading frame on the very beginning
of the LecEGF sequence and only few amino acids of E-selectin were correctly translated
before a stop codon. DNA was sequenced from all grown colonies and was always mutated.
Therefore we concluded that the LecEGF domain of E-selectin which is fused on its N-terminal
to the secretion sequence and ZZ domain of protein A is a toxic protein for a bacterial host, and
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in case of its expression, the cell protection mechanism introduced DNA mutations to prevent
protein synthesis.
5.2.2 LecEGF secretion to the periplasm
Translocation of proteins across the cytoplasmic membrane requires a “translocation
competent” or unfolded state. Proteins that are exported by a cotranslational or translation-
linked mechanism, have to be still unfolded, since folding into stable secondary and tertiary
structures is thought to preclude translocation [276]. The cytoplasmic chaperons that are
thought to bind newly synthesized secretory proteins, like SecB, keep them unfolded until
translocation occurs. Exporting recombinant proteins into the periplasmic space of E.coli has
several advantages. In case of LecEGF expression, the most important one is that in the more
oxidizing environment of the periplasmic space the possibility for obtaining a properly folded and
disulfide bridged proteins is enhanced. Periplasmic proteins are protected from degradation by
cytoplasmic proteases and a simple treatment of the cells by osmotic shock releases them for
easier purification. The translocation of foreign proteins however, is usually not readily
accomplished. Proteins that are normally cytoplasmic in nature will not be translocated
efficiently. Most mature exported proteins lack any positively charged residues in their N-
terminal region. Even in case of success, translocation is often the rate-limiting step in the
production, and numerous parameters such as promoter, signal peptide or sequence of the
mature protein can all affect translocation.
Approximately 20% of E.coli proteins are efficiently translocated across the cytoplasmic
membrane. Their signal peptides (STII, PhoA, OmpA, MalE, etc.) have therefore been used to
export heterologous proteins. In the case of extracellular mammalian proteins the signal
sequences are similar to the E.coli counterparts, but usually do not function as well in E.coli.
Generally, in periplasmic protein production, there are two potential products to differentiate.
Ideally, the mature protein with the signal peptide properly cleaved will be produced, but the
unprocessed precursor protein containing the signal peptide may also accumulate.
Disulfide bond formation and isomerization in bacterial periplasma is catalyzed by enzymes
similar to eukaryotic protein disulfide isomerase (PDI). A set of these bacterial enzymes with
similar properties to those of PDI has been identified and named DsbA family. DsbA genes code
for a 21 kDa periplasmic protein with a CXYC motive in the active site, where X and Y vary
[277]. Within this consensus sequence, the first cysteine residue is characterized by an
unexpectedly low pKa value, thus guaranteeing fast and efficient reaction with the thiol groups
of nascent proteins, leading to enhanced disulfide bridge formation. DsbA coexpression has
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been shown to increase protein solubility, stability and correct folding in several cases [278].
Several studies have defined the essential features of signal peptides: exclusively located at the
amino terminal, they have a long hydrophobic region that is usually preceeded by one or more
positively charged residues in a short, generally hydrophilic region [279]. In our efforts to
express correctly folded and oxidized LecEGF in E.coli, secretion into the periplasmic space
was a promising approach in view of correct formation of the disulfide bridge pattern.
For LecEGF expression in the periplasm we have used the pINompA cloning vector containing
the signal sequence of an outer membrane protein A (ompA), a bacterial protease that is
normally located in the periplasma [250]. The signal sequence is 22 amino acids long and is
preceeding the LecEGF sequence. Multiple cloning sites of this vector enabled us cloning into
EcoRI and BamHI restriction sites. The expressed fusion protein prior to the processing would
contain a methionine from the signal sequence. Prior to the LecEGF sequence an amino acids
triplet (ANS) would be introduced as a consequence of EcoRI restriction site. This vector is a
low copy vector and utilizes a potent lpp promoter to efficiently initiate transcription of the cloned
gene. Transcription via the lpp promoter is controlled by the lac UV5 promoter-operator, inserted
downstream from the lpp promoter, and enables controlled induction of the cloned gene. The
signal sequence is known to be cleaved of from the ompA precursor protein by the nonspecific
signal peptidase I. This expression system has been used for the secretion of β-lactamase and
mouse metallothionein, where the subcloning of a ZZ-fusion protein into the pINompA cloning
vector finally enabled protein secretion in the medium [280]. The fusion of a signal and export
sequences did not harm in this case expression of correctly processed protein.
Initial cloning into DHα5 cloning strain has shown some similarities as compared to our previous
cloning into pEZZ18: low number of grown colonies and, although corrected by restriction
enzyme digestion, all sequenced DNAs had a point mutations, either deletions or insertions.
These mutations took place just downstream of the restriction site, or at the beginning of the
sequence coding for LecEGF. Consequently, the open reading frame of the translated protein
was shifted, resulting in a non-functional protein. In order to improve the basic cloning strategy,
DHα5 cells were electroporated, as a more potent transformation method. In this case,
however, we did not get a single colony to grow, although wide varieties of ligation and
transformation conditions were tested. Control experiments, with plasmid w/o the insert were
positive, therefore excluding E.coli cells as a source of negative results. The fact that
electroporated, cells did not grow at all, and when chemically transformed only few of them grew
however with the incorrect DNA sequence, led us to the conclusion, that fusion of LecEGF with
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a signal transport sequence is toxic for the bacterial hosts. These negative attempts to clone
LecEGF as a secretory protein in the bacterial periplasma were consistent with the negative
results in pEZZ 18, and further strengthened the hypothesis of the toxicity of this fusion protein.
5.2.3 LecEGF expression in the cytoplasma of E.coli
The advantages of intracellular versus periplasmic protein production are generally that higher
expression levels are achived (up to 70% of total cell proteins), that there is no need for protein
translocation and that protein is protected from degradation by periplasmic proteases. In
addition, expressed proteins very often form inclusion bodies, which can be easily isolated,
providing a rapid purification step However, the solubilization has to be achieved in denaturing
medium followed by refolding [233]. In general, translation initiation of foreign genes can be
often inefficient and may require optimization. In addition, cytoplasmic proteases can quickly
degrade a foreign protein, especially if it is small and soluble, and an extra amino terminal
methionine residue that may be retained by the recombinant protein could disturb protein
structure. In case of successful protein expression, preventing inclusion bodies formation is
sometimes a challenge. To date, the precise physiochemical parameters that contribute to the
formation of inclusion bodies remain unclear [281]. According to some evidence [282], the
propensity to form insoluble aggregates does not really correlate with the protein characteristics
such as its size, the use of fusion constructs, the subunit structure or its relative hydrophobicity
Statistical analysis of the amino acid composition of proteins that do and do not form inclusion
bodies in E.coli concluded that 6 parameters might be correlated with their formation: charge
average, turn-forming residues, cysteine and proline amount, hydrophilicity and total number of
residues [281]. Especially the first two parameters were found to strongly correlate with
inclusion body formation. After the first pioneering studies [283] on protein folding, numerous
examples of successful in vitro protein refolding demonstrate that all the information required for
the formation of the native three-dimensional structure of a given protein is encoded in its amino
acid sequence. This is however a multi-step process, since A number of proteins assisting in the
folding of nascent polypeptide chains have been described [233].
Since the efforts to express correct LecEGF as secreted fusion protein have failed, cytoplasmic
expression was tried. Cloning vector pET15b was used, with the strong T7 late promoter. The
activity of this system depends on a transcription unit that supplies the T7 RNA polymerase,
whose tight repression is essential to avoid leakiness of the T7 promoter [284]. Multiple cloning
sites enable sequence insertions in NdeI and BamHI restriction sites, and the vector provides a
6-His tag to facilitate purification. A thrombin cleavage site follows the His-tag and enables its
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removal after successful purification, as shown in figure 5.2A. In total, 16 amino acids are
preceding the native terminal tryptophan of LecEGF. The DNA sequence coding for LecEGF
was successfully cloned into pET15b and expressed in DHα5 cells in the first attempt. This was
consistent with the hypothesis that protein fusion to a secretion signal, and forced translocation
over the cell membrane was the reason for DNA mutations and unsuccessful cloning in prior
attempts. Sequencing from two independent sources (MWG and Syngene) has confirmed the
correct DNA sequence, which was subcloned in production E.coli strains. In preliminary
screenings under different conditions, purification of expressed HisLecEGF was attempt in both
isolated native and denaturing conditions by Ni-NTA chromatography.
As shown in section results, figure 4.27, the protein was exclusively expressed as inclusion
bodies. There are several different approaches to minimize the formation of inclusion bodies
when producing heterologous proteins intracellularly in E.coli. Overproduction itself, i.e., the
increase in concentration of nascent polypeptide chain, is sometimes sufficient to induce the
formation of inactive aggregates. Based on these findings, a kinetic model was proposed that
shows that the yield of native protein increases (and that of inclusion body formation
correspondingly decreases) with a decreasing rate of protein expression [285]. A reduction in
the rate of protein synthesis can be achieved by using moderate or weak promoters or by only
partial induction of a strong promoter [286]. Other means of reducing the protein-synthesis rate
is by growing the culture at lower temperature or to add non-metabolizable carbon sources to
the medium. Increased formation of inclusion bodies is also observed at slow folding rates of
recombinant proteins. Slow folding may be expected upon cytosolic expression of heterologous
proteins containing disulfide bonds in their native state. Although some in vitro folding studies
have demonstrated clearly that native disulfide bonds can be formed even in the reducing
environment found in the cytosol [287,288], disulfide bond formation may be extremely slow
under these reducing conditions.
Considering all these general reasons for inclusion body formation, the aggregation and
insolubility of expressed HisLecEGF was not surprising. Parameters that may influence protein
production rate have been optimized. E.coli strain BL 21 (DE3) has been widely used for protein
production. Strains AD 494 and Rosetta Gami could have been of interest, in the case of soluble
protein production, or in case of incompatible codon usage for HisLecEGF expression in E.coli.
These optimizations, however, did not improve HisLecEGF solubility.
Since preparative amounts of active protein would be needed for our studies, inclusion bodies
were isolated, denaturated, and subsequent attempts to refold the protein have been
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undertaken. Inclusion bodies have a high specific density, and are easily recovered and
separated from the cell membranes by centrifugation and extensive washing in buffer with low
reductant concentrations and protease inhibitors [289]. Although inclusion body proteins may
contain relatively high secondary structure content, they do not readily dissolve in physiological
buffers. Inclusion body solubilization requires rather strong denaturant, such as 6M guanidine
hydrochloride (GuHCl) or 6-8M urea, where GuHCl is preferable to urea for two reasons. First, it
is a stronger chaotrop, which may allow solubilization of extremely sturdy inclusion bodies that
are resistent to urea. Second, urea solutions may contain isocyanate and formaldehyde, which,
even if present in a very low concentration may lead to carbamoylation of free amino groups of
the polypeptide, especially upon long-term incubation at alkaline pH [290]. In the case of
proteins containing cysteines, inclusion bodies usually form interchain, scrambled disulfide
bonds which reduce their solubility. The addition of low molecular weight thiol reagents in
combination with a chaotrop allows complete reduction at mild alkaline pH and enhances
solubilization.
HisLecEGF was initially solubilized in 8M urea, pH 8.0, and purified over a Ni-NTA column with
an average yield of 120 mg/L. MS analysis of reduced and alkylated protein has shown an
increase of the predicted molecular weight of 28-84 Da, which would correspond to different
carbamoylation extents on ε-NH2 groups of lysine. Since HisLecEGF has 7 lysines, three of
which influence ligand binding (K111, K112, and K113), this modification would irreversibly
damage the protein. Therefore, all subsequent inclusion bodies solubilizations have been done
in 6M GuHCl. Although protein folding processes are not strongly affected by other proteins
present in the same renaturation system, better yields are obtained with pure protein. Ni-NTA
chromatography under denaturing conditions allowed purification of HisLecEGF to homogeneity
prior to the refolding. Purified protein (section results, figure 4.29) was digested with trypsin,
Lys-C, and V8 protease, and analyzed by MS with 100% sequence coverage. The initial
methionine was not processed, leaving a total of 10 additional amino acids on the N-terminus of
HisLecEGF.
For the refolding process, several points had to be considered: the folding method, the fact that
the native protein has 5 disulfide bridges, and the influence of small molecular weight additives
as buffer components that can enhance refolding and stabilize correctly folded species. In a first
refolding attempt, different dialysis protocols were applied [291,292]. Since HisLecEGF is a C-
type lectin, calcium was added to all buffers that were used. Upon controlled removal of excess
denaturant, the protein has quantitatively precipitated within the first hour, regardless of
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temperature, pH, and buffer composition. During the slow removal of denaturant by dialysis, the
protein was exposed to decreasing denaturant concentrations for an extended period of time.
This might have a negative effect on the yield of in vitro refolding [285,289]. The major problem
in refolding experiments is kinetic competition of folding and aggregation due to competing intra-
and intermolecular interactions. In folding intermediates, which were formed at intermediate
denaturant concentrations, residues that are normally buried inside the protein were exposed on
the outer side, causing aggregation and precipitation upon slow denaturant removal. Once
aggregates are formed, further aggregation is kinetically favored [293,294].
Unsuccessful dialysis led us to another approach, namely fast dilution. Dilution of the
solubilized, reduced protein directly into a renaturation buffer is the most commonly used
method in small-scale refolding studies [233]. However, protein concentration has to be carefully
controlled to prevent aggregation. Unproductive aggregation processes may originate both from
nonspecific (hydrophobic) interactions of predominantly unfolded, nascent polypeptide chains,
as well as from incorrect interactions of partially structured folding intermediates. On the other
hand, folding intermediates have been shown to shift equilibrium toward fully folded protein
[233,289,295]. Aggregation reactions are second- (or higher) order processes, whereas correct
folding is a first-order reaction. Thus, aggregation predominates upon renaturation above an
optimal concentration of denatured protein [296,297], usually not higher than 100 µg/ml but not
lower then 20 µg/ml. In addition, folding with concomitant disulfide bridge formation requires not
only correct protein structure, but oxidation of the correct disulfide bonds. In case of a five
disulfide bonds-containing proteins, there are 945 combinations for their formation [283].
However, correct cysteine pairing and disulfide bond formation should be favoured by the free
energy gained upon formation of the correct native conformation. Once formed, correct native
disulfide bridges are stable and should not be further shuffled.
Oxidation of cysteine residues can be performed with different reagents. The most common
reagents used are low molecular weight thiols, particularly reduced and oxidized glutathione in
different ratios. Because thiol-disulfide exchange reactions are rapidly reversible, “oxido-
shuffling” reagents increase both the rate and the yield of correct disulfide bond formation by
rapid reshuffling of improper disulfide bonds. Another method of oxidative protein folding relies
on the formation of mixed disulfides on the protein simultaneously to dilution refolding [296,298].
The introduction of mixed disulfides to the denatured state increases the solubility of the
unfolded protein by enhancing the hydrophilic character of the unfolded polypeptide chain.
Considering low molecular weight additives, it is common knowledge that these can have a
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tremendous effect on the folding efficacy. These low molecular weight additives can modulate
protein solubility, stability, and interactions with other molecules and structures in solution
[282,299].
Correct refolding of our construct can be monitored by analytical RP-HPLC, which gives
information on the aggregation state of the protein, and by biological activity as addressed by
binding of the blocking mAb 7A9, which binds only to native, correctly refolded protein. In light of
all these parameters, different experimental set ups were designed and tested for the
optimization of HisLecEGF refolding by fast dilution, but initially no appropriate conditions could
be found. Adding redox reagents during the dilution process or after a presumed refolding did
not make any difference. We tried, however, to separate different protein species present in
solution after refolding by size exclusion chromatography [300], but the best fractions showed
only minor activity. The possibility of a negative impact of the His tag on the refolding process
was investigated by removing of the tag with thrombin under intermediate denaturant
concentration. However, no positive effect could be observed. A broad screen of buffer
compositions that would provide an adequate refolding environment was performed using
screening system called “Affinity flow-field fractionation”. Some similarities have been observed
between experimental conditions for protein crystallography and protein refolding. For this
reason low molecular weight buffer additives usually used for crystallography have been
screened as additives for protein refolding [301]. Figure 4.34, section results, shows the best
screening result (high protein-monomer fraction after fast dilution). The protein precipitated in all
buffers with pH 5.0, regardless of additives, indicating that buffers of higher pH (8-9.5) and ionic
strength were more conducive to refolding. Addition of 0.005%-0.05% n-octylglucoside to the
buffer resulted in the highest yield of monomeric protein fraction as detected by AfFF analysis
and RP-HPLC. N-octylglucoside is a non-ionic detergent consisting of an aliphatic chain and a
glucose moiety and is usually used for solubilization and stabilization of membrane proteins
[302]. Since this detergent showed significant improvement on the monomeric fraction present
after dilution, this might lead to the question whether glycosylation might be a prerequisite for
the refolding of this particular protein. In a eukaryotic organism the addition of sugar chains,
which happens simultaneously with the synthesis of the nascent polypeptide chain, might
prevent exposure of hydrophobic protein parts. Once these are buried within the correctly folded
protein, N-glycans can be removed without affecting protein stability and, in the case of the
LecEGF domain of E-selectin, without affecting activity as well. However, protein stabilized in
the presence of this detergent precipitated immediately after addition of redox reagents.
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To avoid possible influence of a N-terminal tag on the rate of protein refolding, in the last
attempt, amino acids 1-157 of LecEGF were cloned directly w/o any tag into pET11c plasmid
vector (figure 5.2B), that has the same system characteristics as described for pET15b
(Novagen). Cytoplasmic expression and inclusion body production was straightforward,
consistent with the observation that DNA mutations occurred just in case of constructs that
would lead to secretion of LecEGF. This expression strategy led to the co-expression of two
bands: truncated LecEGF missing the last 40 amino acids on the C-terminus, and full-length
LecEGF, as confirmed by MS. This protein truncation occured at translational level, since
different E.coli strains which were transformed with different sequenced DNAs, lower IPTG
concentration, temperature and expression time resulted in the same expression profile. As
presented in figure 4.39, the charge, size, and hydrophobic differences of full-length and
truncated forms were insufficient to separate the different species, even after extensive
optimization. Only 26% of the total fraction was isolated as monomer on preparative RP-HPLC.
Nevertheless, refolding was tried combining the screen results from AfFF, and with n-
dodecylmaltoside, a non-ionic detergent for solubilization and stabilization of membrane
proteins. Initial screens indicated that after refolding the protein was soluble in TBS buffer and
readily eluted from an analytical RP-HPLC column, prior to the oxidation. Oxidation was also
monitored by analytical RP-HPLC, using a decrease in retention time as diagnostics [303], since
a correctly folded protein, with a correct disulfide pattern is more compact. However, when
analyzed with mAb7A9, our presumably refolded protein was inactive. Prolonged oxidation did
not improve its activity; on the contrary, the protein aggregated and could not be eluted from
RP-HPLC any more. The formation of inter-molecular disulfide bridges was confirmed in a non-
reducing SDS-PAGE gel, which has shown existence of monomers, dimers, and higher
molecular weight oligomers in solution. Although the native disulfide pattern should have priority
during in vitro formation, in case of LecEGF the oxidation conditions did not push native
disulfide formation. The addition of oxidant rather enhanced protein aggregation without any
significant active protein formation.
Further improvements of the folding strategy could have been achieved by co-expression of
chaperons or co-secretion with the DsbA family of protein responsible for isomerization of
disulfides, although in latter case yield of active protein was in range of hundred micrograms per
liter [272]. However, it is questionable whether the latter strategy would work, since LecEGF
could never be forced to secrete. Clearly in conclusion, E.coli turned out not to be the
expression strategy for the production of lecEGF of human E-selectin.
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5.3 Expression of LecEGF domain of human E-selectin in
baculovirus-infected insect cells
Baculovirus infected insect cells are one of the most powerful expression systems. One of the
major advantages over bacterial expression systems is its ability to produce functional complex
heterologous proteins [137], [304,305]. The most relevant feature of this expression system is
its eukaryotic-like environment for protein production, particularly important for the production of
heterologous mammalian proteins [235]. Expression levels in baculovirus infected insect cells
can vary from 25-100% of the total cell proteins, and can be as high as 1 g protein per 109 cells,
or 1 liter culture. Protein expression and production is rather simple, and cultivation is performed
at 24°C or 27°C. The rod shaped capsids of baculovirus can extend to accommodate an
additional 100 kbp of DNA or larger and allows for the simultaneous expression of a number of
genes. Baculovirus vectors are helper-virus independent and therefore simple to use and
considerably faster and simpler then the construction of a cloned, high expressing recombinant
eukaryotic cell line. Nevertheless, a baculovirus expression system takes a longer time to
develop then a typical E.coli system and is usually based on transient transfection system.
Important parameters in designing a baculovirus-infected insect cells system for recombinant
protein production are the selection of an expression vector, providing the best expression and
production results. Insect cell lines, growth media (serum supplemented, or serum-free), [306]
and feeding strategies should be carefully chosen to allow for the optimal recombinant virus and
protein expression.
Baculoviruses are the most prominent viruses known to affect insect population. More then 500
baculovirus isolates have been identified, most of which originate in arthropods, particularly
insects of the order of Lepidoptera. The most common isolates used in foreign gene expression
6X His LECTIN EGF-likeNH2T
A
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B
Figure 5.2 A and B: Shematic representation of HisLecEGF and LecEGF constructs of E-selectin expressed in
the cytoplasma of E.coli. A: Construct in pET-15b, B: construct in pET-11C. 6xHis: His tag,
T:Thrombin cleavage site
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are Autographa californica multiple nuclear polyhedrosis virus (AcMNPV) and Bombyx mori
(silkworm) nuclear polyhedrosis virus (BmNPV) [307].
Naturally occurring infection and recombinant in vitro infection are similar with the corresponding
three phases of viral replication, an early phase, a late phase and a very late phase [235]. The
major difference is that the naturally occurring polyhedrin gene within the wild-type bacuovirus
genome is replaced with a recombinant gene or cDNA., and correspondingly a recombinant
product is expressed in place of the naturally occurring polyhedrin promoter.
5.3.1 Intracellular expression of LecEGF
For the above mentioned characteristics of heterologous protein expression, insect cells have
been chosen for the expression of LecEGF. It was planned to express recombinant protein with
an N-terminus His-tag, followed by a PrescissionTM-protease restriction site preceeding the
LecEGF sequence (figure 5.3). A His-tag fused to the Prescission site was available in cloning
vector pBacPak and therefore LecEGF was initially cloned into this vector to generate the above
construct. To avoid any additional amino acids in the protein sequence as a consequence of
restriction endonucleases sites, LecEGF was PCR integrated in pBacPak, according to the
methodology described by Geiser et al [251]. This method utilizes extended protocols for site
directed mutagenesis and exploits endogenous bacterial ligases for efficient gene insertion into
the vector In the next step, HisPreLecEGF was PCR integrated into the pFastBac vector, which
contains elements that enable transposition reactions with the bacmid DNA. In the pFastBac
vector a strong polyhedrin promoter is governing protein expression. In contrast to some other
promoters, (e.g. p10 promoter), this promoter belongs to the group of late viral promoters,
leading to a start of protein expression only 48-72 hours after viral infection. The choice of
promoter can play a significant role for the expression of functional proteins in insect cells,
especially in cases of expression of secreted proteins [235]. The PrescissionTM protease
recognition site (LEVLFQ↓GP) was introduced between the N-terminal His-tag and LecEGF,
because of a greater specificity as compared to other serin protease. Additionally, the enzyme is
very stable under a wide variety of pH and temperature conditions. The generation of a correct
DNA construct was confirmed by sequencing. E.coli DH10Bac was successfully transformed
with pFastBacHPLecEGF. This E.coli strain possesses bacmid DNA and transposition helper
elements that enable transposition reactions between pFastBac and bacmid DNA. Accordingly,
the gene coding for HisPreLecEGF with a polyhedrin promoter and translation important
elements has been incorporate into bacmid DNA. The successful incorporation was defined by
blue-white colony selection, enabled by recombinant bacmid DNA. Transfection of Sf9 insect
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cells (Spodoptera frugiperda) was successful, as indicated by the first signs of viral propagation
in the cells and cell monitoring by cytometry and microscopy. Viral infection takes three-four
days and during this period insect cells undergo changes in their number, shape and viability.
The first transfection of Sf9 insect cells was visually monitored and cells were analyzed on a
cytometer for the signs of infection as extended cell diameter and decreased viability. Improved
transfection protocols were used (S.Rieffel, personal communication), where infection at lower
multiplicity of infection and higher cell number led to the faster generation of a virus with a
stronger infection potency. For single virus isolation and subsequent amplification, as well as for
determining the viral titer, the plaque assay was used. Viral data, as well as infection conditions
were in the standard range of 106 plaque forming units (pfu) and a multiplicity of infection
(M.O.I.) of 6. In order to keep production costs as low as possible and to enhance purification,
cells were grown in Sf 900 medium without serum and without antibiotics. This did not influence
cell growth. HisPreLecEGF expression was directed to the cytoplasma of insect cells, since it
has been reported from different studies that intracellular protein expression usually has higher
yields as compared to secretory constructs. Another advantage of intracellular production has to
do with purification over Ni-NTA. In fact, components of the insect cells-medium and
endogenous proteins secreted from insect cells interfere with the Ni-NTA matrix, necessitating
medium dialysis prior to purification. It is known that the cytoplasma of insect cells is less
reductive as compared to E.coli. In addition, there are few reports on the successful production
of proteins with concomitant disulfide bonds formation in the cytoplasma of the insect cells,
although this compartment would be more suitable for the expression of intracellular proteins or
their domains [235]. HisPreLecEGF was produced intracellularly, as shown in figure 4.38 and
confirmed in reducing and denaturing western blot with an anti-His antibody. However, protein
was not isolated after mild, native lyses, indicating that it was insoluble and inactive. In native
western blots and ELISA with mAb 7A9 it was not functional to any significant extent. Although
insect cells possess processing machineries and chaperons in their cytoplasm that facilitate and
improve protein refolding [68,308]. We have investigated and optimized infection rate, slower
protein production and shorter production time, as factors that influence protein production. A
lower rate of protein synthesis could facilitate the work of the folding machinery in the insect
cells and result in correctly folded protein. However, extensive optimization did not result in any
active protein production, pointing to problems in recombinant protein design, and choice of the
expression compartment (i.e. protein with a tag on the N-terminal, and protein expression
directed to the cytoplasm). In conclusion, lecEGF of human E-selectin expressed in insect cells
intracellularly with an amino terminal His-tag, is not functional and active.
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5.3.2 Extracellular expression of LecEGF
Generally, regarding the ability to produce fully processed and biologically active recombinant
proteins, insect cells with their secretion capabilities are second only to mammalian cells. The
fundamental maturation step is protein folding, followed by quite diverse post-translational
modifications, depending on the protein destination (intracellular or secreted). Although LecEGF
has its native signal sequence and those of mammalian origin are well recognized in insect
cells, an endogenous insect signal sequence, i.e., the signal for the acidic glycoprotein gp67
was used in order to improve the likelihood of correct protein processing. The acidic
glycoprotein gp67 is the most abundant envelope surface glycoprotein of the Autographa
californica nuclear polyhedrosis virus (AcNPV), and is essential for the entry of baculovirus
particles into susceptible cells. Large amounts of this protein are secreted and anchored to the
virus peplomer. Therefore its gene contains one of the most effective baculovirus-encoded
signal sequences for protein secretion. During the transport across the cell membrane,
theoretically, the signal peptide is cleaved after Ala38, leaving mature protein with its native N-
terminal. At the C-terminus of the EGF-like domain a short tag has been placed, i.e. a FLAGTM
tag [309], figure 5.4. This is a hydrophilic octapeptide (DYKDDDDK), and different anti-Flag
antibodies are available against this epitope [310,311]. The Flag tag could be placed either at
the amino-terminus, the carboxy-terminus or in association with other tags. It will usually not
interfere with fusion protein expression, proteolytic maturation or activity. [312]. The most recent
uses of this technique are in transfection of eukaryotic mammalian cells and insect cells and
even transgenic systems. It can be used for a protein coupling to a chip, or for assays
performed in 96-well plates [312,313]. Initially, the DNA construct containing lecEGF of E-
selectin, and a flag-epitope (SSLecEGFFlag) was generated in plasmid pAcGP67, which
contains the desired endogenous signal sequence of gp67, as described above. Using PCR
integration methods described earlier, the LecEGFFlag sequence was integrated without
restriction sites and the generation of overhangs [251]. In a second cloning step, the DNA
fragment coding for SSLecEGFlag was PCR integrated in the final vector pFastBac,
6X His Pre EGF-likeNH2 LECTIN
Figure 5.3: Shematic representation of HisPreLecEGF construct of E-selectin expressed in the cytoplasm of
insect cells. 6xHis: His tag, Pre: PrescissionTM protease cleavage site.
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downstream from the potent polyhedrin promoter, generating our final and
pFastBacSSLecEGFFlag construct. Colony PCR screening and subsequent sequencing
confirmed the correct DNA sequence and E.coli strain DH10Bac has been transformed with the
pFastBacSSLecEGFFlag. Sf9 insect cells have been transfected with the recombinant bacmid
DNA and 96 hours later, first signs of infection appeared. After viral purification by the plaque
assay and a first amplification round, 96 hours post infection cells number and viability dropped
and diameter increased indicating that infection had occurred. Based on the viral titer, the cells
were infected at a M.O.I of 5, i.e., a stronger infection conditions then in the case of intracellular
LecEGFFlag production. As shown in figure 4.43, protein secretion in the medium had started at
48 hours p.i., whereas between 72 and 96 hours p.i. there was not significant difference in the
level of secreted protein. Therefore, protein was harvested 72 hours p.i. in order to avoid
proteolytic cleavage. Baculovirus infected insect cells undergo a lytic cycle, and proteases can
be expressed and released at every step of the limited time span (72-96h) of protein production
[236,314]. Insect cells can produce proteases after baculovirus infection as a stress response;
proteases can be produced from the baculovirus vector itself during the infection cycle, or can
be released following cell lysis (e.g. lysosomal proteases).
On SDS-PAGE, overexpressed protein migrated between 20 kDa and 24 kDa as a smeary
band, typical for glycosylated proteins. The predicted molecular weight of non-glycosylated
LecEGFFlag is of 19.01 kDa. The overexpression of 24 kDa protein was also significant in the
cells (approximately the same amount), as indicated by Western blot analysis under reducing
conditions using the anti-flag M2 antibodies. When expressing secretory proteins in insect cells,
post-translational processing is not completely efficient and partially unprocessed protein will be
retained in the cells, probably in the endoplasmatic reticulum [314]. The higher molecular weight
of this protein fraction is therefore consistent with unprocessed material.
Secreted flag-tagged protein was purified in a single step over a Sepharose affinity matrix
coupled to the anti-flag monoclonal antibody M2. The flag-tagged proteins can bind to M2
antibody independently of the tag placement, in a calcium independent mode. The binding and
elution requirements were very mild with 150 mM NaCl, and neutral pH. Bound LecEGFFlag
was initially eluted by competing mode with excess of flag peptide and purified to homogeneity
in a single step. However, at a later stage we opted for a lowering of the pH to 2.7 for elution
(0.1 M glycine), because of the costs for commercial flag peptide. This pH decrease did not
affect protein activity, since the pH was immediately corrected to neutral with 1 M Tris. However,
some BSA unspecifically bound to the sepharose matrix was also eluted under these conditions,
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but easily removed by a subsequent gel filtration. The activity of the eluted protein was further
tested in Western blots with the 7A9 antibody under native conditions. Positive reaction with this
blocking antibody has confirmed the prediction that once secreted, LecEGFFlag will be active.
The secretion mechanism of the insect cells directs the protein into the ER and Golgi apparatus,
where the environment is oxidative enough to catalyze disulfide bond formation of the nascent
protein chain [314]. The protein migration profile on the SDS-PAGE and its apparent molecular
weight indicated that LecEGFFlag is glycosylated, consistent with the fact that LecEGFlag
posses three potential N-glycosylation sites, figure 5.5 The comparison with E-selectin/IgG in
the reaction with mAb 7A9, under native Western blot conditions, shows that LecEGFFlag has a
somewhat lower affinity toward this antibody. Since it has been reported that protein clustering
increases affinity and avidity of this reactions, this might be a consequence of E-selectin/IgG
dimerization. Therefore we have investigated the LecEGFFlag status in solution. Since
glycosylation in insect cells did not increase significantly the molecular weight of the expressed
protein, the LecEGFFlag is more appropriate for this analysis, as compared to the LecEGF
secreted from CHO or COS cells.
Under different SDS-PAGE and native PAGE conditions, LecEGFFlag migrated as a double
band, but as a monomer in solution, consistent with the previous molecule description of an
asymmetric monomer [91]. STD NMR [208,216]. with the sialyl Lewisx antagonist BW69669 has
further confirmed the activity of LecEGFFlag However, signals obtained in this measurement
were less intense as compared to the signals obtained and published for E-selectin/IgG
[210,269,315]. This can not be solely explained as a lower protein activity but also by the fact
that the size of the protein unit that carries 1 binding site is seven times smaller in the
LecEGFFlag then E-selectin/IgG (21 kDa, vs. 148 kDa resp.). In addition, the dimerization of E-
selectin/IgG can contribute as well. It has been published that lower intensities of STD NMR
signals are proportional to the molecular weight of the investigated protein and are less
sensitive for the proteins of less then 30 kDa [316]. Since to the best of our knowledge these
would be the first NMR experiments with a truncated version of E-selectin, differences in the
NMR intensities and interpretation should be thoroughly examined The glycosylation status of
LecEGFFlag has been examined by treatment with PNGaseF and O-glycosidase. Under
reducing and denaturing conditions, the protein was fully deglycosylated with PNGaseF,
confirming the typical glycosylation pattern of insect cells [307,317]. High mannose type of N-
linked glycans could be completely removed by this enzyme (GlcNAc2Man5-9). These results
indicate the absence of any branching, or fucosylation in 3 position of mannose. In native, fully
glycosylated conditions the molecular weight of two main glycosylated species was 21151.87
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Da, and 19958.57 Da respectively. According to the predicted molecular weight of the naked
protein, this would account for additional 2203.03 and 855.41 Da respectively, and pointing to 2
distinct N-linked sites that are in different stages of glycosylation. MS analysis has revealed
protein heterogeneity even within the two separated species. In conclusion and after many
unsuccessful attempts, active lectin and EGF-like domains the end we conclude that active
lecEGF of human E-selectin could be successfully expressed in either insect cells Sf9, or
Trichoplusia Ni (High fiveTM), in sufficient amounts (18 mg/l) for structural studies and with an
easy purification protocol by anti-flag affinity chromatography.
Figure 5.5: LecEGF of E-selectin with designated cysteins involved in formation of 5 disulfide bridges and
potential N-glycosylation sites.
NH2 LECTIN
FLAG (DYKDDDDK)
EGF-like
Figure 5.4: Shematic representation of LecEGFFlag secreted from insect cells
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5.4 Bioassay development
In our efforts to discover potential selectin antagonists, it was necessary to develop, adapt and
evaluate novel screening assays appropriate for molecular targets and lead validation. In a
process of drug discovery, potential ligands are evaluated with different, independent
experimental approaches, such as bioassays, NMR, or surface plasmon resonance. Moreover,
bioassay for measuring the interactions of carbohydrates and lectins can be developed in a
variety of solid or solution phase formats with sensitivity from nano- to the millimolar range.
Availability of recombinant selectins and their thorough functional characterization allowed the
development of a bioassay for the quantitative evaluation of selectin antagonists. Selectin-
based bioassays were created using different approaches, leading to target-based and function-
based formats. The latter were cellular assays based on inflammatory induction and subsequent
selectin up-regulation or neutrophil reperfusions. There are, however, significant differences
among data obtained with different assays and a high throughput robust screen is still lacking
[241,257,318,319].
Selectin-expressing cells binding to a solid phase of ligand glycolipids [217,218]. In order to test
our “in house” potential antagonists under different experimental conditions, but as close as
possible to the physiological ones, molecule-molecule and cell-molecule assays were
developed using a sLea-bearing polymer and a human promyelitic leukemia cell line (HL-60
cells) known to express selectin ligands, respectively [160].
5.4.1 E-selectin/IgG-sLea polyacrylamide assays
Molecule-molecule assays were based on binding of the sLea-polymer in the presence of
selectin antagonists with an optical density-measurable read-out, as described under materials
and methods. The assay was designed in a standard 96-wells format and optimized for
standard conditions. When the plate was pre-coated with an anti-human Fc mouse IgG1, the
control signal was not as stable and strong as when the protein was coated directly to the plate.
Reasons for this are probably steric hindrance and/or inaccessibility of the ligand binding site on
the protein. Further optimizations were directed toward the amount used in the assay. As a
measure for standard conditions, a triple increase in the signal intensity as compared to the
background (wells without proteins) was taken, according to Weitz-Schmidt [240]. The signal to
noise and signal to background ratio could be one of the major reasons for inconsistencies in
the assay performance among different groups. In the case of E-selectin/IgG, protein
concentration in the wells was 3 µg/ml, whereas in the case of L-selectin and P-selectin/IgG, the
standard protein amount was higher, up to 15 µg/ml. These differences point out the necessity
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to characterize the protein preparation in term of the really active fraction. The amount of sLea-
polymer used was the same in all three assays, i.e. 100 ng/ml, comparable with published
results [92]. Since the physiological selectin-carbohydrate interaction is in the millimolar range,
the sensitivity has to be higher. Assays were run under mild conditions, optimizing incubation
time and number of the washing steps. Incubation at 37°C and for 4 hours gave the most stable
and reproducible signals for standard conditions. The reliability of the assay for preliminary
antagonist screening was based on the results obtained for sLex, and BW69669, an E-selectin
antagonists thoroughly tested in similar assays and in animal models. The obtained data were in
close agreement with the published one [201,208,216]. This consistency has enabled the
interpretation of IC50 values of tested antagonists relative to the sLe
a polymer control. There
were, however, several drawbacks in the assay in terms of stability and robustness. The optical
density as an experimental read-out is rather sensitive to even small differences in the assay
performance. This can have a great impact on the assay results and shift the IC50 values
significantly. That is why an effort has to be made to utilize maybe fluorescence as a read-out
and to find more robust assay conditions. The shifts in the IC50 values of some antagonists, and
even of controls, were either due to this instability, or because of the quality of used protein.
Selectin antagonists were tested in the polymer-based assay discussed above as a proof-of-
concept with the aim of decreasing standard deviations, and improving assay reproducibility and
accuracy. The use of a polymer presenting the natural carbohydrate epitope in a multivalent
form has been discussed from several points of view [213,217,257]. Since the nature of selectin
ligand interaction and physiological rolling conditions require fast and transient contacts, a
polymer-presented ligand would form a more stable interaction and would promote the
likelihood of interactions at other position on the polymer backbone. Although this is supposed
to enhance the inhibitor effect in physiological conditions, the static assay stability should be
improved in this way as well [217].
5.4.2 E-selectin/IgG- HL-60 assays
Cell-molecule assay with cells measure the potency of the inhibitor to block the interaction
between naturally expressed selectin ligands on the cells and proteins coated to the plastic
support of a 96-wells plate. Studies have been showing that the protein orientation, or more
precisely, the orientation of the protein biding site, plays an important role in its ability to interact
with the ligands expressed on the HL-60 cells [320]. The presence of the Fc-part of human IgG
and consensus repeats on each of the selectins assayed seems to enable a correct protein
orientation and protein-ligand interactions. As mentioned for the molecule-molecule assay,
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standard conditions regarding protein amount coated, cell number used in the assay, and wash
steps were also optimized. For standard conditions, proteins were used at 10-15 µg/ml, a higher
concentration as compared to the molecule-molecule assay. The read-out in this cell-molecule
bioassay is fluorescence, a more robust and preferable method, as compared to the optical
density. Since fluorescence is expressed in arbitrary units, a direct comparison of the different
data from assay to assay is not possible, rather, data have to be expressed relative to controls.
In our case BW69669 has been taken as a control, and the IC50 values of tested antagonists
were expressed relative to this antagonist. The obtained IC50 values were higher as compared
to the values from molecule-molecule assay. This inconsistency is rather typical for cell-based
assay. One of the reasons is the uncontrolled cell machinery that synthesizes and expresses
functional ligands and difficulties with the cell maintenance [160]. All tested compounds were
run in triplicates of three independent experiments, but again the IC50 values were fluctuating on
a day-to day basis. In case of L- and P-selectin/IgG only preliminary screens were done, aiming
at defining standard assay conditions. The need to use higher protein concentration, as
compared to the E-selectin/IgG assay could be the consequence of the protein quality, since P-
selectin/IgG should bind to HL-60 cells with the highest affinity. PSGL-1 is the most abundant
selectin ligand on these cells and binds P-selectin with a nanomolar binding constant. The
incubation time and temperature in HL-60 assays were consistent with physiological conditions
for all three selectins (at 37°C, and incubation time was reduced to only one hour). This shorter
incubation was predominantly due to the toxicity of the fluorescent BCECF dye. The cell-
molecule assay would need improvements in terms of reproducibility and accuracy but is very
useful for preliminary antagonist screening.
5.4.3 LecEGFFlag-sLea-polyacrylamide assay
Up to date all experimental systems for studying selectin-carbohydrate interactions, have been
exploiting recombinant E-selectin that contains complete extracellular domain. Truncated E-
selectin version with LecEGF domains only was screened for the activity with the ligand bearing
cells [90] but was never used for the antagonists screening assay. To further characterize the
biological activity LecEGFFlag, a cell-free assay for a quantitative screen of E-selectin
antagonists was developed in 96-wells format. Several previous assay formats that were
established for E-selectin/IgG [240], were adopted and adjusted to LecEGFFlag. Li et al.,
reported on unsuccessful coating with LecEGF expressed in COS cells and pointed out the
necessity to pre-coat the wells with the non-blocking anti-E-selectin antibody 1D6 [97] to capture
the protein. Accordingly, we have initially pre-coated the wells with an anti-flag M2 antibody, but
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we did not get any signal that would indicate even very low affinity binding to the sLea polymer.
Most probably sterical hindrance prevents the reaction between the sLea bearing polymer and
the lectin domain of LecEGFFlag, although the polymer presents a scaffold with a high density
of sLea molecules. Similar results were observed in the case of E-selectin/IgG when precoating
with an anti-human Fc antibody resulted with lower signal intensity the direct E-selectin/IgG
coating. When LecEGFFlag was directly coated to the wells, the result was a clear
concentration-dependent sLea-polymer binding. Optimization of a protein and polymer
concentration was performed in a similar way as for E-selectin/IgG. Apparent activity and the
assay performance with LecEGFFlag was comparable to that of E-selectin/IgG. Apparent
LecEGFFlag affinity for the sLea, based on the saturation binding to the polymer was slightly
lower then reported for E-selectin/IgG [92,103], 72 nM vs. 49 nM, respectively, but well within
the experimental error (range). Specificity of the assay was confirmed with the non-sialylated
saccaride, which, in a wide concentration range did not block the polymer binding to any extent.
The IC50 values for the tested antagonists [216] were expressed relative to sLe
a-polymer as
control and were in close agreement with either published values, or those obtained in assay..
On the other hand, these data could also indicate that the presence of ith E-selectin/IgG as a
target molecule. One of the major advantageous of a cell-free assay using LecEGFFlag is an
excellent reproducibility, stability and accuracy, i.e., there were no fluctuations in the results on
a day-to-day or batch-to-batch base, as described for E-selectin/IgG. The good reproducibility of
the assay makes it very suitable for the quantitative determination of sLea-polymer interaction
with LecEGFFlag and particularly for the rapid screen and determination of inhibitory potencies
of selectin antagonists. The cell-based assay with HL-60 was not functional since very low
fluorescence values were obtained in control experiments. This is in agreement with peviously
described studies with the LecEGF of E-selectin [90]. Kinetic analysis of molecules and ligand
orientations supports the important role of domain orientation and exposure for ligand binding in
cell-based assay. The fact that LecEGFFlag does not have consensus repeats that could
improve lectin domain orientation might explain the lack of functionality in this type of assay.
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6 Conclusions and Outlook
Selectins, belonging to the C-type lectin family of cell adhesion molecules, initiate the
inflammatory cascade by mediating leukocytes tethering and rolling prior to the extravasation
into the inflammed tissue. According to their expression topology, selectins have been termed L-
(leukocytes), P-(platelets and endothelium) and E-(endothelium) selectin [85]. Although
inflammation represents a physiological defense mechanism, an excessive leukocyte
extravasation leads to numerous pathological and disease states including angiogenetic and
metastatic cancer spread. These findings have strengthened the pharmacological hypothesis
that inhibitors of selectin-ligand interactions would block the subsequent cell adhesion events
preceding inflammation and would thus be prospective anti-inflammatory agents [321]. The
physiological ligands of all three selectins contain a common tetrasaccharide epitope, the so-
called sialyl Lewisx (sLex). It serves as a lead structure in our search for selectin antagonists.
The bioactive conformation of sLex bound to the full length extracellular E-selectin (lectin, EGF-
like and 6 consensus repeat domains) has been solved by NMR technologies and enabled
rational design of E-selectin antagonists [209,322,323]. The structures of truncated E- and P-
selectin (lectin and EGF-like domains) co-crystalized with sLex have been solved as well [188].
Despite all these efforts, there are still no potent selectin antagonists on the market. To get
detailed insight into selectin/ligand interactions refined structural studies including selectin co-
crystallization with the second and third generation antagonists and NMR studies of E-
selectin/ligand complexes with 15N/13C labeled protein should be conducted. For aforementioned
structural studies, sufficient amounts of expressed, active and characterized protein are needed.
Recombinant human E-, P- and L-selectin/IgG have been expressed as secreted proteins in
mammalian expression system (CHO cells) and purified to homogeneity by protein A affinity-
and size exclusion chromatography. Activity of the expressed proteins has been confirmed in
reaction with blocking monoclonal antibodies and in NMR studies ligand binding was confirmed.
Although expressed in a highly glycosylated state, protein activity was resistant to the treatment
with PNGaseF, i.e., partial removal of N-linked sugars.
Bioassays were developed in cell-free and cell-based formats with E-selectin/IgG to quantify
binding affinity of in-house synthesized E-selectin antagonists. In a cell-free assay we utilized
polymer-presented sLea as a control and IC50 values obtained for tested antagonists have been
expressed relative to this ligand. In a cell-based format, physiological ligands were presented by
HL-60 cells. However, the reproducibility of the assays was unsatisfactory with variations on
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day-to-day and batch-to-batch base to accurately quantify inhibitory potencies of tested
antagonists.
To fullfil the requirements for structural studies, we decided to express truncated form of E-
selectin that contains only the lectin and EGF-like domains. This protein of approximately 20
kDa would be suitable for X-ray crystal structure determination (co-crystallization), as well as
NMR studies with labeled protein. In addition, for kinetic studies with surface plasmon
resonance, the smaller protein would be more suitable as well. Initially, LecEGF domains have
been cloned and expressed in E.coli as either secreted into the medium, periplasma or in form
of inclusion bodies. Subsequent protein refolding was not successful and despite preparative
amounts of expressed protein (80-120 mg/L), yields of active protein obtained under a variety of
refolding conditions (0.8-2%) were unsuitable for any scale-up.
In search for an alternative expression system lectin and EGF-like domains have been cloned
and expressed in baculovirus infected insect cells. This eukaryotic expression system enables
post translational modifications and disulfide bonds formation. Initially expressed intracellularly
protein was inactive. Finally, LecEGF was cloned in a secretable form as a fusion protein with
the C-terminal flag epitope (DYKDDDK) as an affinity tag. Protein expressed in Sf9 and Hi5
insect cells was secreted in the medium and purified to homogeneity by an anti-flag M2
antibodies-affinity column. Activity was confirmed by the intereaction with the monoclonal
blocking antibody against human E-selectin and in STD NMR studies. LecEGFFlag was
monomeric in solution, as judged by its migration profile in reducing, non-reducing and native
conditions. Two glycosylation isoforms were present in solution with molecular weights of 19.96
kDa and 21.15 kDa. In denaturing conditions, deglycosylation with N-glycanase (PNGase F)
was complete. In native conditions, however, deglycosylation remained incomplete. The
expression of LecEGFFlag as secreted protein in baculovirus infected insect cells with yields of
18 mg/L is efficient enough to envisage protein production for structural studies. Directed protein
secretion into the medium enabled it to pass through the endoplasmatic reticulum and Golgi
where it was posttranslationally modified (glycosylated and with correctly formed disulfide
bonds).
For the first time, a cell-free assay was developed with a truncated form of E-selectin.
LecEGFFlag was used for the characterization of E-selectin antagonists with the sLea polymer
as a control ligand. In addition, similar to the assay developed for E-selectin/IgG, the same
concentrations of polymer and protein (0.1 µg/ml polymer and 3 µg/ml protein) were used in
standard assay conditions. The assay has shown an excellent stability, reproducibility and
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accuracy on day-to-day and batch-to-batch basis. Three characterized selectin antagonists
have been tested for proof-of-concept and the results obtained were in close agreement with
published data [216]. Therefore, we conclude that cell-free polymer assay developed with
LecEGFFlag as a target protein is indeed suitable for evaluation and precise quantification of
inhibitory potencies of E-selectin antagonists.
In outlook, LecEGFFlag expressed in baculovirus infected insect cells will be used for X-ray
crystal structure analysis of E-selectin co-crystallized with second and third generation
antagonists. Prior to these studies, LecEGFFlag should be further purified over an anti E-
selectin blocking monoclonal antibody column to isolate only functional protein.
Selective 15N/13C amino acids labeling of the protein expressed in insect cells and subsequent
NMR studies will further refine the characterization of the bioactive conformation of the ligand
and the pharmacophores/amino acids involved in binding.
The expression system that was developed for E-selectin is straightforward and applicable for
P- and L- selectin. Therefore, the structural characterization of ligand binding to these two
selectins can be solved or significantly refined as well. More precise data could further point to
differences in binding modes of all three selectins and contribute to the development of highly
selective antagonists. These experiments and novel information will rapidly improve the search
for potent selectin antagonists as anti-inflammatory agents.
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8 Abbreviations
ABTS (2’2-azino-di(3-ethylbenzthiazoline)-6-sulfonic acid)
AcNPV Autographa californica nuclear polyhedrosis virus
Arg Arginine
Asn Asparagine
Asp Aspartate
ATP Adenosine triphosphate
BCECF-AM 2’,7’-Bis(2-carboxyethyl)-5(6)-carboxy-fluorescein 
tetrakis(acetoxymethyl) ester
BHK Baby hamster kidney
BmPV Bombyx mori polyhedrosis virus
BSA Bovine serum albumine
cAMP Cyclic adenosine monophosphate
CD Cluster of definition
cDNA Complementary deoxyribonucleic acid
CEA Carcinoembrionic antigen
CH3CN Acetonitrile
CHO Chinese hamster ovary
CIP Calf intestine phosphatase
COS African green monkey’s kidney cells
CRD Consensus repeat domains
Cys Cystein
DTH Delayed type hypersensitivity
DTT Ditrhiothreithol
E.coli Escherichia coli
EDTA Ethylendiaminotetraacetic acid
EGF Epidermal growth factor
E-LE E-selectin lectin and EGF-like domains
E-sel/IgG E-selectin lectin, EGF-like and consensus repeat 
domains fused to the Fc part of human IgG
FBS Fetal bovine serum
FCS Fetal calb serum
fMLP formyl-methionyl-leucyl-phenylalanine
FPLC Fast protein liquid chromatography
Fuc Fucose
FucT Fucosyl transferase
Gal Galactose
G-CSF Granulocyte-monocyte colony-stimulating factor
GlcNAc N-acetyl glucosamine
Glu Glutamine
GlyCAM Glycosylation dependent cell adhesion molecule
GSH Reduced glutathione
GSSG Oxidized glutathione
GuHCl Guanidium hydrochloride
HAB Hepes assay buffer
HEV High endothelial venules
His Histidine
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HisLecEGF, HLE E-selectin lectin and EGF-like domains with N-
terminal 6XHistidine
HisPreLecEGF, HPLE E-selectin lectin and EGF-like domains with N-
terminal 6XHistidine and prescission protease 
restriction site
HL-60 Human promyelocytic leukemia cells
HTS High throughput screening
HUVECs Human umbilical vein endothelial cells
ICAM Intracellular adhesion molecule
IFN-γ Interferon γ
IgG Imminoglobulin G
IL Interleukin
IMAC Immobilized metal ion affinity chromatography
IPTG Isopropyl-_-D-Thiogalactosid
JNK c-Jun N-terminal kinase
Kd Dissociation constant
LB Lauria Bretani
LDL Low density lipoprotein
LE E-selectin lectin and EGF-like domains
LecEGF E-selectin lectin and EGF-like domain
LecEGFFlag E-selectin lectin and EGF-like domains with C-
terminal Flag epitope
LFA Leukocyte function associated antigen
LPS Lipopolysaccharide
L-sel/IgG L-selectin lectin, EGF-like and consensus repeat 
domains fused to the Fc part of human IgG
M.O.I. Multiplicity of infection
mAb Monoclonal antibody
Mac Macrophage antigen
MadCAM Mucosal addressin cell adhesion molecule
MAPK Mitogen-activated protein kinase
M-CSF Mavrophage colony-stimulating factor
MECA multi-endocrine cellular antigen
MEM Minimal essential medium
MS Mass spectrometry
NBT/BCIP Nitro-blue tetrazolium chloride/5-bromo-4-chloro-3-
indolylphosphate
NCA Non-specific cross reactive antigen
NeuNAc N-acetylneuraminic acid
NF-κB Nuclear factor kappa B
Ni-NTA Nickel-nitrilotriacetic acid
NMR Nuclear magnetic resonance
NOE Nuclear overhouser effect
OD Optical density
PBS Phosphate buffer saline
PCLP Podocalyxin-like protein
PCR Polymerase chain reaction
PECAM Platelet endothelial cell adhesion molecule
Pfu Plaque forming units
P-LE P-selectin lectin and EGF-like domains
PMN Polymorphonuclear leukocytes
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PMSF Polymethylsulfonile fluoride
PNGaseF N-glycosidase F
POD Peroxidase
P-sel/IgG P-selectin lectin, EGF-like and consensus repeat 
domains fused to the Fc part of human IgG
PSGL-1 P-selectin glycoprotein ligand-1
PST Polystirene
RP-HPLC Reversed phase high pressure liquid 
chromatography
RT Room temperature
SDS-PAGE Sodium-dodecyl-sulfat polyacrylamide-gel-
electrophoresis
Sf Spodoptera frugiperda
SFM Serum-free medium
Sia Sialic acid
sLea Sialyl Lewisa
sLex Sialyl Lewisx
SN Supernatant
SPR Surface plasmon resonance
STAT Signal transducer and activator of transcription
STD Saturation transfer difference
TBS Tris buffered saline
TCR T-cell antigen receptor
TEMED N,N,N’,N’-Tetramethylethylendiamine
TFA Trifluoroacetic acid
TNF-α Tumor necrosis factor α
TPO Thrombopoetin
Tris (Hydroxymethyl)-Aminomethan
TTBS TBS with 0.05% Tween 20
Tyr Tyrosine
VCAM-1 Vascular cell adhesion molecule
VLA Very late antigen
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Attachment 1: 
Human E-selectin bibliography: 
 
Expasy address: http://au.expasy.org/cgi-bin/niceprot.pl?P16581 
 
Name: LYAM2_HUMAN 
 
Synonyms: Endothelial leukocyte adhesion molecule 1 (ELAM-1) 
 Leukocyte-endothelial cell adhesion molecule 2 (LECAM2) 
CD62E antigen 
Domain organization: 
SIGNAL    1    21   21         
CHAIN    22   610   589      E-selectin.   
DOMAIN    22   556   535      Extracellular (Potential).   
TRANSMEM    557   578   22      Potential.   
DOMAIN    579   610   32      Cytoplasmic (Potential).   
DOMAIN    22   139   118      C-type lectin.   
DOMAIN    140   175   36      EGF-like.   
DOMAIN    178   239   62      Sushi 1.   
DOMAIN    240   301   62      Sushi 2.   
DOMAIN    303   364   62      Sushi 3.   
DOMAIN    366   427   62      Sushi 4.   
DOMAIN    429   490   62      Sushi 5.   
DOMAIN    491   549   59      Sushi 6.  
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Attachment 2:
SsLecEGFFlag sequences:
DNA
SSLecEGF+Flag
1   ATGCTACTAG TAAATCAGTC ACACCAAGGC TTCAATAAGG AACACACAAG
60  CAAGATGGTA AGCGCTATTG TTTTATATGT GCTTTTGGCG GCGGCGGCGC
120 ATTCTGCCTT TGCGTGGTCT TACAACACCT CCACGGAAGC TATGACTTAT
180 GATGAGGCCA GTGCTTATTG TCAGCAAAGG TACACACACC TGGTTGCAAT
240 TCAAAACAAA GAAGAGATTG AGTACCTAAA CTCCATATTG AGCTATTCAC
320 CAAGTTATTA CTGGATTGGA ATCAGAAAAG TCAACAATGT GTGGGTCTGG
380 GTAGGAACCC AGAAACCTCT GACAGAAGAA GCCAAGAACT GGGCTCCAGG
440 TGAACCCAAC AATAGGCAAA AAGATGAGGA CTGCGTGGAG ATCTACATCA
500 AGAGAGAAAA AGATGTGGGC ATGTGGAATG ATGAGAGGTG CAGCAAGAAG
560 AAGCTTGCCC TATGCTACAC AGCTGCCTGT ACCAATACAT CCTGCAGTGG
620 CCACGGTGAA TGTGTAGAGA CCATCAATAA TTACACTTGC AAGTGTGACC
680 CTGGCTTCAG TGGACTCAAG TGTGAGCAAA TTGTGGACTA CAAGGACGAT
740 GACGATAAGT AA
Protein:
1   MLLVNQSHQG FNKEHTSKMV SAIVLYVLLA AAAHSAFAWS YNTSTEAMTY
50  DEASAYCQQR YTHLVAIQNK EEIEYLNSIL SYSPSYYWIG IRKVNNVWVW
100 VGTQKPLTEE AKNWAPGEPN NRQKDEDCVE IYIKREKDVG MWNDERCSKK
150 KLALCYTAAC TNTSCSGHGE CVETINNYTC KCDPGFSGLK CEQIVDYKDD
200 DDK
1-37: Signal sequence of gp67a insect acidic glycoprotein
38-194: LecEGF of human E-selectin (1-157)
195-202: Flag tag: DYKDDDDK
Underlined: potential N-glycosylation sites
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Attachment 3:
Molecular weight determination of LecEGFFlag by MS
Lane 1.: Load, non-separated LecEGFFlag, 4 µg
Lane 2.: -
Lane 3.: Load, non separated LecEGFFlag, 0.5 µg
Lane 4.: LMW marker
Lane 5.: Peak 1
Lane 6.: Peak 2
      1                2      3           4          5          6
MW determination of peak 1: Heterogenuos protein population
with prepredominant MW of 21.15 kDa.
MW determination of peak 2: Heterogenuos protein population
with prepredominant MW of 19.96 kDa.
RP-HPLC desalting and separation of two protein
species of LecEGFFlag
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